WO2009087578A2 - Sensation modifying topical composition foam - Google Patents

Sensation modifying topical composition foam Download PDF

Info

Publication number
WO2009087578A2
WO2009087578A2 PCT/IB2009/005005 IB2009005005W WO2009087578A2 WO 2009087578 A2 WO2009087578 A2 WO 2009087578A2 IB 2009005005 W IB2009005005 W IB 2009005005W WO 2009087578 A2 WO2009087578 A2 WO 2009087578A2
Authority
WO
WIPO (PCT)
Prior art keywords
agent
composition
sensation
weight
foam
Prior art date
Application number
PCT/IB2009/005005
Other languages
French (fr)
Other versions
WO2009087578A3 (en
Inventor
Dov Tamarkin
Meir Eini
Doron Friedman
Ella Zlatkis
David Schuz
Tal Berman
Original Assignee
Foamix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/971,197 external-priority patent/US20080253973A1/en
Application filed by Foamix Ltd. filed Critical Foamix Ltd.
Priority to CA2711703A priority Critical patent/CA2711703A1/en
Publication of WO2009087578A2 publication Critical patent/WO2009087578A2/en
Publication of WO2009087578A3 publication Critical patent/WO2009087578A3/en
Priority to ZA2010/05630A priority patent/ZA201005630B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/16Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24Thermal properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24Thermal properties
    • A61K2800/242Exothermic; Self-heating; Heating sensation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24Thermal properties
    • A61K2800/244Endothermic; Cooling; Cooling sensation

Definitions

  • compositions of various types have incorporated within them components or agents which provide a sensation to mucosal membranes and/or to skin.
  • the sensation may be a warming, cooling, relaxation stimulation or refreshing feeling or a combination of two or more feelings.
  • the sensation or feeling may be real or artificial.
  • Compositions which include a sensation agent include, inter alia, toothpastes, mouthwashes, perfumes, lotions, shaving cream, shampoos, antiperspirants, deodorants, beverages, chewing gum, tobacco products, and pharmaceutical products.
  • Most compositions known to date, comprising one or more sensation agents cannot retain the sensation at the site of application thereof in a subject over extended periods of time.
  • topical formulations do not retain the sensational effect for more than a few seconds.
  • the sensation agent may be volatile, such as menthol, used for providing a topical cooling effect, and the formulation may not retain the active agent for more than a few seconds.
  • Substances which are known to provide a sensation of warmth or warmth modulation on application and are called “warming agents” include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal,
  • Foams are considered a more convenient vehicle for topical delivery of active agents.
  • topical foams including aqueous foams, such as commonly available shaving foams; hydroalcoholic foams, emulsion-based foams, comprising oil and water components and oleaginous foams, which consist of high oil content, and which are foamable compositions having a specific surfactant selected from the group consisting of ethoxylated lanolin oil, propoxylated lanolin oil, and mixtures thereof and high levels of water that produce fast breaking foams that disappears rapidly into the skin with cooling sensation is described.
  • Some formulations make a sound or crackling effect when foam is dispensed.
  • Dimethyl ether is a substance which evaporates very rapidly and its use with an aqueous non emollient gel composition, lotion composition and a solution in producing a cooling effect (as opposed to mere sensation without cooling).
  • High levels of propellant have also been used to provide a solid or semi ointment deposit with a temperature between minus to plus 5 0 C.
  • Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam. There is, therefore, a need for a foam composition, which provides desirable properties to the skin and can remain stable whilst accommodating a variety of sensation agents or active ingredients.
  • Formulations based on oil or ointment or emollients have a number of useful attributes making them suitable candidates for topical pharmaceutical and cosmetic compositions including foamable compositions. They are inherently stable and inert which are clearly desirable characteristics. They are able to moisturize and soften the skin and in appropriate amounts can act as a protective or barrier layer and can form a barrier to water. By appropriate formulation they can act to improve agent delivery to the skin and yet remain resistant to being washed off. On the other hand they are by their nature greasy materials and can be difficult to formulate particularly into a topical foamable composition that can deliver substantially uniform and stable composition or foam that ameliorates or overcomes the look and feel of a greasy material, especially where that composition is waterless or substantially so.
  • one of the challenges in preparing such waterless or substantially waterless foamable compositions is ensuring that the one or more active sensation, pharmaceutical or therapeutic agents does not react, isomerize or otherwise break down to any significant extent during is storage and use.
  • the one or more active sensation, pharmaceutical or therapeutic agents does not react, isomerize or otherwise break down to any significant extent during is storage and use.
  • the application relates to aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality.
  • the aqueous vehicles may be emulsion or gel vehicles.
  • the application also relates to non aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. Upon contact with the body surface an effective amount of one or more sensory agents are capable of causing a perceived sensory effect.
  • the formulations are resistant to aging as indicated by their ability to withstand centrifugation. In other embodiments the formulations have a significant and suitable collapse time of 300 or more seconds.
  • the formulations are considered to be pleasant for use.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation over a sustained period of time.
  • the sustained period of time is at least five minutes, more preferably, at least 15 minutes, yet more preferably, at least 30 minutes, still more preferably, at least one hour.
  • the sensation may be felt for up to two hours or more.
  • a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
  • a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
  • foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non aqueous carrier.
  • foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface
  • the foamable composition comprises a substantially aqueous emollient carrier.
  • This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical and cosmetic compositions, containing an active agent, having a sensation or sensation modifying affect on a body surface, upon application.
  • a stable foamable composition that is stable on a surface at the delivery site for at least one minute, more preferably, at least two minutes, yet more preferably, for at least five minutes.
  • a composition that provides to a subject at least one sensation for a sustained period of time following application to the skin.
  • the composition includes: a. at least one sensation or sensation modifying agent, including one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent; b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition.
  • composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
  • the sensation effect is provided at a delivery site of the subject.
  • the sustained sensation is not primarily due to the propellant or an exothermic reaction.
  • the foamable carrier is resistant to aging and/or suitable for delivery of at least one sensation or sensation modifying agent.
  • the relaxing or soothing agent includes a herb extract, an astringent, a sea weed extract, an oat extract; an oil, a waxy or unctuous substance, a mineral, a vitamin, a pharmaceutical agent, menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-l-menthoxypropane-1 ,2-diol, ethyl l-menthyl carbonate, (1 S,3S,4R)-p- menth-8-en-3-ol, menthyl pyrrolidone carboxylate, an N-substituted-p-menthane-3- carboxamide, hamamelis extract, ginger oil, or any mixture of two or more thereof.
  • a herb extract an astringent, a sea weed extract, an oat extract
  • the herb extract comprises one or more of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, and yarrow.
  • the astringent comprises one or more of calendula, comfrey, and witch hazel.
  • the oil includes one or more of almond oil, avocado oil, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary.
  • the waxy or unctuous substance includes one or more of lanolin and petrolatum (e.g., vaseline jelly).
  • the mineral includes one or more of zinc oxide, calamine and selenium.
  • the vitamin includes tocopheryl acetate.
  • the pharmaceutical agent includes one or more of an analgesic, an anesthetic, an anti-inflammatory agent, an antihistamine, and a muscle relaxant.
  • the stimulating or refreshing agent includes an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine, quinine, or any mixture of two or more thereof.
  • the foamable carrier indues about 40% to about 99% by weight of the total composition, excluding the propellant, and is an aqueous emulsion, an aqueous gel, or a non-aqueous carrier.
  • the foamable carrier includes: i. at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier; ii. at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and iii. at least one non-aqueous solvent.
  • the foamable carrier further includes one or more of: i. a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; ii. a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; iii. a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; iv. a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition; v.
  • a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition
  • ii. a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition
  • iii. a co-solvent at a concentration of about 0.1 % to about 20% by
  • a foam adjuvant agent comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1 % to about 25% by weight of the total composition; vi. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and vii. an agent providing an occlusive effect, at a concentration of about 5% to about
  • the composition further includes at least one additional active agent, which is a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
  • the at least one additional active agent comprises at least one of an active herbal extract, an acaricide, an age spot and keratosis removing agent, an allergen, an analgesic, a local anesthetic, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial, an antibiotic, an antibum agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic, an antihistamine, an antihelminth, an antihyperkeratolytic agent, an antiinflammatory agent, an antiirritant, an antilipemic, an antimicrobial, an antimycotic, an antiproliferative agent, an antioxidant, an anti-wrinkle agent, an antipruritic, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic, an antiswelling agent, an antiviral agent, an anti-yeast agent, an an allergen, an analgesic
  • the composition further includes an additional component, which is an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, a moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, a vitamin, or a mixture of any two or more thereof.
  • an additional component which is an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a hume
  • the polymeric agent comprises at least one of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, a cationic guar, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, a polyvinylpyrrolidone, a polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, a polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, a methylcellulose, a hydroxypropyl cellulose, a hydroxypropyl methylcellulose, a hydroxyeth
  • the composition upon dispensing as a foam, has a density of about 0.01 to about 0.2 g/ml.
  • the compositions described herein contain a sensation or sensation modifying including at least one of: a combination of a cooling and a warming agent; a combination of a cooling and a soothing or relaxing agent; a combination of a cooling and a stimulating or refreshing agent; a combination of a warming and a stimulating or refreshing agent; a combination of a warming and a soothing or relaxing agent; a combination of a cooling, a warming and a soothing or relaxing agent; and a combination of a cooling, a warming and stimulating or refreshing agent.
  • the compositions described herein contain: a.
  • a sensation or sensation modifying agent including menthol at a concentration of 0.5 to about 3% by weight of the composition; b. at least one additional active agent including: i. coal tar or coal tar extract at a concentration of about 2% to about 20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0.5% to about 10% by weight of the composition.
  • a composition for providing a subject with at least one sensation for a sustained period of time includes: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a silicone oil; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • a composition for providing a subject with at least one sensation for a sustained period of time includes: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a triglyceride; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • a composition for providing a subject with at least one sensation for a sustained period of time includes: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a silicone oil and a triglyceride; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • the buffering system comprises an EDTA, a citrate buffer, or a mixture thereof.
  • the compositions described herein further includes a polymeric agent, a foam adjuvant, or a combination thereof.
  • the compositions described herein further includes a penetrating agent, a humectant, or a combination thereof.
  • the coal tar or coal tar extract is present in the compositions described herein at a concentration of about 2% to about 20% by weight.
  • the surfactant is present in the compositions described herein at a concentration of about 2% to about 8.5% by weight.
  • a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time includes: a. about 10% by weight of a cooling agent; b. about 81 % to about 83% by weight of a glycol; c. about 6% by weight of one or more surfactants; d. about 1 % by weight of a polymeric agent; and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • the cooling agent is peppermint oil or menthol crystals.
  • the glycol is propylene glycol.
  • the surfactant includes steareth 2, polysorbate 80, glyceryl monostearate, or mixtures thereof.
  • the polymeric agent is hydroxypropyl cellulose.
  • the composition further includes a foam adjuvant.
  • the foam adjuvant is cetostearyl alcohol.
  • a waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time.
  • the composition includes: a. about 0.03% by weight of a warming agent; b. about 97.97% by weight of a glycol; c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • the warming agent is capsaicin.
  • the glycol is propylene glycol.
  • the surfactant is steareth 2.
  • a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time includes: a. about 10% by weight of a warming agent comprising ginger; b. about 81 % to about 85% by weight of water; c. about 4.5% to about 6% by weight of one or more surfactants; d. about 0.6% by weight of a polymeric agent; e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • the warming agent includes ginger oil.
  • the surfactant includes steareth 2, steareth 21 , polysorbate 80, glyceryl monostearate, PEG-40 stearate, or a mixture thereof.
  • the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof.
  • the foam adjuvant includes cetostearyl alcohol.
  • a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time includes: a. about 2% by weight of aloe vera; b. about 90% to about 94% by weight of a polar solvent; c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
  • the composition further includes a propellant at a concentration of about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • the polar solvent includes water, diethylene glycol monoethyl ether, or a mixture thereof.
  • the surfactant includes polysorbate.
  • the polymeric agent includes Avicel RC581.
  • a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time includes: a. about 2% by weight of aloe vera; b. about 77% by weight of a polar solvent; c. about 1 1 % by weight of a hydrophobic carrier; d. about 7% by weight of one or more surfactants; e. about 2% by weight of a foam adjuvant; f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
  • the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
  • the surfactant includes steareth 2, steareth 21 , or a mixture thereof.
  • the polar solvent includes water.
  • the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof.
  • the foam adjuvant includes cetostearyl alcohol.
  • compositions described herein further include a hydrophobic solvent, wherein the combination of the additional hydrophobic solvent and silicone oil, the combination of the additional hydrophobic solvent and triglyceride, or the combination of the additional hydrophobic solvent, silicone oil, and triglyceride, is present in the composition at about 6% to about 22% by weight of the composition.
  • a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time including: at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; and a stimulating or refreshing agent; or mixtures thereof; a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction.
  • the composition does not effect a substantial temperature change to the surface.
  • the cooling agent is selected from menthol; an isomer of menthol, a menthol derivative; 4-Methyl-3-(1-pyrrolidinyl)-2[5H]- furanone; WS-23, lcilin, lcilin Unilever Analog, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone; 4,5-dimethyl-3-(1-pyrrolidinyl)-2[5H]-furanone; isopulegol, 3-(l-menthoxy)propane-1 ,2-diol, 3-(l-menthoxy)-2-methylpropane-1 ,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6- isopropyl-9-methyl-1 ,4-dioxas- piro[4,5]decane-2-methanol, menthyl
  • the menthol derivative is selected from the group consisting of: menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, menthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®) and 3- (/-Menthoxy)-1 ,2-propanediol.
  • Frescolat® type MGC menthol Propylene Glycol Carbonate
  • Frescolat ML® menthyl lactate
  • Menthone Glycerin Acetal Fescolat MGA®
  • the warming agent is selected from polyhydric alcohols, capsaicin, capsicum powder, a capsicum tincture, capsicum extract, capsaicin, hamamalis, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil
  • the relaxing or soothing agent is selected from a herb extracts, selected from the group consisting of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, selected from the group consisting of: almond oil, avocado oil, and comfrey; and essential oils, selected from the group consisting of: cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances selected from the group consisting of: lanolin or vaselline jelly, minerals, selected from the group consisting of: zinc oxide, calamine and selenium; vitamins, selected from the group consisting of: tocopheryl acetate (vitamin E), and pharmaceutical agents selected from the group consisting of:
  • compositions wherein the stimulating or refreshing agent is selected from an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate .acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine and quinine.
  • the short term stable foam is stable at the delivery site for at least one minute. In some further cases, the short term stable foam is stable at the delivery site for at least five minutes.
  • the sustained period of time is at least 15 minutes. According to some further embodiments, the sustained period of time is at least 30 minutes. In some further cases, the sustained period of time is at least one hour.
  • the foamable carrier is at a concentration of about 40% to about 99% by weight of the total composition excluding propellant and is selected from the group consisting of an aqueous emulsion, and aqueous gel and a non aqueous carrier wherein the carrier includes: at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier; at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and at least one non aqueous solvent.
  • the non aqueous solvent is in the case of the aqueous emulsion, a hydrophobic emollient; in the case of the aqueous gel, a penetration enhancer; and in the case of the non aqueous carrier, a polyol.
  • compositions wherein the at least one emollient is selected from the group consisting of: avocado oil, isopropyl myristate, mineral oil; capric triglyceride, capryllic triglyceride mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaery
  • the at least one stabilizing surface active agent is selected from the group consisting of: stearyl alcohol; steareth-2, steareth-21 ; polysorbate 80, PEG-40 stearate, glyceryl monostearate, cetostearyl alcohol, laureth 4, and Ceteareth-20, or is a combination of at least two surfactants selected from the group consisting of combinations of polyoxyethylene alkyl ethers, particularly Brij 59 / Briji O; Brij 52 / Brij 10; Steareth 2 / Steareth 20; Steareth 2 / Steareth 21 (Brij 72 / BRIJ 721 ); Myrj 52 / Myrj 59; combinations of sucrose esters, particularly Surphope 1816 / Surphope 1807; combinations of sorbitan esters, particularly Span 20 / Span 80; Span 20 / Span 60; combinations of sucrose esters and sorbitan esters, particularly Surphope 181 1
  • the at least one polymeric agent is selected from the group consisting of: locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxye
  • the foamable carrier further includes one or more of the following: a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition; a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain at a concentration of about 0.1 % to about 25% by weight of the total composition; a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and an agent capable of having an occlusive effect at a concentration of about 0.1 % to about 5% by weight of the
  • the composition further includes at least one additional active agent.
  • the at least one additional active agent includes, according to some embodiments, a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
  • the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antibum agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents
  • compositions wherein the foamable carrier includes at least one carrier medium, selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
  • carrier medium selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
  • the foamable carrier further includes a polar solvent.
  • compositions further including an additional component selected from the group consisting of an anti- perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin.
  • an additional component selected from the group consisting of an anti- perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an e
  • compositions wherein the sensation or sensation modifying is selected from the group consisting of: a combination of a cooling and a warming agent; a combination of a cooling and a soothing or relaxing agent; a combination of a cooling and a stimulating or refreshing agent; a combination of a warming and a stimulating or refreshing agent; a combination of a warming and a soothing or relaxing agent; a combination of a cooling; a warming and a soothing or relaxing agent; and a combination of a cooling; a warming and stimulating or refreshing agent.
  • the propellant provides an initial cooling sensation combined with a sensation agent to provide a prolonged sensation.
  • the foamable carrier further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
  • the composition includes: the at least one sensation or sensation modifying agent including menthol in a concentration of 0.5 to about 3% by weight;
  • the at least one active agent includes: coal tar extract in a concentration of around 2% up to around 20% by weight; and at least one other active agent selected from salicylic acid and hydrocortisone in a concentration of around 0.5% up to around 10% by weight; and the menthol is adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar extract.
  • compositions wherein: the at least one sensation or sensation modifying agent includes menthol crystals in a concentration of 0.5 to about 3% by weight; the at least one active agent includes: coal tar in a concentration of around 2% up to around 20% by weight; and hydrocortisone butyrate in a concentration of around 0.5% up to around 10% by weight; and the menthol crystals are adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar.
  • a method for providing a subject with at least one sensation at a delivery site including administering to the delivery site of the subject a composition including: at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent; ii. a warming agent; iii. a relaxing or soothing agent; and iv.
  • a stimulating or refreshing agent or mixtures thereof; a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction, so as to provide the subject with the at least one sensation for the sustained period of time.
  • the method allows for the foam being stable at the delivery site for at least one minute. In some cases, the foam is stable at the delivery site for at least five minutes.
  • the method allows for the subject to sense the at least one sensation at the delivery site for at least at least 15 minutes. In some cases, the subject senses the at least one sensation at the delivery site for at least 30 minutes. In some further cases, the subject senses the at least one sensation at the delivery site for at least one hour. In yet some further cases, the subject senses the at least one sensation as increasing, peaking and decreasing over the sustained period of time. [0088] According to some embodiments, the method allows for the subject to sense at least one sensation at the delivery site selected from a cooling sensation, a warming sensation, a heating sensation, a soothing sensation, a relaxing sensation, a stimulating sensation and a refreshing sensation.
  • the administration step further includes spreading the foam over a surface at the delivery site.
  • the delivery site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum.
  • the method includes administering compositions further including at least one additional active agent.
  • the at least one additional active agent includes a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
  • the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antibum agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents,
  • the method further includes treating a disorder selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post
  • the foamable composition includes: a. a foamable carrier; b. at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent; ii. a warming agent; iii. a relaxing or soothing agent; iv. stimulating or refreshing agent; or mixtures thereof; c. a propellant at a concentration of about 3% to about 45% by weight of the total composition wherein the composition is stored in an aerosol container and upon release expands to form a foam.
  • a foamable carrier selected from the group of i. a cooling agent; ii. a warming agent; iii. a relaxing or soothing agent; iv. stimulating or refreshing agent; or mixtures thereof
  • a propellant at a concentration of about 3% to about 45% by weight of the total composition wherein the composition is stored in an aerosol container and upon release expands to form a foam.
  • a foamable base composition for use with a sensation or sensation modifying agent comprising i. a foamable carrier; and ii. a propellant at a concentration of about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a foam.
  • the foamable composition further comprises at least one component, selected from the group consisting of: a. a surface active agent; and b. a polymeric agent; wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
  • the foamable composition further comprises at least one component, selected from the group consisting of: a. a co-emulsifier and foam stabilizer; b. a viscosity, bulking or firming agent; c. a stabilizer; d. a co-solvent; e. a penetration enhancer; and f. an agent capable of having an occlusive effect.
  • the foamable emollient emulsion carrier composition comprises: a. an aqueous carrier; b. an emollient; and c. a surfactant; or polymeric agent and optionally d.
  • a co-emulsifier and foam stabilizer a viscosity, bulking or firming agent; a stabilizer; a co-solvent; a penetration enhancer and or an agent capable of having an occlusive effect wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
  • the foamable waterless carrier composition comprises: a. a non-aqueous carrier; b. a surfactant; and or a polymeric agent and optionally c. a co-emulsifier and foam stabilizer; and a viscosity, bulking or firming agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing or soothing sensation.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non-aqueous carrier.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the sensation or sensation modifying effect is of short, medium or long term duration or grades thereof.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that onset of sensation or sensation modifying effect is of a quick, medium or slow onset or grades thereof.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the relative overall magnitude of sensation or sensation modifying effect is of a mild, medium or strong magnitude or grades thereof.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect increases peaks and then decreases.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect is with no or little skin irritation.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect comprises a fragrance.
  • a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect can be useful, beneficial or therapeutic in cosmetic, toiletry, bath additive, and pharmaceutical compositions.
  • the composition further contains a compatible fragrance so as for example to provide in addition aromatherapy on application of the sensation foam.
  • the composition further contains a compatible washable pigment so as to provide an attractive color to the dispensed foam.
  • the composition is a waterless composition with hygroscopic ingredients, which upon absorbing water present on a body surface give an initial warming sensation in addition to the prolonged sensation of the sensation agent.
  • foaming the oils with a propellant to produce a low density aerated foam by foaming the oils with a propellant to produce a low density aerated foam, the greasy property of the oil in the formulation is ameliorated or minimized.
  • foamable compositions using more than one different foamable platforms or carriers. More specifically it was discovered, for example, that effective foamable compositions can be produced with a sensation or sensation modifying effect with a substantially waterless carrier and can also be produced with a substantially aqueous carrier.
  • the ability to produce sensation or sensation modifying foam in waterless and aqueous environments allows the production of foams to suit, benefit or improve a wide variety of skin, mucosa and body cavity conditions. Based on this discovery it is possible to develop and create a multitude of foams, which provide a sensation or sensation modifying feeling with the following advantages:
  • Sensation agent may mask, neutralize, ameliorate or hide one or more undesired properties of other ingredients of the composition
  • the evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
  • the propellant is at a concentration from about 3% to about 25% by weight of the total composition.
  • the propellant is at a concentration from about 25% to about 45% by weight of the total composition.
  • the foamable base composition is flowable.
  • the main carrier solvent is at a concentration of about 40% to about 90% by weight of the total composition.
  • the foamable composition further comprises at least one component, selected from the group consisting of: a. a surface active agent; b.
  • a polymeric agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
  • the surface active agent is a stabilizing combination of at least two surface active agents.
  • the surface active agent is at a concentration of about 0.1 % to about 10% by weight of the total composition.
  • the polymeric agent is at a concentration of about 0.05% to about 5% by weight of the total composition.
  • the surface active agent is combination of at least two surfactants.
  • the polymeric agent is preferably a combination of hydroxy propylmethyl cellulose and xantham gum.
  • the polymeric agent is sodium carboxymethyl-cellulose, hydroxyethyl-cellulose, microcrystalline- cellulose, aluminum starch octyl succinate, and polyacrylates such as carbopol.
  • the polymeric agent is preferably a hydroxypropyl-cellulose such as
  • Klucel EF aluminum starch octyl succinate, and polyacrylates such as carbopol.
  • the co-emulsifier is at a concentration of about 0.05% to about 10% by weight of the total composition.
  • the viscosity, bulking or firming agent is at a concentration of about 0.1 % to about 15% by weight of the total composition.
  • the stabilizer is at a concentration of about 0.1 % to about 10% by weight of the total composition.
  • the co-solvent is at a concentration of about 0.1 % to about 30% by weight of the total composition.
  • the penetration enhancer is at a concentration of about 0.1 % to about 30% by weight of the total composition.
  • the agent capable of having an occlusive effect is at a concentration of about 0.1 % to about 30% by weight of the total composition.
  • a sensation or sensation modifying topical composition wherein the resultant foam has a density of about 0.01 to about 0.2 g/ml.
  • a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 60 seconds or more.
  • a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 120 seconds or more.
  • a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 300 seconds or more.
  • the foamable sensation modifying topical composition is an aqueous composition, containing water and further comprises a surface active agent.
  • the foamable sensation modifying topical composition comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
  • the foamable sensation modifying topical composition is an emulsion, comprising water, a hydrophobic solvent, a surface-active agent and a polymeric agent.
  • the emulsion-type foamable composition further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
  • a foam adjuvant agent selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
  • the emulsion is an oil in water emulsion, while in additional embodiments the emulsion is a water in oil emulsion.
  • the hydrophobic carrier is an oil. Exemplary oils include mineral oil, silicone oil, a triglyceride and an ester of a fatty acid.
  • the hydrophobic solvent is occlusive, such as petrolatum, while in other embodiments the hydrophobic carrier in non-occlusive.
  • the foamable sensation modifying topical composition is an oleaginous foamable composition, including at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a polar solvent and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent and at least one polymeric agent.
  • the foamable sensation modifying topical composition includes more than 50% of a polar solvent (as used herein, the term “polar solvent” shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water), a surface-active agent and a polymeric agent.
  • a polar solvent shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water
  • the foamable composition contains up to 80% water, while in additional embodiments the foamable composition contains up to 25% water.
  • the composition is substantially alcohol free
  • the composition is substantially non-aqueous.
  • an aqueous carrier at a concentration of about 40% to about 90% by weight of the total composition; ii. an emollient at a concentration of about 5% to about 15% by weight of the total composition; iii. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition; iv. a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; v. a propellant at a concentration of about 3% to about 45% by weight of the total composition; vi. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; and optionally; vii.
  • a co-emulsifier and foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; a stabilizer; a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; a penetration enhancer at a concentration of about 0.1 % to about 20% by weight of the total composition; and or an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition; wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam. b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
  • a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject comprising: a. administering an effective amount of a sensation or sensation modifying topical substantially waterless foamable composition to a target site on a mammalian subject, comprising: aa. a non-aqueous carrier at a concentration of about 40% to about 90% by weight of the total composition; bb. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition; and or a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; cc.
  • At least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; dd. a propellant at a concentration of about 3% to about 25% by weight of the total composition and optionally; ee. a co-emulsifier and foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; and a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition.
  • a propellant at a concentration of about 3% to about 25% by weight of the total composition and optionally
  • ee. a co-emulsifier and foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition
  • a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition.
  • a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam. b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
  • a "hydrophobic solvent” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 ml_, more preferable less than about 0.5 gm per 100 ml_, and most preferably less than about 0.1 gm per 100 ml_.
  • the hydrophobic organic carrier is an oil, such as mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridec
  • oil such as mineral oil, iso
  • a "polar solvent” is an organic solvent, typically soluble both in water and oil but is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition.
  • the emollient emulsion and waterless formulations may contain polar solvents, which may contribute to the penetration of an active or therapeutic agent including a sensation or sensation modifying agent.
  • a polymeric agent can be selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxy
  • the solvent is a polyol.
  • a polyol is an organic substance that contains at least two hydroxy groups in its molecular structure.
  • the foamable carrier contains at least one diol (a compound that contains two hydroxy groups in its molecular structure).
  • diols examples include propylene glycol (e.g., 1 ,2-propylene glycol and 1 ,3-propylene glycol), butanediol (e.g., 1 ,2-butanediol, 1 ,3-butanediol, 2,3-butanediol and 1 ,4-butanediol), butanediol (e.g., 1 ,3-butanediol and 1 ,4-butenediol), butynediol, pentanediol (e.g., pentane-1 ,2-diol, pentane-1 ,3-diol, pentane-1 ,4-diol, pentane-1 ,5-diol, pentane-2,3-diol and pentane-2,4- diol), hexanediol (e.g.
  • the foamable carrier contains at least one triol (a compound that contains three hydroxy groups in its molecular structure), such as glycerin, butane-1 ,2,3-triol, butane-1 ,2,4-triol and hexane-1 ,2,6-triol.
  • the polyol is a mixture of polyols.
  • the mixture of polyols contains at least one diol and at least one triol. According to certain embodiments the ratio between the diol and triol is between 9:1 and 1 :1.
  • part of mixture of polyols is a saccharide. Exemplary saccharides include, but are not limited to monosaccharide, disaccharides, oligosaccharides and sugar alcohols.
  • a sugar alcohol also known as a polyol, polyhydric alcohol, or polyalcohol
  • saccharide whose carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. They are commonly used for replacing sucrose in foodstuffs, often in combination with high intensity artificial sweeteners to counter the low sweetness.
  • Some exemplary sugar alcohols, which are suitable for use according to the present invention are mannitol, sorbitol, xylitol, maltitol, lactitol. (Maltitol and lactitol are not completely hydrogenated compounds - they are a monosaccharide combined with a polyhydric alcohol).
  • Mixtures of polyols, including (1 ) at least one polyol selected from a diol and a triol; and (2) a saccharide are contemplated within the scope of the present invention.
  • the solvent consists of a polymerized ethylene glycol, namely polyethylene glycol, which is also termed "PEG".
  • PEG polyethylene glycol
  • the PEG is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG 6000 and PEG 8000.
  • the foamable carrier according to the present invention can contain a single PEG or a mixture of two or more PEGs.
  • the concentration of the PEG should be in a level that results in viscosity, prior to filling of the composition into aerosol canisters, of less than 12,000 CPs, and more preferably, less than 10,000 CPs.
  • a secondary solvent is added to the foamable composition of the present invention.
  • the secondary solvent is selected from a variety of organic solvents that are typically miscible on both water and oil.
  • solvent that can be contained in the foamable carrier of the present invention include dimethyl isosorbide, tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol), DMSO, pyrrolidones, (such as N-Methyl-2-pyrrolidone and 1-Methyl-2-pyrrolidinone), ethyl proxitol, dimethylacetamide (DMAc), PEG-type surfactants and alpha hydroxy acids, such as lactic acid and glycolic acid.
  • DMAc dimethylacetamide
  • a “skin penetration enhancer”, also termed herein “penetration enhancer,” is an organic solvent, typically soluble in both water and oil.
  • penetration enhancer include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen- ols, limonene, terpene-ol, 1 -menthol, dioxolane, ethylene glycol, hexylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, dimethylisosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecyl
  • the penetration enhancer is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature
  • PEG polyethylene glycol
  • polyols, PEGs and solvents possess a high solubilizing power and thus, they can enable increased concentrations of a pharmaceutical active agent.
  • Polyols, PEGs and solvents are also known for their skin penetration enhancement properties. These properties enable high drug bioavailability in the target area of treatment, resulting in an enhanced therapeutic effect.
  • combinations of a polyol, PEGs and a secondary solvent exhibit an increased permeability across the skin, as suggested, for example, in Eur. J. Pharm. Biopharm. 1998 Nov. 46(3):265-71.
  • the foamable carrier contains (1 ) at least one solvent, selected from a polyol (selected from a diol and a triol) and PEG; and (2) at least one secondary solvent.
  • the foamable carrier contains (1 ) a mixture of at least two polyols; and (2) at least one secondary solvent.
  • the foamable carrier contains a mixture of at least one polyol and at least one PEG; yet in other embodiments the foamable carrier contains (1 ) a mixture of at least one polyol and at least one PEG and (2) at least one secondary solvent.
  • the ratio between the polyol and/or PEG and the secondary solvent is between 9:1 and 1 :1.
  • the polyol is selected from the group consisting of propylene glycol, hexylene glycol and glycerin (and mixtures thereof); and the secondary solvent is selected from the group consisting of dimethyl isosorbide, diethylene glycol monoethyl ether, a liquid polyethylene glycol and glycofurol.
  • the foamable carrier contains (1 ) at least one polyol; and (2) dimethyl isosorbide.
  • the foamable composition includes a potent solvent, in addition to, or in place, of one of the hydrophobic solvents, polar solvents or emollients of the composition.
  • a potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum.
  • a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent; or even solubilizes the active agent 10-fold better than a hydrocarbon solvent.
  • the composition includes at least one active agent in a therapeutically effective concentration; and at least one potent solvent in a sufficient amount to substantially solubilize the at least one active agent in the composition.
  • substantially soluble means that at least 95% of the active agent has been solubilized, i.e., 5% or less of the active agent is present in a solid state.
  • the concentration of the at least one potent solvent is more than about 40% of the at least one solvent of the composition of the present invention; or even more than about 60%.
  • Non-limiting examples of pairs of active agent and potent solvent include: Betamethasone valerate: Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1 % in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1 % in glycofurol; Metronidazole: Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1 % in dimethyl isosrbide; Ketoconazole: Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1 % in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1 % in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent: Practical
  • a non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butaneediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol) and laurocapram .
  • a potent solvent in a foam composition provides an improved method of delivering poorly soluble therapeutic agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment. Foam compositions of the present invention, for which the solvent includes a potent solvent, increase the levels of the active agent in solution and thus, provide high delivery and improved therapy.
  • Potent solvents are usually liquid. Formulations comprising potent solvents and active agents are generally disadvantageous as therapeutics, since their usage involves unwanted dripping and inconvenient method of application; resulting in inadequate dosing. Surprisingly, the foams of the present invention, which are drip- free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing.
  • the foamable pharmaceutical composition may additionally include a mixture of two or more of the solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art.
  • the PPG alkyl ether may act as a potent solvent.
  • the composition further contains a surface-active agent.
  • Surface-active agents include any agent linking oil and water in the composition, in the form of emulsion.
  • a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
  • Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions.
  • the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
  • a single surfactant may suffice.
  • a combination of two or more surfactants is desired.
  • Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants can be significant in producing breakable forms of good quality.
  • the composition contains a single surface active agent having an HLB value between about 2 and 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9.
  • the composition contains a single surface active agent having an HLB value between about 7 and 14, (preferably about 7 to about 12) or more than one surface active agent and the weighted average of their HLB values is between about 7 and about 14 (preferably about 7 to about 12).
  • the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
  • HLB values In a waterless or substantially waterless environment a wide range of HLB values may be suitable.
  • the composition contains a non-ionic surfactant.
  • non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21 , brij 721 , brij 38, brij 52, brij 56 and brij W1 , a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglycer
  • the surfactant is an ether for example polyoxyethylene (26) glycerol ether.
  • surfactants are selected which can provide a close packed surfactant layer.
  • combinations of at least two surfactants are selected.
  • they should be complex emulgators and more preferably they should both be of a similar molecular type; for example, a pair of ethers, like steareth 2 and steareth 21 , or a pair of esters, for example, PEG-40 stearate and polysorbate 80.
  • the surfactants can be ethers.
  • POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
  • a series of dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable.
  • Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB-4.9); glyceryl monostearate/PEG 100 stearate ( Av
  • HLB-1 1.2 stearate Laureth 4
  • cetomacrogol ether e.g., polyethylene glycol 1000 monocetyl ether
  • Non-limiting examples of preferred surfactants which have a HLB of 4-19 are set out in the Table below:
  • Sepigel 305 Another component of the formulations of the present invention is a compound used in the present invention is Sepigel 305.
  • Sepigel 305 comprises Polyacrylamide and C13-14 lsoparaffin and Laureth-7. It acts as a surfactant and as a thickening and emulsifying agent, and comes in a liquid, very easy to handle form. It requires neither premixing, nor high rate of shear nor neutralisation.
  • Sepigel 305 can be used to emulsify all types of oil phase without heating, producing gel-cream with a rich, silky texture that are easy to apply and rapidly absorbed by the skin.
  • PEG-Fatty Acid Monoester Surfactants such as:
  • PEG-Fatty Acid Diester Surfactants such as:
  • Polyglycerized Fatty Acids such as:
  • PEG-Sorbitan Fatty Acid Esters such as:
  • Polyethylene Glycol Alkyl Ethers such as:
  • the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable formulation or improved foam quality than a single surfactant.
  • the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
  • surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59 / Briji O; Brij 52 / Brij 10; Steareth 2 / Steareth 20; Steareth 2 / Steareth 21 (Brij 72 / Brij 721 ); combinations of polyoxyethylene stearates such as Myrj 52 / Myrj 59; combinations of sucrose esters, such as Surphope 1816 / Surphope 1807; combinations of sorbitan esters, such as Span 20 / Span 80; Span 20 / Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, such as Tween 80 / PEG-40 stearate; methyl glucaso sequistearate; polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121
  • the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21 , PEG 40 stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80.
  • the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21 , ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60
  • the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
  • the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed.
  • the ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1 :8 and 8:1 , or at a ratio of 4:1 to 1 :4.
  • the resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
  • a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1 :8 and 8: 1 , or at a ratio of 4:1 to 1 :4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
  • the surface active agent is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
  • amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect
  • the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals.
  • Surfactants which tend to form liquid crystals may improve the quality of foams.
  • Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
  • the at least one surface active agent is liquid. Moreover for the purposes of formulating with liquid ethers a liquid surfactant is preferred. [0221] In one or more embodiments the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
  • the at least one surface active agent is solid, semi solid or waxy. In a further embodiment they are soluble in oil and in another embodiment have a HLB of less than about 12.
  • the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art.
  • a solid or semi solid emulsifier combination it can also comprise a solid or semi solid emulsifier and a liquid emulsifier.
  • at least one surfactant is a liquid.
  • the surface-active agent includes at least one non-ionic surfactant.
  • Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
  • the composition contains a non-ionic surfactant.
  • the composition includes a mixture of non-ionic surfactants as the sole surface active agent.
  • the foamable composition includes a mixture of at least one non- ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1.
  • the non-ionic to ionic surfactant ratio is greater than about 6:1 , or greater than about 8:1 ; or greater than about 14:1 , or greater than about 16:1 , or greater than about 20:1.
  • surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1 :1 and 20:1.
  • a combination of a non-ionic surfactant and an ionic surfactant is employed, at a ratio of between 1 :1 and 20:1 , or at a ratio of 4:1 to 10:1 ; for example, about 1 :1 , about 4:1 , about 8:1 , about 12:1 , about 16:1 and about 20: 1 or at a ratio of 4: 1 to 10: 1 , for example, about 4:1 , about 6:1 , about 8:1 and about 10:1.
  • the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. Subject to its miscibility, solid surfactants may be added first, and may require gentle warming and then cooling before being combined with the other ingredients. In general terms, as the amount of non-liquid surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation can become non shakable and unsuitable. Thus in one embodiment, any effective amount of surfactant may be used provided the formulation remains shakable.
  • the upper limit for foamable formulations may be determined by flowability such that any effective amount can be used provided the formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam. This may be due without being bound by any theory to one or more of a number of factors such as the viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition. [0229] In certain embodiments the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%. or between about 0.05% to about 10%. In a preferred embodiment the concentration of surface active agent is between about 0.2% and about 8%.
  • the concentration of surface active agent is between about 1 % and about 6% or between about 1 % and about 4%.
  • the surface active agent does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surface active agents.
  • POE polyoxyethylene
  • the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surface active agents are employed.
  • POE - free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
  • sorbitan esters such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorb
  • a humectant is a substance that helps retain moisture and also prevents rapid evaporation.
  • Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin.
  • Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
  • a moisturizer is a substance that helps retain moisture or add back moisture to the skin.
  • examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA.
  • Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
  • Pharmaceutical compositions of the present invention may in one or more embodiments usefully comprise in addition a heumectant or a moisturizer or combinations thereof.
  • modulating agent is used to describe an agent which can improve the stability of or stabilize a carrier or a foamable composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition.
  • the substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or substantially non aqueous environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or substantially non aqueous environment or it may be an ionisation agent or it may be an oxidizing agent.
  • the modulating agent is used in a waterless composition.
  • the modulating agent is used to describe an agent which can affect pH in an aqueous solution.
  • the agent can be any of the known buffering systems used in pharmaceutical or cosmetic formulations as would be appreciated by a man of the art. It can also be an organic acid, a carboxylic acid, a fatty acid an amino acid, an aromatic acid, an alpha or beta hydroxyl acid an organic base or a nitrogen containing compound.
  • the modulating agent is used to describe an agent, which is a chelating or sequestering or complexing agent that is sufficiently soluble or functional in the waterless solvent to enable it to "mop up" or "lock” metal ions.
  • modulating agent is used to describe an agent which can effect pH in an aqueous solution
  • modulating agent more particularly means an acid or base or buffer system or combinations thereof, which is introduced into or is present in and acts to modulate the ionic or polar characteristics and any acidity or basisity balance of a waterless or substantially non aqueous carrier, composition, foamable carrier or foamable composition or resultant foam described herein.
  • the terms pH, pKa, and pKb, buffers such measurements and terms are artificial in a waterless environment.
  • sufficient modulating agent is added to achieve an artificial pH in which the active agent is preferably stable. Such artificial pH may be acidic, maybe basic or may be neutral.
  • the modulating or additional component is a pH adjusting agent or a buffering agent.
  • the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid ("EDTA”) and salts thereof such as disodium EDTA, tetrasodium EDTA and calsium disodium EDTA; diethylenetriaminepentaacetic acid (“DTPA”) and salts thereof; hydroxyethlethylenediaminetriacetic acid (“HEDTA”) and salts thereof and nitrilotriacetic acid (“NTA”); more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts; citric acid buffers including, but not limited to citric acid and salts of citric acid, such as sodium citrate; an alpha hydroxyl acid; an aliphatic beta hydroxy acid; an aromatic acid; an aliphatic carboxylic acid; a dicarboxylic acid; organic acids (including, but not limited to, ascorbic acid, isoascorbic acid, e
  • EDTA ethylenediaminetetraace
  • a preferred non limiting example of the chelating agent is EDTA.
  • the chelating and sequestering agent is present in the composition at a level of up to about 5.0%, preferably 1.0 percent, by weight, of the composition.
  • Combinations of Modulating Agents may be a useful for example chelating agents may be usefully used in combination with another modulating agent such as an acid, a base or a buffer system or with various combinations of modulating agents.
  • the modulating agent to the foamable composition of the present invention is further useful for adjusting the pH of the target area of application.
  • the modulating agent may also be a preservative or an antioxidant or an ionization agent. Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used. Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol.
  • the modulating agent is a flavonoid.
  • Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected. Ionization agents may for example act to protect or reduce sensitivity of active agents.
  • Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride.
  • Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
  • formulations described herein may further contain a modulating agent.
  • the Microsponges are rigid, porous and spongelike round microscopic particles of cross-linked polymer beads (e.g., polystyrene or copolymers thereof), each defining a substantially noncollapsible pore network.
  • the Microsponges can be loaded with an active ingredient and can provide a controlled time release of the active ingredient to skin or to a mucosal membrane upon application of the formulation. The slow release is intended to reduce irritation by the active.
  • Microsponge® delivery technology was developed by Advanced Polymer Systems.
  • the composition comprises one or more active agents loaded into Microponges with an aqueous carrier or with a waterless carrier described herein which may comprise a modulating agent.
  • propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof.
  • the propellant is1681 , which is a mixture of propane, isobutene and butane.
  • AP 70 which is a mixture of propane, isobutene and butane with a higher pressure.
  • the propellant makes up about 5-25 wt% of the foamable composition. In some circumstances the propellant may be up to 35%.
  • the propellants are used to generate and administer the foamable composition as a foam.
  • the total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable composition.
  • Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons.
  • HFC hydrofluorocarbon
  • Exemplary non-flammable propellants include propellants made by DuPont under the registered trademark Dymel, such as 1 , 1 , 1 ,2 tetrafluorethane (Dymel 134), and 1 , 1 , 1 ,2,3,3,3 heptafluoropropane (Dymel 227) 1 ,1 , difluoro ethane (Dymel 152) and 1 ,1 ,1 ,3,3,3 hexafluoropropane HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
  • Dymel such as 1 , 1 , 1 ,2 tetrafluorethane (Dymel 134), and 1 , 1 , 1 ,2,3,3,3 heptafluoropropane (Dymel 227) 1 ,1 , difluoro ethane (Dymel 152) and 1 ,1 ,1 ,3,3,3 hexa
  • the non inflammbale propellants are used in combination with the more traditional hydrocarbon propellants.
  • Dymel is used in such levels that the sensation effect is not primarily due to the propellant.
  • the stability of foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
  • foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
  • a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
  • Some propellants may have a cooling effect.
  • the evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
  • the sensation is mild and in other cases the propellant can actually produce physical cooling on the skin surface.
  • such cooling effect may increase relative to the ability of the formulation to deliver increasing levels of propellant in contact with the skin.
  • Dimethyl ether is a product which evaporates very rapidly to produce a cooling effect and in one or more embodiments is used as part of the propellant system.
  • the propellant is a mixture of propane, butane and isobutene.
  • the propellant is a mixture of propane, butane and isobutene together with dimethyl ether.
  • the propellant makes up about 5-25 wt% of the foamable composition.
  • the amount of propellant can be increased to up to less than half of the composition, for example, where it is desired to produce a cooling effect in addition to a cooling sensation or where it is sought to produce an initial cooling effect followed by a cooling or other sensation .
  • Additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin or derivative thereof.
  • the additional component is one or more of a colored active agent, a colored excipient, a pigment, a dye, a colorant and a coloring agent.
  • the additional component is a fragrance or fragrance masking agent
  • Sensation or sensation modifying agent Sensation or sensation modifying agent
  • the sensation modifying agent is selected from a cooling agent, a warming agent a relaxing or soothing agent; a stimulating agent; a refreshing agent; or mixtures thereof.
  • two or more soothing, relaxing, cooling, stimulating, refreshing, and warming agents may be effectively combined in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
  • cooling agents substances, which are known to provide a "cool" sensation or cooling effect on or following application to a body surface; and substances that, on or following topical application can ameliorate a hot sensation or a heating effect are called “cooling agents”. Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a cooling sensation or effect or to ameliorate a hot sensation or heating effect, is suitable for use a cooling agent in accordance with the present invention.
  • the cooling agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or a propellant or combinations of two or more agents.
  • the cooling agent has a further sensation or sensation modifying feeling or effect.
  • the cooling agent is menthol.
  • the cooling agent is an isomer or a derivative of menthol, as exemplifies in the following schemes:
  • menthol derivatives are monomenthyl esters of di- and polycarboxylic acids:
  • menthol ethylene glycol carbonate which is now known as Frescolat® type MGC, enthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®).
  • Cooling Agent 10 3-(/-Menthoxy)-1 ,2-propanediol, known as Cooling Agent 10; and the same structure with an additional methyl group in the glycerin part of the molecule:
  • Cooling Agent 10 /-Menthoxy-2-methyl 1 ,2-propanediol
  • Menthoxy-coolants are additional cooling menthol derivatives:
  • Cubebol is an example of a coolant with a C-C bond in the 3d position of p- menthane.
  • Cooling agents which are not menthol derivatives, are also suitable for use in accordance with the present invention. Examples of such cooling agents are provided below:
  • Exemplary cooling agents which can be used in the invention include, but are not limited to, menthol, isopulegol, 3-(l-menthoxy)propane-1 ,2-diol, 3-(l-menthoxy)-2- methylpropane-1 ,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl- 1 ,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl ⁇ -isopropyl- ⁇ -methylcyclohexanecarb- oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(l-menthoxy)ethan-1-ol
  • the cooling agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a cooling sensation or cooling effect upon application of the cooling foamable composition onto a body surface.
  • the cooling agent also possesses therapeutic properties.
  • menthol is being used in the therapy of psoriasis; relief of nasal complaints and sore throats; and WS-3 (N-Ethyl-p-menthane-3-carboxamide) and related N- substituted p-menthane carboxamides, as well as p-Menthane-3,8-diols are known insect repellents
  • warming agents substances, which are known to provide a warming sensation or warming effect on or following application to a body surface; and substances that, upon or following topical application can ameliorate a cold sensation or a cooling effect are called "warming agents". Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a warming sensation or warming effect or to ameliorate a cold sensation or cooling effect, is suitable for use a warming agent in accordance with the present invention.
  • the warming agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or combinations of two or more agents.
  • Exemplary substances which are known to provide a sensation of warmth on application and called “warming agents”, include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives (JP-A-57-9729), such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin
  • the warming agent also possesses therapeutic properties.
  • capsicum powder, capsicum tincture and extract, as well as capsaicin and homocapsaicin are used for topically treating muscle and joint pain.
  • Combination of a cooling agent and a warming agent are used for topically treating muscle and joint pain.
  • the sensation effect or sensation induced by a first sensation or sensation modifying agent maybe reduced by addition of a second sensation or sensation modifying agent in the composition.
  • the cooling sensation of a cooling formulation may be reduced by the presence of a warming or warming modifying agent.
  • the warming sensation of a warming formulation may be reduced by the presence of a cooling or cooling modifying agent.
  • the composition comprises an effective amount of cooling peppermint oil and a lesser effective amount of capsaicin warming agent such that the cooling sensation is the predominant sensation.
  • the composition comprises an effective amount capsaicin of and a lesser effective amount of peppermint oil cooling agent such that the warming sensation is the predominant sensation.
  • the cooling and warming agents are selected so that the cooling and warming effects or sensations are staggered.
  • the composition comprises an effective amount capsaicin of and an effective amount of dimethyl ether cooling agent such that the cooling sensation is the initial predominant sensation and the warming sensation follows on as the subsequent predominant sensation.
  • Other cooling and warming agents may be effectively combined as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
  • agents which have a soothing effect there are many different categories of agents which have a soothing effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other soothing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
  • Non limiting examples of soothing agents are herb extracts, such as, aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, such as, almond oil, avocado oil, and comfrey; and essential oils, such as, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances such as lanolin or vaselline jelly, minerals, such as, zinc oxide, calamine and selenium; vitamins, such as, tocopheryl acetate (vitamin E), and drugs, such as, analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, muscle relaxants and the like.
  • herb extracts such as, aloe vera, al
  • menthol camphor
  • eugenol eucalyptol
  • safrol methyl salicylate
  • menthyl lactate menthyl ethoxyacetate
  • menthone glycerinacetal 3-l-menthoxypropane-1 ,2-diol, ethyl l-menthyl carbonate
  • (1 S,3S,4R)-p- menth-8-en-3-ol menthyl pyrrolidone carboxylate
  • N-substituted-p-menthane-3- carboxamides as described in U.S. Pat. No.
  • the composition comprises an effective amount of soothing hamamelis and a lesser effective amount of frescolate cooling agent such that the soothing sensation is the predominant sensation.
  • the composition comprises an effective amount capsaicin of and a lesser effective amount of hamamelis soothing agent such that the warming sensation is the predominant sensation.
  • the soothing and warming agents are selected so that the soothing and warming effects or sensations are staggered or partially overlapping.
  • the soothing and cooling agents are selected so that the soothing and cooling effects or sensations are staggered or partially overlapping.
  • agents which have a stimulating or refreshing sensation or effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other stimulating or refreshing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
  • Non limiting examples are alcohols, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate .acetyl choline, serotonin, histamine , prostaglandins, other neurotransmitters; CNS stimulants; caffeine, quinine, and the like might be suitable stimulants in dosages or delivery systems where they essentially or primarily have a local or topical as opposed to systemic effect.
  • Ginger is said to have several pharmacological activities, including anti-emetic, antithrombotic, antimicrobial, anticancer, antioxidant and anti-inflammatory properties. Also, ginger has been reported to have hypoglycaemic, hypo- and hypertensive, cardiac, prostaglandin and platelet aggregation inhibition, antihypercholesterolaemic, cholagogic and stomachic properties. Ginger has carminative properties and has also been tried for the prophylaxis of motion sickness and nausea and vomiting in pregnancy. In vitro studies have demonstrated that constituents of ginger, such as 6-, 8- and 10-gingerols and galanolactone, have antiserotonergic activity. Ginger oil is used in aromatherapy.
  • capsaicinoids are principally responsible for the biological activity of capsicum. These pungent principles are thought to stimulate and aid digestion and to act as a counter-irritant when applied externally. Capsaicin has also been used as a neurochemical tool for studying sensory neurotransmission. Topical creams containing capsaicin 0.025% and 0.075% are used for symptomatic relief of osteoarthritis, and postherpetic neuralgia, respectively. Capsicum oleoresin and capsaicin are ingredients of a number of over-the-counter topical preparations for relief of pain in muscle, tendon and joints. Capsaicin has effects on nervous, cardiovascular, respiratory, thermoregulatory and gastrointestinal systems. Capsaicin has been used as a neurochemical tool for studying sensory neurotransmission.
  • Witch hazel is characterized by its tannin constituents and astringent properties. It is also said to have haemostatic properties. The documented herbal uses are related to these astringent properties. It has been used topically in the treatment of haemorrhoids, eczema and dermatitis. Vasoconstriction was reduced in the hindquarters of rabbits. A fraction of an aqueous ethanolic bark extract was significantly active against herpes simplex virus type 1 (HSV-1 ). Topical applications of a hydroglycolic extract of witch hazel leaf reduced skin temperature perhaps due to a vasoconstrictor effect. After- sun lotion containing 10% hamamelis was reported to have suppressed erythema.
  • Peppermint oil is an aromatic carminative that relaxes gastrointestinal smooth muscle and relieves flatulence and colic. Peppermint oil is also used with other volatile agents in preparations for respiratory-tract disorders. It is also used in aromatherapy.
  • Menthol is chiefly used to relieve symptoms of bronchitis, sinusitis, and similar conditions. For this purpose it may be used as an inhalation, usually with benzoin or eucalyptus oil, as pastilles, or as an ointment with camphor and eucalyptus oil for application to the chest or. When applied to the skin menthol dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect. It relieves itching and is used in creams, lotions, or ointments in pruritus and urticaria. It has also been applied to the forehead, presumably as a counter-irritant, for the relief of headache. Menthol has a carminative action. (Sources: Matindale and Herbal Extracts Electronic Edition 2008)
  • the foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients.
  • active pharmaceutical ingredients and active cosmetic ingredients are collectively termed “additional active agent” or “additional active agents”.
  • Suitable additional active agents include but are not limited to active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antibum agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, antiyeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids,
  • foamable composition is suitable for treating any inflicted surface.
  • foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein "target site").
  • target site e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum
  • target site e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum
  • a sensation modifying foamable composition can be used in any condition that can benefit from the modification of a cold or warm sensation, and in any condition that can benefit from stabilizing a cold or warm sensation, by applying a cooling or a warming foam on the target site.
  • Examples of uses of a cooling foam composition include:
  • Examples of uses of a warming foam composition include:
  • the foamable composition is useful in treating an animal or a human patient having any one of a variety of dermatological disorders, including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, ery
  • the foamable composition is suitable for treating a disorder of a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum.
  • a disorder of a body cavity or mucosal surface e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum.
  • Non limiting examples of such conditions include chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders,
  • the composition is useful for the treatment of an infection.
  • the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
  • the composition is useful for the treatment of wound, ulcer and burn.
  • the composition is also suitable for administering a hormone to the skin or to a mucosal membrane or to a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
  • compositions and carriers comprise one or more higher alcohols. These generally exclude “lower alcohols”.
  • the fatty alcohols are typically liquid at ambient temperature.
  • Fatty alcohols may defined as follows:
  • the fatty alcohols hereof have a melting point of 30° C. or less, preferably about 25° C. or less, more preferably about 22° C. or less.
  • the unsaturated fatty alcohols hereof are also nonvolatile.
  • nonvolatile what is meant is they have a boiling point at 1.0 atmospheres of at least about 260° C, preferably at least about 275° C, more preferably at least about 300° C.
  • Suitable fatty alcohols include unsaturated monohydric straight chain fatty alcohols, saturated branched chain fatty alcohols, saturated C8 -C12 straight chain fatty alcohols, and mixtures thereof.
  • the unsaturated straight chain fatty alcohols will typically have one degree of unsaturation.
  • Di- and tri- unsaturated alkenyl chains may be present at low levels, preferably less than about 5% by total weight of the unsaturated straight chain fatty alcohol, more preferably less than about 2%, most preferably less than about
  • the unsaturated straight chain fatty alcohols will have an aliphatic chain size of from C12 -C22, more preferably from C12 -C18, most preferably from C16 -
  • Especially preferred alcohols of this type include oleyl alcohol and palmitoleic alcohol.
  • the branched chain alcohols will typically have aliphatic chain sizes of from
  • Exemplary branched chain alcohols for use herein include isostearyl alcohol, octyl dodecanol, and octyl decanol.
  • saturated C8 -C12 straight chain alcohols include octyl alcohol, caprylic alcohol, decyl alcohol, and lauryl alcohol.
  • the higher alcohols may be selected from straight chain fatty alcohols, having 6 or more carbon atoms, which are liquid at ambient temperature, such as, but not limited to Hexanol, Octanol, Nonanol,
  • Decanol branched alcohols, such as: 2 Octanol (Capryl Alcohol), Undecanol (Undecyl
  • Octyl Decanol 2 Hexyl Dodecanol, Isostearyl Alcohol , Isooctadecanol, lsooleyl Alcohol
  • lsoarachidyl Alcohol 2 Decyl Tetradecanol, lsolignoceryl Alcohol, 2 Decyl Tetradecanol , 2 Tetradecyl Octadecanol, 2 Tetradecyl Eicosanol, 2 Hexadecyl Octadecanol , 2 Hexadecyl Eicosanol; additionally unsaturated alcohols, such as Erucyl Alcohol, Linoleyl Alcohol, oleyl alcohol may be employed.
  • the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols.
  • Short chain alcohols having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or solvents due to their skin-irritating effect.
  • the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1 %.
  • any of the active ingredients; the solvents; the surfactants; foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants; moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
  • the formulas of the present invention may be made in the following general way with appropriate adjustments for each formulation as will be appreciated by someone skilled in the art.
  • Polymers if any, are mixed, swelled and solubilized in the waterless medium, when necessary, with appropriate heat until it forms a clear solution.
  • Stabilizing surfactants added usually with heat, until a homogeneous mixture is obtained, the mixture is then allowed to cool.
  • the remainder of the ingredients are then added with mixing until they have dissolved in the medium.
  • the active agent is usually added at the end once the modulating agent, if present, has been incorporated.
  • the canisters are then filled with the above waterless formula, sealed and crimped with a valve and pressurized with the propellant.
  • a pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
  • the foamable composition of the present invention is stable, having an acceptable shelf-life of at least one year, or preferably, at least two years at ambient temperature, as revealed in accelerated stability tests or aging tests.
  • a product may satisfy stability tests if upon light shaking a homogenous formulation is restored and remains stable until well after dispensing.
  • Organic carriers and propellants tend to impair the stability of emulsions and to interfere with the formation of stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
  • composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
  • Foam quality can be graded as follows:
  • Grade E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
  • Grade G (good): rich and creamy in appearance, very small bubble size, "dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
  • Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
  • Grade F very little creaminess noticeable, larger bubble structure than a "fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
  • Grade P no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
  • Grade VP dry foam, large very dull bubbles, difficult to spread on the skin.
  • Topically administrable foams are typically of quality grade E or G, or occasionally FG, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
  • a "stable foam” is defined herein as a composition, which upon release from an aerosol can, creates a foam mass, which is sustained on a surface for at least one minute, more preferably at least two minutes, and yet more preferably for at least 5 minutes.
  • a period of minutes is regarded as a short term, but nevertheless it allows a good and more than sufficient period of time for a subject to receive foam dispensed on a body surface and to spread it or to transfer it to another region and to spread it.
  • Foam texture should vary from a very fine creamy foam to a fine bubble structure.
  • Foam has to have specific gravity in the range of about 0.02 gr/mL to about
  • an acceptable foam is one, that does not readily collapse upon dispensing on the skin; spreads easily on a skin surface; at least partially absorbed following rubbing onto the skin, and more preferably, substantially absorbed following rubbing on the skin.
  • an acceptable foam is one, that: creates a pleasant feeling after application; leaves minimal oily residue; and leaves minimal shiny residual look.
  • 'Shakability means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases it may still be possible to have a foamable composition which is flowable but not apparently shakable.
  • a breakable foam is thermally stable or substantially so, yet breaks under sheer force.
  • the breakable foam of the present invention is not "quick breaking", i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
  • a further aspect of the foam is breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
  • the foam of the present invention has several notable advantages, when compared with hydroalcoholic foam compositions, such as Breakability.
  • the foam of the present invention is thermally stable and breakable under sheer force but is not "quick breaking which allows comfortable application and well directed administration to the target area.
  • foams Another property of the foam is specific gravity, as measured upon release from the aerosol can.
  • foams typically have specific gravity of less than 0.12 g/mL; or less than 0.10 g/mL; or less than 0.08 g/mL, depending on their composition and on the propellant concentration.
  • formulations are expressed in amounts up to 100% including the propellant. In other cases the formulations are expressed in amounts up to
  • the sensation or sensation modifying topical compositions can be prepared according to the general methodology set out below with appropriate changes as would be well appreciated by a man of the art.
  • Emulsion Foam
  • the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid.
  • the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping. Canisters Filling and Crimping
  • Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine.
  • the process of applying a vacuum will cause most of the oxygen present to be eliminated.
  • Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient.
  • Pressurizing is carried out using a hydrocarbon gas or gas mixture. Canisters are filled and then warmed for 30 sec in a warm bath at 50oC and well shaken immediately thereafter. Closure Integrity Test.
  • Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 60 0 C water bath for 2 minutes. Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
  • LFRA100 instrument is used to characterize hardness.
  • a probe is inserted into the test material.
  • the resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display.
  • Preferably at least three repeat tests are made.
  • the textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
  • Collapse time is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36°C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
  • Viscosity is measured with Brookfield LVDV-II + PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10RPM. However, at about the apparent upper limit for the spindle of ⁇ >50,000CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
  • the amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter.
  • the canisters are stored in controlled temperature incubators at 5°C, at 25°C, at, 40 0 C and at 50°C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
  • the centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion.
  • Foams are made of gas bubbles entrapped in liquid.
  • the bubble size and distribution reflects in the visual texture and smoothness of the foam.
  • Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software.
  • the camera used was a Nikon D40X Camera (resolution 10MP) equipped with Sigma Macro Lens (ref: APO MACRO 150mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels x 400 pixels.
  • compositions of the present invention were separately applied to clean skin of a group of human subjects. After 5 minutes tested subjects were asked to provide a gauge of their satisfaction relating to the following parameters: Ease of application, skin absorption, stickiness, odor, oily residue, skin surface shiny appearance, composition stability; overall satisfaction; sensation change, such as cooling, relaxing, heating etc. The subjects gauged their response according to the following scoring system:
  • Prolonged period of time or “sustained period of time” or “substantial period of time” (used interchangeably herein), is meant a period of time of about five or more minutes, more typically, at least 15 minutes in which the subject senses a sensation pertaining to a sensation agent applied to a target or delivery site on/in the subject.
  • thermometer Place a thermometer in a clean glass vial and allow it to come to equilibrium.
  • a main aim is to deliver a sensation via a foam vehicle, where the prime sensation is due to pharmaceutical stimulation rather than an actual physical effect.
  • the sensation may be a combination of pharmaceutical stimulation and physical effect.
  • an excess of propellant may provide an initial physical cooling and the sensation agent provides a prolonged sensation, without further cooling.
  • the vehicles disclosed herein are adapted to provide the main sensation with or without an initial physical cooling sensation.
  • Example 1- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and avocado Oil a) Formulation
  • Emollient + avocado oil +10% menthol crystals Mean cooling effect on three subjects over time is 12.7
  • Emollient emulsion foam provided a reasonable and prolonged cooling sensation; excellent foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents.
  • the co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
  • the propellant can be added at a concentration of about 3% to about 25% or more.
  • Example 2- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil and 15% Ethanol a) Emollient +10% menthol crystals +15% ethanol: Formulation
  • Emollient + avocado oil +10% menthol crystals + 15% ethanol Mean cooling effect on four subjects over time is 13.34
  • Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, water phase, surfactant combination supported by co emulsifiers and a combination of polymeric agents plus a polar solvent as a penetration enhancer. Menthol in the above formulation achieves good penetration on its own so the presence of 15% ethanol is of only marginal effect. Ethanol is not essential and may be omitted or replaced by other penetrating agents such as transcutol; DMI; and the like. See section on penetration agents. Note: The propellant can be added at a concentration of about 3% to about 25% or more.
  • Emollient +15% menthol crystals Mean cooling effect on four subjects over time is 13.88
  • Emollient foam provided excellent and prolonged cooling sensation; good foam quality; moisturizing.
  • the propylene glycol is non essential.
  • the propellant can be added at a concentration of about 3% to about 25% or more.
  • Emollient +15% peppermint oil Mean cooling effect on four subjects over time is 11.75
  • Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents.
  • the propylene glycol is non-essential.
  • the peppermint oil reduces the viscosity of the emulsion and is matrix destabilizing.
  • the propellant can be added at a concentration of about 3% to about 25% or more.
  • Emollient +25% propellant + Menthol crystals Mean cooling effect on four subjects over time
  • the propellant can be added at a concentration of about 3% to about 25% or more.
  • Example 7 Waterless Foamable Composition with 10% Peppermint Oil (Formula number - 32) a) Formulation
  • Example 8 Emollient Emulsion Foamable Relaxing or Soothing Composition with Hamamelis
  • Emollient foam capable of providing a soothing sensation; excellent foam quality; moisturizing. It comprises an oil phase, water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents, plus a preservative and a chelating agent.
  • the chelating agent is non essential.
  • the co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
  • the propellant can be added at a concentration of about 3% to about 25% or more.
  • methyl salicylate is an analgesic and counter irritant. Lists of applicable warming agents are described in the specification. An effective amount of the warming agent is introduced into the formulation in place of capsaicin and the amount of the main carrier is adjusted to bring the formulation to 100%, which in the case of the waterless composition is propylene glycol and in the case of the emollient emulsion composition is water. The amount of methyl salicylate is of the order of 5 to 10%.
  • capsaicin with methyl salicylate, for example, may be useful.
  • Methyl salicylate has a quick onset whilst capsaicin does not so a combination may be helpful in cases where pain relief is sought.
  • the warming effect or sensation maybe reduced by addition of a cooling agent in the composition.
  • the formulations may contain polar solvents, which contribute to skin penetration of an active agent
  • Example 12 Fluorescence In Water Emulsion Foamable Compositions, Containing Menthol As Cooling Agent And Coal Tar Extract And Salicylic Acid As Additional Therapeutic Agents
  • This waterless single phase formulation provides a stable vehicle for peppermint oil that can generate good quality foam and which can withstand 3000rpm.
  • the surfactants and a polymeric agent provide viscosity support and aid foaming. On forming foam there is no significant temperature change when measured on a glass surface.
  • the peppermint oil provides a sensation of cooling, which may be potentiated by the evaporation of propellant and the lower temperature of the foam compared to the skin.
  • Formulation 5 is a single phase composition that provides a stable vehicle for menthol crystals that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes.
  • the surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming.
  • the other two formulations 6 and 7 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. All the formulations can accommodate substantial amounts of cooling sensation agent.
  • the cooling agent is a combination of at least two cooling agents.
  • the cooling agent may be used in combination with a soothing agent.
  • the coal tar formulation is yellow prior to addition of the propellant but upon discharge from the canister and release as a foam the color is dissipated such that the foam is only slightly yellow, which may be an advantage for its use. Warming
  • Example 14 A waterless PG formulation and two oil in water emulsion formulations containing capsaicin as warming agent
  • Formulation 3 is a waterless single phase composition that provides a stable vehicle for capsaicin that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes.
  • the surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming.
  • the other two formulations 1 and 2 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the capsaicin should provide a sensation of warming.
  • the warming agent is a combination of at least two warming agents. In a further embodiment the warming agent may be used in combination with a soothing agent.
  • These water gel formulations are single phase compositions that provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 1.5 minutes.
  • the aloe vera should provide a sensation of soothing.
  • the soothing agent is a combination of at least two soothing agents.
  • the soothing agent may be used in combination with a cooling agent or with a warming agent.
  • emollient emulsion formulations provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 5 minutes and is stable to centrifugation.
  • the aloe vera should provide a sensation of soothing.
  • the soothing agent is a combination of at least two soothing agents.
  • the soothing agent may be used in combination with a cooling agent or with a warming agent.

Abstract

This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to a composition that provides to a subject at least one sensation for a sustained period of time following application to the skin. The composition includes (a) at least one sensation or sensation modifying agent, comprising one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent; (b) a foamable carrier; and (c) a propellant having a concentration about 3% to about 45% by weight of the total composition. The composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.

Description

SENSATION MODIFYING TOPICAL COMPOSITION FOAM
BACKGROUND
[0001] Compositions of various types have incorporated within them components or agents which provide a sensation to mucosal membranes and/or to skin. The sensation may be a warming, cooling, relaxation stimulation or refreshing feeling or a combination of two or more feelings. The sensation or feeling may be real or artificial. [0002] Compositions which include a sensation agent include, inter alia, toothpastes, mouthwashes, perfumes, lotions, shaving cream, shampoos, antiperspirants, deodorants, beverages, chewing gum, tobacco products, and pharmaceutical products. [0003] Most compositions known to date, comprising one or more sensation agents, cannot retain the sensation at the site of application thereof in a subject over extended periods of time. Typically, topical formulations do not retain the sensational effect for more than a few seconds. Additionally, the sensation agent may be volatile, such as menthol, used for providing a topical cooling effect, and the formulation may not retain the active agent for more than a few seconds.
[0004] The mechanism of cooling and warming sensation or sensation modification for example is poorly understood at present. It has been suggested that, among other options, the action of menthol and other cooling agents and capsaicin, camphor and other heat compounds occurs via "thermoreceptors" that register "cool" and "hot" sensation, respectively. It has been suggested that the 'cooling' effect of menthol is a physiological effect due to the direct action of menthol on the nerve endings of the human body responsible for the detection of hot or cold and is not due to latent heat of evaporation such that menthol acts as a direct stimulus on the cold receptors at the nerve endings which, in turn, stimulate the central nervous system.
[0005] Substances which are known to provide a sensation of warmth or warmth modulation on application and are called "warming agents" include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol, and gingeron. [0006] Foams are considered a more convenient vehicle for topical delivery of active agents. There are several types of topical foams, including aqueous foams, such as commonly available shaving foams; hydroalcoholic foams, emulsion-based foams, comprising oil and water components and oleaginous foams, which consist of high oil content, and which are foamable compositions having a specific surfactant selected from the group consisting of ethoxylated lanolin oil, propoxylated lanolin oil, and mixtures thereof and high levels of water that produce fast breaking foams that disappears rapidly into the skin with cooling sensation is described. Some formulations make a sound or crackling effect when foam is dispensed. Dimethyl ether is a substance which evaporates very rapidly and its use with an aqueous non emollient gel composition, lotion composition and a solution in producing a cooling effect (as opposed to mere sensation without cooling). High levels of propellant have also been used to provide a solid or semi ointment deposit with a temperature between minus to plus 50C.
[0007] Foam forming refrigerant compositions, suitable for emergency treatment of burns have also been described.
[0008] Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam. There is, therefore, a need for a foam composition, which provides desirable properties to the skin and can remain stable whilst accommodating a variety of sensation agents or active ingredients.
[0009] Formulations based on oil or ointment or emollients have a number of useful attributes making them suitable candidates for topical pharmaceutical and cosmetic compositions including foamable compositions. They are inherently stable and inert which are clearly desirable characteristics. They are able to moisturize and soften the skin and in appropriate amounts can act as a protective or barrier layer and can form a barrier to water. By appropriate formulation they can act to improve agent delivery to the skin and yet remain resistant to being washed off. On the other hand they are by their nature greasy materials and can be difficult to formulate particularly into a topical foamable composition that can deliver substantially uniform and stable composition or foam that ameliorates or overcomes the look and feel of a greasy material, especially where that composition is waterless or substantially so. It is further a problem to incorporate into such a vehicle, effective amounts of one or more active sensation and/or pharmaceutical ingredients such that they are uniformly present throughout the formulation and are effectively delivered without the use of a lower alcohol in the formulation. [0010] On one level it is far from simple or obvious to produce waterless foamable compositions that when released produce foams of quality suitable for sensation, pharmaceutical or cosmetic application. On a further level having realized a carrier that will produce a waterless foam of quality there is an additional difficulty to be overcome, namely how to adapt the formula and achieve a formulation, which can accept a range of various active sensation, pharmaceutical and cosmetic agents such that the composition and active agent are stable and the foam produced remains of quality. Specifically, one of the challenges in preparing such waterless or substantially waterless foamable compositions is ensuring that the one or more active sensation, pharmaceutical or therapeutic agents does not react, isomerize or otherwise break down to any significant extent during is storage and use. Particularly, there remains an unmet need for improved, easy to use, stable and non-irritating foam formulations, with unique sensation, therapeutic or beneficial properties containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent.
[0011] There remains an unmet need for improved, easy to use, stable and non- irritating topical foam formulations containing a stable or stabilized active sensation, pharmaceutical or cosmetic agent having a therapeutic or beneficial effect, intended for treatment of dermal and mucosal tissues.
[0012] There is still a need to provide stable aqueous and non-aqueous compositions comprising one or more sensation agents for sustained provision of at least one sensation from the sensation agent(s).
SUMMARY [0013] The application relates to aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. The aqueous vehicles may be emulsion or gel vehicles. The application also relates to non aqueous foamable vehicles capable of delivering one or more sensation agents to a body surface in a breakable foam of quality. Upon contact with the body surface an effective amount of one or more sensory agents are capable of causing a perceived sensory effect.
[0014] In one or more embodiments the formulations are resistant to aging as indicated by their ability to withstand centrifugation. In other embodiments the formulations have a significant and suitable collapse time of 300 or more seconds.
[0015] In one or more embodiments the formulations are considered to be pleasant for use. [0016] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
[0017] There is further provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation over a sustained period of time. The sustained period of time is at least five minutes, more preferably, at least 15 minutes, yet more preferably, at least 30 minutes, still more preferably, at least one hour. According to some embodiments the sensation may be felt for up to two hours or more.
[0018] There is further provided a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
[0019] There is provided a stable foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
[0020] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
[0021] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
[0022] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non aqueous carrier.
[0023] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier. [0024] This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical and cosmetic compositions, containing an active agent, having a sensation or sensation modifying affect on a body surface, upon application.
[0025] There is provided a stable foamable composition that is stable on a surface at the delivery site for at least one minute, more preferably, at least two minutes, yet more preferably, for at least five minutes.
[0026] There is thus provided according to some aspects of the present invention, a composition that provides to a subject at least one sensation for a sustained period of time following application to the skin. The composition includes: a. at least one sensation or sensation modifying agent, including one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent; b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
[0027] According to some embodiments, the sensation effect is provided at a delivery site of the subject.
[0028] According to some embodiments, upon contact at a delivery site the sustained sensation is not primarily due to the propellant or an exothermic reaction.
[0029] According to some embodiments, 4 the foamable carrier is resistant to aging and/or suitable for delivery of at least one sensation or sensation modifying agent.
[0030] According to some embodiments, the relaxing or soothing agent includes a herb extract, an astringent, a sea weed extract, an oat extract; an oil, a waxy or unctuous substance, a mineral, a vitamin, a pharmaceutical agent, menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-l-menthoxypropane-1 ,2-diol, ethyl l-menthyl carbonate, (1 S,3S,4R)-p- menth-8-en-3-ol, menthyl pyrrolidone carboxylate, an N-substituted-p-menthane-3- carboxamide, hamamelis extract, ginger oil, or any mixture of two or more thereof.
[0031]
[0032] According to some embodiments, the herb extract comprises one or more of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, and yarrow.
[0033] According to some embodiments, the astringent comprises one or more of calendula, comfrey, and witch hazel. [0034] According to some embodiments, the oil includes one or more of almond oil, avocado oil, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary.
[0035] According to some embodiments, the waxy or unctuous substance includes one or more of lanolin and petrolatum (e.g., vaseline jelly).
[0036] According to some embodiments, the mineral includes one or more of zinc oxide, calamine and selenium.
[0037] According to some embodiments, the vitamin includes tocopheryl acetate.
[0038] According to some embodiments, the pharmaceutical agent includes one or more of an analgesic, an anesthetic, an anti-inflammatory agent, an antihistamine, and a muscle relaxant.
[0039] According to some embodiments, the stimulating or refreshing agent includes an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine, quinine, or any mixture of two or more thereof.
[0040] According to some embodiments, the foamable carrier indues about 40% to about 99% by weight of the total composition, excluding the propellant, and is an aqueous emulsion, an aqueous gel, or a non-aqueous carrier.
[0041] According to some embodiments, the foamable carrier includes: i. at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier; ii. at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and iii. at least one non-aqueous solvent.
[0042] According to some embodiments, the foamable carrier further includes one or more of: i. a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; ii. a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; iii. a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; iv. a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition; v. a foam adjuvant agent, comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1 % to about 25% by weight of the total composition; vi. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and vii. an agent providing an occlusive effect, at a concentration of about 5% to about
30% by weight of the total composition.
[0043] According to some embodiments, the composition further includes at least one additional active agent, which is a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
[0044] According to some embodiments the at least one additional active agent comprises at least one of an active herbal extract, an acaricide, an age spot and keratosis removing agent, an allergen, an analgesic, a local anesthetic, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial, an antibiotic, an antibum agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic, an antihistamine, an antihelminth, an antihyperkeratolytic agent, an antiinflammatory agent, an antiirritant, an antilipemic, an antimicrobial, an antimycotic, an antiproliferative agent, an antioxidant, an anti-wrinkle agent, an antipruritic, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic, an antiswelling agent, an antiviral agent, an anti-yeast agent, an astringent, a topical cardiovascular agent, a chemotherapeutic agent, coal tar or an extract thereof, a corticosteroid, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an insecticide, an insect repellent, a keratolytic agent, a lactam, a metal, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a photodynamic therapy agent, a retinoid, a sanative, a scabicide, a self tanning agent, a skin whitening agent, a vasoconstrictor, a vasodilator, a vitamin, a vitamin derivative, vitamin A or a derivative thereof, vitamin D or a derivative thereof, a wound healing agent, and a wart remover.
[0045] According to some embodiments, the composition further includes an additional component, which is an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, a moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, a vitamin, or a mixture of any two or more thereof. [0046] According to some embodiments, the polymeric agent comprises at least one of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, a cationic guar, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, a polyvinylpyrrolidone, a polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, a polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, a methylcellulose, a hydroxypropyl cellulose, a hydroxypropyl methylcellulose, a hydroxyethyl cellulose, a hydroxypropyl methyl cellulose, a methylhydroxyethylcellulose, a methylhydroxypropylcellulose, a hydroxyethylcarboxymethylcellulose, a carboxymethyl cellulose, a carboxymethylcellulose, a carboxymethylhydroxyethylcellulose, a cationic cellulose, a ployethylene glycol, xanthan gum, a sodium carboxymethylcellulose, microcrystalline- cellulose, aluminum starch octyl succinate, and a polyacrylate.
[0047] According to some embodiments, upon dispensing as a foam, the composition has a density of about 0.01 to about 0.2 g/ml.
[0048] According to some embodiments, the compositions described herein contain a sensation or sensation modifying including at least one of: a combination of a cooling and a warming agent; a combination of a cooling and a soothing or relaxing agent; a combination of a cooling and a stimulating or refreshing agent; a combination of a warming and a stimulating or refreshing agent; a combination of a warming and a soothing or relaxing agent; a combination of a cooling, a warming and a soothing or relaxing agent; and a combination of a cooling, a warming and stimulating or refreshing agent. [0049] According to some embodiments, the compositions described herein contain: a. a sensation or sensation modifying agent including menthol at a concentration of 0.5 to about 3% by weight of the composition; b. at least one additional active agent including: i. coal tar or coal tar extract at a concentration of about 2% to about 20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0.5% to about 10% by weight of the composition. [0050] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation for a sustained period of time. The composition includes: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a silicone oil; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam.
[0051] There is is provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation for a sustained period of time. The composition includes: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a triglyceride; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam.
[0052] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation for a sustained period of time. The composition includes: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a silicone oil and a triglyceride; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the buffering system comprises an EDTA, a citrate buffer, or a mixture thereof. According to some embodiments, the compositions described herein further includes a polymeric agent, a foam adjuvant, or a combination thereof. According to some embodiments, the compositions described herein further includes a penetrating agent, a humectant, or a combination thereof. According to some embodiments, the coal tar or coal tar extract is present in the compositions described herein at a concentration of about 2% to about 20% by weight. According to some embodiments, the surfactant is present in the compositions described herein at a concentration of about 2% to about 8.5% by weight. [0053] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes: a. about 10% by weight of a cooling agent; b. about 81 % to about 83% by weight of a glycol; c. about 6% by weight of one or more surfactants; d. about 1 % by weight of a polymeric agent; and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the cooling agent is peppermint oil or menthol crystals. According to some embodiments, the glycol is propylene glycol. According to some embodiments, the surfactant includes steareth 2, polysorbate 80, glyceryl monostearate, or mixtures thereof. According to some embodiments, the polymeric agent is hydroxypropyl cellulose. According to some embodiments, the composition further includes a foam adjuvant. According to some embodiments, the foam adjuvant is cetostearyl alcohol. [0054] There is further provided according to some embodiments of the present invention, a waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes: a. about 0.03% by weight of a warming agent; b. about 97.97% by weight of a glycol; c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the warming agent is capsaicin. According to some embodiments, the glycol is propylene glycol. According to some embodiments, the surfactant is steareth 2.
[0055] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes: a. about 10% by weight of a warming agent comprising ginger; b. about 81 % to about 85% by weight of water; c. about 4.5% to about 6% by weight of one or more surfactants; d. about 0.6% by weight of a polymeric agent; e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the warming agent includes ginger oil. According to some embodiments the surfactant includes steareth 2, steareth 21 , polysorbate 80, glyceryl monostearate, PEG-40 stearate, or a mixture thereof. According to some embodiments, the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof. According to some embodiments, the foam adjuvant includes cetostearyl alcohol.
[0056] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes: a. about 2% by weight of aloe vera; b. about 90% to about 94% by weight of a polar solvent; c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
According to some embodiments, the composition further includes a propellant at a concentration of about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the polar solvent includes water, diethylene glycol monoethyl ether, or a mixture thereof. According to some embodiments, the surfactant includes polysorbate. According to some embodiments, the polymeric agent includes Avicel RC581.
[0057] There is further provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time. The composition includes: a. about 2% by weight of aloe vera; b. about 77% by weight of a polar solvent; c. about 1 1 % by weight of a hydrophobic carrier; d. about 7% by weight of one or more surfactants; e. about 2% by weight of a foam adjuvant; f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition.
The composition is stored in an aerosol container and upon release expands to form a short term stable foam. According to some embodiments, the surfactant includes steareth 2, steareth 21 , or a mixture thereof. According to some embodiments, the polar solvent includes water. According to some embodiments, the polymeric agent includes xanthan gum, Methocell K100M, or a mixture thereof. According to some embodiments, the foam adjuvant includes cetostearyl alcohol.
[0058] According to some embodiments, the compositions described herein further include a hydrophobic solvent, wherein the combination of the additional hydrophobic solvent and silicone oil, the combination of the additional hydrophobic solvent and triglyceride, or the combination of the additional hydrophobic solvent, silicone oil, and triglyceride, is present in the composition at about 6% to about 22% by weight of the composition.
[0059] There is thus provided according to some embodiments of the present invention, a composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition including: at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; and a stimulating or refreshing agent; or mixtures thereof; a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction.
[0060] According to some embodiments, the composition does not effect a substantial temperature change to the surface.
[0061] According to some further embodiments, the cooling agent is selected from menthol; an isomer of menthol, a menthol derivative; 4-Methyl-3-(1-pyrrolidinyl)-2[5H]- furanone; WS-23, lcilin, lcilin Unilever Analog, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone; 4,5-dimethyl-3-(1-pyrrolidinyl)-2[5H]-furanone; isopulegol, 3-(l-menthoxy)propane-1 ,2-diol, 3-(l-menthoxy)-2-methylpropane-1 ,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6- isopropyl-9-methyl-1 ,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl-2-isopropyl-5- methylcyclohexanecarb-oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(l-menthoxy)ethan-1-ol, 3-(I- menthoxy)propan-1-ol, 3-(l-menthoxy)butan-1-ol, l-menthylacetic acid N-ethylamide, I- menthyl-4-hydroxypentanoate, l-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1- methylethyl)-butanamide and spearmint oil.
[0062] According to some embodiments, the menthol derivative is selected from the group consisting of: menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, menthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®) and 3- (/-Menthoxy)-1 ,2-propanediol.
[0063] According to some further embodiments, the warming agent is selected from polyhydric alcohols, capsaicin, capsicum powder, a capsicum tincture, capsicum extract, capsaicin, hamamalis, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives, such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol and gingeron.
[0064] According to some additional embodiments, the relaxing or soothing agent is selected from a herb extracts, selected from the group consisting of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, selected from the group consisting of: almond oil, avocado oil, and comfrey; and essential oils, selected from the group consisting of: cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances selected from the group consisting of: lanolin or vaselline jelly, minerals, selected from the group consisting of: zinc oxide, calamine and selenium; vitamins, selected from the group consisting of: tocopheryl acetate (vitamin E), and pharmaceutical agents selected from the group consisting of: analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, and muscle relaxants; menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-l-menthoxypropane-1 ,2-diol, ethyl l-menthyl carbonate, (1 S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3-carboxamides hamamelis extract and ginger oil. [0065] Further provided, according to some embodiments, are compositions wherein the stimulating or refreshing agent is selected from an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate .acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine and quinine. [0066] In some cases, the short term stable foam is stable at the delivery site for at least one minute. In some further cases, the short term stable foam is stable at the delivery site for at least five minutes.
[0067] According to some embodiments, the sustained period of time is at least 15 minutes. According to some further embodiments, the sustained period of time is at least 30 minutes. In some further cases, the sustained period of time is at least one hour. [0068] Further provided, according to some embodiments, are compositions, wherein the foamable carrier is at a concentration of about 40% to about 99% by weight of the total composition excluding propellant and is selected from the group consisting of an aqueous emulsion, and aqueous gel and a non aqueous carrier wherein the carrier includes: at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier; at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and at least one non aqueous solvent.
[0069] According to some embodiments, the non aqueous solvent is in the case of the aqueous emulsion, a hydrophobic emollient; in the case of the aqueous gel, a penetration enhancer; and in the case of the non aqueous carrier, a polyol. [0070] Further provided, according to some embodiments, are compositions, wherein the at least one emollient is selected from the group consisting of: avocado oil, isopropyl myristate, mineral oil; capric triglyceride, capryllic triglyceride mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils; essential oils; and silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane). [0071] According to some embodiments, the at least one stabilizing surface active agent is selected from the group consisting of: stearyl alcohol; steareth-2, steareth-21 ; polysorbate 80, PEG-40 stearate, glyceryl monostearate, cetostearyl alcohol, laureth 4, and Ceteareth-20, or is a combination of at least two surfactants selected from the group consisting of combinations of polyoxyethylene alkyl ethers, particularly Brij 59 / Briji O; Brij 52 / Brij 10; Steareth 2 / Steareth 20; Steareth 2 / Steareth 21 (Brij 72 / BRIJ 721 ); Myrj 52 / Myrj 59; combinations of sucrose esters, particularly Surphope 1816 / Surphope 1807; combinations of sorbitan esters, particularly Span 20 / Span 80; Span 20 / Span 60; combinations of sucrose esters and sorbitan esters, particularly Surphope 181 1 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, particularly Twin 80 / PEG-40 stearate / methyl glucaso sequistearate.
[0072] Further provided, according to some embodiments, the at least one polymeric agent is selected from the group consisting of: locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose, methocel K100M, PEG 1000, PEG 4000, PEG 6000 and PEG 8000 xanthan gum; sodium carboxymethyl-cellulose, hydroxypropyl-cellulose, microcrystalline-cellulose, Avicel RC581 , aluminum starch octyl succinate and a polyacrylate.
[0073] Additionally, according to some embodiments, the foamable carrier further includes one or more of the following: a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition; a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain at a concentration of about 0.1 % to about 25% by weight of the total composition; a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition. [0074] In some cases, the propellant is a cooling agent.
[0075] According to some embodiments, the composition further includes at least one additional active agent. The at least one additional active agent includes, according to some embodiments, a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect. [0076] Additionally, according to some further embodiments, the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antibum agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A and derivatives, vitamin D and derivatives, wound healing agents and wart removers.
[0077] Further provided, according to some embodiments, are compositions, wherein the foamable carrier includes at least one carrier medium, selected from the group consisting of water, an oil, a silicone oil, an alcohol, a polyol, a polyethylene glycol (PEG), a propylene glycol, and a solvent or combinations thereof.
[0078] According to some embodiments, the foamable carrier further includes a polar solvent. [0079] Further provided, according to some embodiments, are compositions further including an additional component selected from the group consisting of an anti- perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin. [0080] Further provided, according to some embodiments, are compositions, wherein the sensation or sensation modifying is selected from the group consisting of: a combination of a cooling and a warming agent; a combination of a cooling and a soothing or relaxing agent; a combination of a cooling and a stimulating or refreshing agent; a combination of a warming and a stimulating or refreshing agent; a combination of a warming and a soothing or relaxing agent; a combination of a cooling; a warming and a soothing or relaxing agent; and a combination of a cooling; a warming and stimulating or refreshing agent. [0081] Further provided, according to some embodiments, are compositions, wherein the propellant provides an initial cooling sensation combined with a sensation agent to provide a prolonged sensation.
[0082] Additionally, according to some embodiments, the foamable carrier further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain. [0083] Further provided, according to some embodiments, the composition includes: the at least one sensation or sensation modifying agent including menthol in a concentration of 0.5 to about 3% by weight; the at least one active agent includes: coal tar extract in a concentration of around 2% up to around 20% by weight; and at least one other active agent selected from salicylic acid and hydrocortisone in a concentration of around 0.5% up to around 10% by weight; and the menthol is adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar extract. [0084] Further provided, according to some embodiments, are compositions, wherein: the at least one sensation or sensation modifying agent includes menthol crystals in a concentration of 0.5 to about 3% by weight; the at least one active agent includes: coal tar in a concentration of around 2% up to around 20% by weight; and hydrocortisone butyrate in a concentration of around 0.5% up to around 10% by weight; and the menthol crystals are adapted to provide an improved sensation by ameliorating a negative sensation effect of the coal tar.
[0085] Additionally, there is thus provided according to some further embodiments of the present invention, a method for providing a subject with at least one sensation at a delivery site, the method including administering to the delivery site of the subject a composition including: at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent; ii. a warming agent; iii. a relaxing or soothing agent; and iv. a stimulating or refreshing agent; or mixtures thereof; a foamable carrier resistant to aging suitable for delivery of at least one sensation or sensation modifying agent; and a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam; and wherein upon contact with a surface at the delivery site the prolonged sensation is not primarily due to the propellant or an exothermic reaction, so as to provide the subject with the at least one sensation for the sustained period of time.
[0086] According to some embodiments, the method allows for the foam being stable at the delivery site for at least one minute. In some cases, the foam is stable at the delivery site for at least five minutes.
[0087] Additionally, according to some further embodiments, the method allows for the subject to sense the at least one sensation at the delivery site for at least at least 15 minutes. In some cases, the subject senses the at least one sensation at the delivery site for at least 30 minutes. In some further cases, the subject senses the at least one sensation at the delivery site for at least one hour. In yet some further cases, the subject senses the at least one sensation as increasing, peaking and decreasing over the sustained period of time. [0088] According to some embodiments, the method allows for the subject to sense at least one sensation at the delivery site selected from a cooling sensation, a warming sensation, a heating sensation, a soothing sensation, a relaxing sensation, a stimulating sensation and a refreshing sensation.
[0089] According to some further embodiments, the administration step further includes spreading the foam over a surface at the delivery site.
[0090] According to yet some further embodiments, the delivery site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum. [0091] According to some embodiments, the method includes administering compositions further including at least one additional active agent. In some cases, the at least one additional active agent includes a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
[0092] According to yet some further embodiments, the at least one additional active agent is selected from the group consisting of active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antibum agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, cal tar, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A and derivatives, vitamin D and derivatives, wound healing agents and wart removers. [0093] The method, according to some embodiments, further includes treating a disorder selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, grannuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum; and wherein the at least one active agent is suitable for treating the disorder.
[0094] Thus, according to one or more embodiments, the foamable composition, includes: a. a foamable carrier; b. at least one sensation or sensation modifying agent, selected from the group of i. a cooling agent; ii. a warming agent; iii. a relaxing or soothing agent; iv. stimulating or refreshing agent; or mixtures thereof; c. a propellant at a concentration of about 3% to about 45% by weight of the total composition wherein the composition is stored in an aerosol container and upon release expands to form a foam.
[0095] In accordance with one or more embodiments, there is provided a foamable base composition for use with a sensation or sensation modifying agent comprising i. a foamable carrier; and ii. a propellant at a concentration of about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a foam.
[0096] In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of: a. a surface active agent; and b. a polymeric agent; wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
[0097] In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of: a. a co-emulsifier and foam stabilizer; b. a viscosity, bulking or firming agent; c. a stabilizer; d. a co-solvent; e. a penetration enhancer; and f. an agent capable of having an occlusive effect.
[0098] In accordance with one or more embodiments the foamable emollient emulsion carrier composition comprises: a. an aqueous carrier; b. an emollient; and c. a surfactant; or polymeric agent and optionally d. a co-emulsifier and foam stabilizer; a viscosity, bulking or firming agent; a stabilizer; a co-solvent; a penetration enhancer and or an agent capable of having an occlusive effect wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
[0099] In accordance with one or more embodiments, the foamable waterless carrier composition comprises: a. a non-aqueous carrier; b. a surfactant; and or a polymeric agent and optionally c. a co-emulsifier and foam stabilizer; and a viscosity, bulking or firming agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
DETAILED DESCRIPTION
[0100] In the detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that these are specific embodiments and that the present invention may be practiced also in different ways that embody the characterizing features of the invention as described and claimed herein.
[0101] There is provided a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface.
[0102] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a cooling or warming sensation.
[0103] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing or soothing sensation.
[0104] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is primarily a relaxing, soothing, stimulating or refreshing sensation.
[0105] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, where the sensation is a combination of two or more sensations.
[0106] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is further modulated, potentiated, increased, reduced, or ameliorated by the presence of a sensation modifying agent.
[0107] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, in which the sensation is caused by a sensation agent and the sensation is complementary, supplementary or in addition to or superimposed on a cosmetic, therapeutic or pharmaceutical effect.
[0108] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially non-aqueous carrier.
[0109] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the foamable composition comprises a substantially aqueous emollient carrier.
[0110] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the sensation or sensation modifying effect is of short, medium or long term duration or grades thereof.
[0111] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that onset of sensation or sensation modifying effect is of a quick, medium or slow onset or grades thereof.
[0112] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the formulation is adapted so that the relative overall magnitude of sensation or sensation modifying effect is of a mild, medium or strong magnitude or grades thereof.
[0113] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect increases peaks and then decreases.
[0114] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect is with no or little skin irritation.
[0115] There is further provided in one or more embodiments, a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect comprises a fragrance.
[0116] There is further provided in one or more embodiments , a foamable composition that is capable of producing a sensation or sensation modifying effect upon application on a body surface, wherein the sensation or sensation modifying effect can be useful, beneficial or therapeutic in cosmetic, toiletry, bath additive, and pharmaceutical compositions.
[0117] In one or more embodiments, the composition further contains a compatible fragrance so as for example to provide in addition aromatherapy on application of the sensation foam.
[0118] In one or more embodiments, the composition further contains a compatible washable pigment so as to provide an attractive color to the dispensed foam.
[0119] In one or more embodiments, the composition is a waterless composition with hygroscopic ingredients, which upon absorbing water present on a body surface give an initial warming sensation in addition to the prolonged sensation of the sensation agent.
[0120] It was discovered that incorporating a sensation or sensation modifying agent in a foamable composition results in a product that, when compared with the composition which is not foamed provides an improved effect.
[0121] While not wishing to be limited to any particular theory, it is presently believed that the expansion of the formulations caused by the presence of a propellant causes the product to spread in the form of a thin film on the skin or delivery site, thereby giving a soft, silky, and cosmetically elegant feel. The observed effect is analogous to a comparison between whipped cream and butter. While both of these products are produced from cream, butter is a dense, greasy water in oil emulsion, whereas whipped cream is a light air in oil emulsion in which the oil is extended over a much greater volume, thereby masking its greasy properties to a substantial extent. In the present invention, by foaming the oils with a propellant to produce a low density aerated foam, the greasy property of the oil in the formulation is ameliorated or minimized. [0122] Moreover it was further discovered that it is possible to prepare such foamable compositions using more than one different foamable platforms or carriers. More specifically it was discovered, for example, that effective foamable compositions can be produced with a sensation or sensation modifying effect with a substantially waterless carrier and can also be produced with a substantially aqueous carrier. The ability to produce sensation or sensation modifying foam in waterless and aqueous environments allows the production of foams to suit, benefit or improve a wide variety of skin, mucosa and body cavity conditions. Based on this discovery it is possible to develop and create a multitude of foams, which provide a sensation or sensation modifying feeling with the following advantages:
1. Improvement of user compliance especially in children or sensitive patients;
2. Enhancement of user comfort;
3. Improvement of skin absorption, due to the foam texture;
4. Improvement of skin appearance due to the non-shiny appearance thereof, after administration of the composition;
5. Easier spreading on the body surface, without the need of extensive rubbing;
6. Remains substantially intact for a sufficient period to facilitate convenience of application;
7. Sensation agent may mask, neutralize, ameliorate or hide one or more undesired properties of other ingredients of the composition;
8. Improvement in absorption through skin of one or more active agents;
9. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect.
[0123] In accordance with one or more further embodiments, the propellant is at a concentration from about 3% to about 25% by weight of the total composition. [0124] In accordance with one or more further embodiments, the propellant is at a concentration from about 25% to about 45% by weight of the total composition. [0125] In accordance with one or more embodiments, the foamable base composition is flowable. [0126] In accordance with one or more embodiments, the main carrier solvent is at a concentration of about 40% to about 90% by weight of the total composition. [0127] In accordance with one or more embodiments, the foamable composition further comprises at least one component, selected from the group consisting of: a. a surface active agent; b. a polymeric agent wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam.
[0128] In accordance with one or more embodiments, the surface active agent is a stabilizing combination of at least two surface active agents.
[0129] In accordance with one or more embodiments, the surface active agent is at a concentration of about 0.1 % to about 10% by weight of the total composition.
[0130] In accordance with one or more embodiments, the polymeric agent is at a concentration of about 0.05% to about 5% by weight of the total composition.
[0131] In accordance with one or more embodiments, the surface active agent is combination of at least two surfactants.
[0132] In accordance with one or more embodiments, where the composition is an emollient emulsion the polymeric agent is preferably a combination of hydroxy propylmethyl cellulose and xantham gum. In certain other embodiments the polymeric agent is sodium carboxymethyl-cellulose, hydroxyethyl-cellulose, microcrystalline- cellulose, aluminum starch octyl succinate, and polyacrylates such as carbopol.
[0133] In accordance with one or more embodiments, wherein the composition is an emollient emulsion, the polymeric agent is preferably a hydroxypropyl-cellulose such as
Klucel EF, aluminum starch octyl succinate, and polyacrylates such as carbopol.
[0134] In accordance with one or more embodiments, the co-emulsifier is at a concentration of about 0.05% to about 10% by weight of the total composition.
[0135] In accordance with one or more embodiments, the viscosity, bulking or firming agent is at a concentration of about 0.1 % to about 15% by weight of the total composition.
[0136] In accordance with one or more embodiments, the stabilizer is at a concentration of about 0.1 % to about 10% by weight of the total composition.
[0137] In accordance with one or more embodiments, the co-solvent is at a concentration of about 0.1 % to about 30% by weight of the total composition.
[0138] In accordance with one or more embodiments, the penetration enhancer is at a concentration of about 0.1 % to about 30% by weight of the total composition. [0139] In accordance with one or more embodiments, the agent capable of having an occlusive effect is at a concentration of about 0.1 % to about 30% by weight of the total composition.
[0140] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam has a density of about 0.01 to about 0.2 g/ml.
[0141] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 60 seconds or more.
[0142] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 120 seconds or more.
[0143] In accordance with one or more embodiments, there is also provided a sensation or sensation modifying topical composition wherein the resultant foam is a breakable foam, which if not subjected to mechanical shear break, is capable of remaining substantially intact without substantial foam collapse for about 300 seconds or more.
[0144] In an exemplary embodiment, the foamable sensation modifying topical composition is an aqueous composition, containing water and further comprises a surface active agent.
[0145] In an exemplary embodiment, the foamable sensation modifying topical composition comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
[0146] In an exemplary embodiment, the foamable sensation modifying topical composition is an emulsion, comprising water, a hydrophobic solvent, a surface-active agent and a polymeric agent.
[0147] Optionally, in one or more embodiments the emulsion-type foamable composition further contains a foam adjuvant agent, selected from the group consisting of a fatty alcohol having 15 or more carbons in their carbon chain; a fatty acid having 16 or more carbons in their carbon chain.
[0148] In certain embodiments, the emulsion is an oil in water emulsion, while in additional embodiments the emulsion is a water in oil emulsion. [0149] In certain embodiments the hydrophobic carrier is an oil. Exemplary oils include mineral oil, silicone oil, a triglyceride and an ester of a fatty acid. In certain embodiments, the hydrophobic solvent is occlusive, such as petrolatum, while in other embodiments the hydrophobic carrier in non-occlusive.
[0150] In an exemplary embodiment, the foamable sensation modifying topical composition is an oleaginous foamable composition, including at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a polar solvent and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent and at least one polymeric agent.
[0151] In an exemplary embodiment, the foamable sensation modifying topical composition includes more than 50% of a polar solvent (as used herein, the term "polar solvent" shall mean a material that produces a uniform, clear or hazy, mixture when combined with at least a weight equivalent of water), a surface-active agent and a polymeric agent.
[0152] In certain embodiments the foamable composition contains up to 80% water, while in additional embodiments the foamable composition contains up to 25% water. [0153] In one or more embodiments, the composition is substantially alcohol free [0154] In one or more embodiments, the composition is substantially non-aqueous. [0155] In accordance with one or more embodiments, there is provided a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject, comprising: a. administering an effective amount of a sensation or sensation modifying topical emollient emulsion carrier composition to a target site on a mammalian subject, comprising: i. an aqueous carrier at a concentration of about 40% to about 90% by weight of the total composition; ii. an emollient at a concentration of about 5% to about 15% by weight of the total composition; iii. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition; iv. a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; v. a propellant at a concentration of about 3% to about 45% by weight of the total composition; vi. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; and optionally; vii. a co-emulsifier and foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; a stabilizer; a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; a penetration enhancer at a concentration of about 0.1 % to about 20% by weight of the total composition; and or an agent capable of having an occlusive effect at a concentration of about 5% to about 30% by weight of the total composition; wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam. b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
[0156] In accordance with one or more embodiments, there is provided a method of treating, alleviating or preventing a dermatological reaction, sensation or disorder of a mammalian subject, comprising: a. administering an effective amount of a sensation or sensation modifying topical substantially waterless foamable composition to a target site on a mammalian subject, comprising: aa. a non-aqueous carrier at a concentration of about 40% to about 90% by weight of the total composition; bb. a surfactant at a concentration of about 0.1 % to about 10% by weight of the total composition; and or a polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; cc. at least one active agent in an effective amount which is intended to prevent, alleviate, treat or cure said reaction, sensation or disorder; dd. a propellant at a concentration of about 3% to about 25% by weight of the total composition and optionally; ee. a co-emulsifier and foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; and a viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition. wherein a destabilizing foam effect of the sensation or sensation modifying agent is capable of being reduced, ameliorated or countered to some extent by the introduction of a stabilizing polymer and wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam. b. applying mechanical shear break to the applied foam such that it is spread at, about and within the target site.
Hydrophobic carrier
[0157] A "hydrophobic solvent" as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 ml_, more preferable less than about 0.5 gm per 100 ml_, and most preferably less than about 0.1 gm per 100 ml_.
[0158] In one or more embodiments, the hydrophobic organic carrier is an oil, such as mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils; essential oils; and silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.
Polar Solvent
[0159] A "polar solvent" is an organic solvent, typically soluble both in water and oil but is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition. The emollient emulsion and waterless formulations may contain polar solvents, which may contribute to the penetration of an active or therapeutic agent including a sensation or sensation modifying agent.
Polymeric agent
[0160] A polymeric agent can be selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG1500, PEG2000, PEG 4000, PEG 6000 and PEG 8000. Polyol
[0161] In an embodiment of the present invention, the solvent is a polyol. A polyol is an organic substance that contains at least two hydroxy groups in its molecular structure. [0162] In one or more embodiments, the foamable carrier contains at least one diol (a compound that contains two hydroxy groups in its molecular structure). Examples of diols include propylene glycol (e.g., 1 ,2-propylene glycol and 1 ,3-propylene glycol), butanediol (e.g., 1 ,2-butanediol, 1 ,3-butanediol, 2,3-butanediol and 1 ,4-butanediol), butanediol (e.g., 1 ,3-butanediol and 1 ,4-butenediol), butynediol, pentanediol (e.g., pentane-1 ,2-diol, pentane-1 ,3-diol, pentane-1 ,4-diol, pentane-1 ,5-diol, pentane-2,3-diol and pentane-2,4- diol), hexanediol (e.g., hexane-1 ,6-diol hexane-2,3-diol and hexane-2,56-diol), octanediol (e.g., 1 ,8-octanediol), neopentyl glycol, 2-methyl-1 ,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol and dibutylene glycol. [0163] In one or more embodiments, the foamable carrier contains at least one triol (a compound that contains three hydroxy groups in its molecular structure), such as glycerin, butane-1 ,2,3-triol, butane-1 ,2,4-triol and hexane-1 ,2,6-triol. [0164] In one or more embodiments, the polyol is a mixture of polyols. In one or more embodiments, the mixture of polyols contains at least one diol and at least one triol. According to certain embodiments the ratio between the diol and triol is between 9:1 and 1 :1. [0165] In one or more embodiments, part of mixture of polyols is a saccharide. Exemplary saccharides include, but are not limited to monosaccharide, disaccharides, oligosaccharides and sugar alcohols.
[0166] A monosaccharide is a simple sugar that cannot be hydrolysed to smaller units. Empirical formula is (CH2O)n and range in size from trioses (n=3) to heptoses (n=7). Exemplary monosaccharide compounds are ribose, glucose, fructose and galactose. [0167] Disaccharides are made up of two monosaccharides joined together, such as sucrose, maltose and lactose.
[0168] A sugar alcohol (also known as a polyol, polyhydric alcohol, or polyalcohol) is a hydrogenated form of saccharide, whose carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group. They are commonly used for replacing sucrose in foodstuffs, often in combination with high intensity artificial sweeteners to counter the low sweetness. Some exemplary sugar alcohols, which are suitable for use according to the present invention are mannitol, sorbitol, xylitol, maltitol, lactitol. (Maltitol and lactitol are not completely hydrogenated compounds - they are a monosaccharide combined with a polyhydric alcohol). Mixtures of polyols, including (1 ) at least one polyol selected from a diol and a triol; and (2) a saccharide are contemplated within the scope of the present invention.
Polyethylene glycol
[0169] In an embodiment of the present invention, the solvent consists of a polymerized ethylene glycol, namely polyethylene glycol, which is also termed "PEG". Exemplary PEGs are provided in the following table.
Figure imgf000034_0001
[0170] Thus, in an embodiment of the present invention, the PEG is selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG 6000 and PEG 8000. The foamable carrier according to the present invention can contain a single PEG or a mixture of two or more PEGs. PEGs having molecular weight of more that about 1000 possess gelling properties; i.e., they increase the viscosity of a composition. Therefore, by combining PEGs with different molecular weights/melting points, one can attain varying levels of flowability as desirable for the treatment of a given target site. The concentration of the PEG should be in a level that results in viscosity, prior to filling of the composition into aerosol canisters, of less than 12,000 CPs, and more preferably, less than 10,000 CPs.
Secondary polar solvent
[0171] Optionally, a secondary solvent is added to the foamable composition of the present invention. The secondary solvent is selected from a variety of organic solvents that are typically miscible on both water and oil. Examples of solvent that can be contained in the foamable carrier of the present invention include dimethyl isosorbide, tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol), DMSO, pyrrolidones, (such as N-Methyl-2-pyrrolidone and 1-Methyl-2-pyrrolidinone), ethyl proxitol, dimethylacetamide (DMAc), PEG-type surfactants and alpha hydroxy acids, such as lactic acid and glycolic acid.
Solubilization and penetration enhancement
[0172] A "skin penetration enhancer", also termed herein "penetration enhancer," is an organic solvent, typically soluble in both water and oil. Examples of penetration enhancer include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen- ols, limonene, terpene-ol, 1 -menthol, dioxolane, ethylene glycol, hexylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, dimethylisosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2- (n-nonyl)-1 ,3-dioxolane, esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl- myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various alkanoic acids such as caprylic acid; lactam compounds, such as azone; alkanols, such as dialkylamino acetates, and admixtures thereof. [0173] According to one or more embodiments, the penetration enhancer is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature [0174] In many cases, polyols, PEGs and solvents possess a high solubilizing power and thus, they can enable increased concentrations of a pharmaceutical active agent. Polyols, PEGs and solvents are also known for their skin penetration enhancement properties. These properties enable high drug bioavailability in the target area of treatment, resulting in an enhanced therapeutic effect. Occasionally, combinations of a polyol, PEGs and a secondary solvent, exhibit an increased permeability across the skin, as suggested, for example, in Eur. J. Pharm. Biopharm. 1998 Nov. 46(3):265-71. [0175] Thus, in one or more embodiments, the foamable carrier contains (1 ) at least one solvent, selected from a polyol (selected from a diol and a triol) and PEG; and (2) at least one secondary solvent.
[0176] In one or more embodiments, the foamable carrier contains (1 ) a mixture of at least two polyols; and (2) at least one secondary solvent. In additional embodiments, the foamable carrier contains a mixture of at least one polyol and at least one PEG; yet in other embodiments the foamable carrier contains (1 ) a mixture of at least one polyol and at least one PEG and (2) at least one secondary solvent.
[0177] According to certain embodiments the ratio between the polyol and/or PEG and the secondary solvent is between 9:1 and 1 :1.
[0178] In certain embodiments, the polyol is selected from the group consisting of propylene glycol, hexylene glycol and glycerin (and mixtures thereof); and the secondary solvent is selected from the group consisting of dimethyl isosorbide, diethylene glycol monoethyl ether, a liquid polyethylene glycol and glycofurol.
[0179] In certain embodiments, the foamable carrier contains (1 ) at least one polyol; and (2) dimethyl isosorbide.
Potent Solvent
[0180] In one or more embodiments of the present invention, the foamable composition includes a potent solvent, in addition to, or in place, of one of the hydrophobic solvents, polar solvents or emollients of the composition. A potent solvent is a solvent other than mineral oil that solubilizes a specific active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum. For example, a potent solvent solubilizes the active agent 5 fold better than a hydrocarbon solvent; or even solubilizes the active agent 10-fold better than a hydrocarbon solvent. [0181] In one or more embodiments of the present invention, the composition includes at least one active agent in a therapeutically effective concentration; and at least one potent solvent in a sufficient amount to substantially solubilize the at least one active agent in the composition. The term "substantially soluble" means that at least 95% of the active agent has been solubilized, i.e., 5% or less of the active agent is present in a solid state. In one or more embodiments, the concentration of the at least one potent solvent is more than about 40% of the at least one solvent of the composition of the present invention; or even more than about 60%.
[0182] Non-limiting examples of pairs of active agent and potent solvent include: Betamethasone valerate: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in glycofurol; Hydrocortisone butyrate: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in glycofurol; Metronidazole: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in dimethyl isosrbide; Ketoconazole: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in glycofurol, propylene glycol and dimethyl isosrbide; Mupirocin: Practically insoluble in mineral oil (<0.01 %); soluble more than 1 % in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400); Meloxicam, a nonsteroidal anti-inflammatory agent: Practically insoluble in mineral oil (<0.001 %); soluble in propylene glycol: 0.3 mg/mL; and in PEG 400: 3.7 mg/mL; and Progesterone: Practically insoluble in mineral oil (<0.001 %); soluble in PEG 400: 15.3 mg/mL.
[0183] A non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butaneediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol) and laurocapram .
[0184] The use of a potent solvent in a foam composition provides an improved method of delivering poorly soluble therapeutic agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment. Foam compositions of the present invention, for which the solvent includes a potent solvent, increase the levels of the active agent in solution and thus, provide high delivery and improved therapy.
[0185] Potent solvents, as defined herein, are usually liquid. Formulations comprising potent solvents and active agents are generally disadvantageous as therapeutics, since their usage involves unwanted dripping and inconvenient method of application; resulting in inadequate dosing. Surprisingly, the foams of the present invention, which are drip- free, provide a superior vehicle for such active agents, enabling convenient usage and accurate effective dosing. [0186] In one or more embodiments of the present invention the present invention the foamable pharmaceutical composition may additionally include a mixture of two or more of the solvents selected from the group of hydrophobic solvents, silicone oils, emollients, polar solvents and potent solvents in an appropriate proportion as would be appreciated to a person skilled in the art.
[0187] In one or more embodiments of the present invention, the PPG alkyl ether may act as a potent solvent.
Surface active agent
[0188] The composition further contains a surface-active agent. Surface-active agents (also termed "surfactants") include any agent linking oil and water in the composition, in the form of emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. HLB is defined for non-ionic surfactants. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers form water-in-oil (w/o) emulsions; hydrophilic surfactants form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average). In many cases a single surfactant may suffice. In other cases a combination of two or more surfactants is desired. Reference to a surfactant in the specification can also apply to a combination of surfactants or a surfactant system. As will be appreciated by a person skilled in the art which surfactant or surfactant system is more appropriate is related to the vehicle and intended purpose. In general terms a combination of surfactants can be significant in producing breakable forms of good quality. It has been further discovered that the generally thought considerations for HLB values for selecting a surfactant or surfactant combination are not always binding for emulsions and moreover for waterless and substantially non aqueous carriers the usual guidelines are less applicable . Surfactants also play a significant role in foam formation where the foamable formulation is a single phase composition.
[0189] According to one or more embodiments the composition contains a single surface active agent having an HLB value between about 2 and 9, or more than one surface active agent and the weighted average of their HLB values is between about 2 and about 9.
[0190] According to one or more embodiments the composition contains a single surface active agent having an HLB value between about 7 and 14, (preferably about 7 to about 12) or more than one surface active agent and the weighted average of their HLB values is between about 7 and about 14 (preferably about 7 to about 12). [0191] According to one or more other embodiments the composition contains a single surface active agent having an HLB value between about 9 and about 19, or more than one surface active agent and the weighted average of their HLB values is between about 9 and about 19.
[0192] In a waterless or substantially waterless environment a wide range of HLB values may be suitable.
[0193] Preferably, the composition contains a non-ionic surfactant. Nonlimiting examples of possible non-ionic surfactants include a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59; a polyoxyethylene alkyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, steareths such as steareth 2, brij 21 , brij 721 , brij 38, brij 52, brij 56 and brij W1 , a sucrose ester, a partial ester of sorbitol and its anhydrides, sorbitan monolaurate, sorbitan monolaurate, a monoglyceride, a diglyceride, isoceteth-20 and mono-, di- and tri-esters of sucrose with fatty acids. In certain embdiments, suitable sucrose esters include those having high monoester content, which have higher HLB values.
[0194] In an embodiment the surfactant is an ether for example polyoxyethylene (26) glycerol ether.
[0195] In certain embodiments, surfactants are selected which can provide a close packed surfactant layer. To achieve such objectives combinations of at least two surfactants are selected. Preferably, they should be complex emulgators and more preferably they should both be of a similar molecular type; for example, a pair of ethers, like steareth 2 and steareth 21 , or a pair of esters, for example, PEG-40 stearate and polysorbate 80. Ideally, the surfactants can be ethers. In certain circumstances POE esters cannot be used and a combination of sorbitan laurate and sorbitan stearate or a combination of sucrose stearic acid ester mixtures and sodium laurate may be used. All these combinations due to their versatility and strength may also be used satisfactorily and effectively with ether formulations, although the amounts and proportion may be varied according to the formulation and its objectives as will be appreciated by a man of the art.
[0196] It has been discovered also that by using a derivatized hydrophilic polymer with hydrophobic alkyl moieties as a polymeric emulsifier such as pemulen it is possible to stabilize the emulsion better about or at the region of phase reversal tension. Other types of derivatized polymers like silicone copolymers, derivatized starch [Aluminum Starch Octenylsuccinate (ASOS)] / [DRY-FLO AF Starch], and derivatized dexrin may also a similar stabilizing effect.
[0197] A series of dextrin derivative surfactants prepared by the reaction of the propylene glycol polyglucosides with a hydrophobic oxirane-containing material of the glycidyl ether are highly biodegradable. [Hong-Rong Wang and Keng-Ming Chen,
Colloids and Surfaces A: Physicochemical and Engineering Aspects Volume 281 , Issues
1-3, 15 June 2006, Pages 190-193] .
[0198] Non-limiting examples of non-ionic surfactants that have HLB of about 7 to about 12 include steareth 2 (HLB-4.9); glyceryl monostearate/PEG 100 stearate ( Av
HLB-1 1.2); stearate Laureth 4 (HLB-9.7) and cetomacrogol ether (e.g., polyethylene glycol 1000 monocetyl ether).
[0199] Non-limiting examples of preferred surfactants, which have a HLB of 4-19 are set out in the Table below:
Figure imgf000040_0001
[0200] Another component of the formulations of the present invention is a compound used in the present invention is Sepigel 305. Sepigel 305 comprises Polyacrylamide and C13-14 lsoparaffin and Laureth-7. It acts as a surfactant and as a thickening and emulsifying agent, and comes in a liquid, very easy to handle form. It requires neither premixing, nor high rate of shear nor neutralisation. Sepigel 305 can be used to emulsify all types of oil phase without heating, producing gel-cream with a rich, silky texture that are easy to apply and rapidly absorbed by the skin.
[0201] More exemplary stabilizing surfactants which may be suitable for use in the present invention are found below.
[0202] PEG-Fatty Acid Monoester Surfactants, such as:
Figure imgf000041_0001
[0203] PEG-Fatty Acid Diester Surfactants, such as:
Figure imgf000041_0002
[0204] Transesterification Products of Oils and Alcohols, such as:
Figure imgf000041_0003
[0205] Polyglycerized Fatty Acids, such as:
Figure imgf000042_0001
[0206] PEG-Sorbitan Fatty Acid Esters, such as:
Figure imgf000042_0002
[0207] Polyethylene Glycol Alkyl Ethers, such as:
Figure imgf000042_0003
[0208] Sugar Ester Surfactants, such as:
Figure imgf000042_0004
[0209] Sorbitan Fatty Acid Ester Surfactants, such as:
Figure imgf000043_0001
[0210] In one or more embodiments the surface active agent is a complex emulgator in which the combination of two or more surface active agents can be more effective than a single surfactant and provides a more stable formulation or improved foam quality than a single surfactant. For example and by way of non-limiting explanation it has been found that by choosing say two surfactants, one hydrophobic and the other hydrophilic the combination can produce a more stable emulsion than a single surfactant. Preferably, the complex emulgator comprises a combination of surfactants wherein there is a difference of about 4 or more units between the HLB values of the two surfactants or there is a significant difference in the chemical nature or structure of the two or more surfactants.
[0211] Specific non limiting examples of surfactant systems are, combinations of polyoxyethylene alkyl ethers, such as Brij 59 / Briji O; Brij 52 / Brij 10; Steareth 2 / Steareth 20; Steareth 2 / Steareth 21 (Brij 72 / Brij 721 ); combinations of polyoxyethylene stearates such as Myrj 52 / Myrj 59; combinations of sucrose esters, such as Surphope 1816 / Surphope 1807; combinations of sorbitan esters, such as Span 20 / Span 80; Span 20 / Span 60; combinations of sucrose esters and sorbitan esters, such as Surphope 1811 and Span 60; combinations of liquid polysorbate detergents and PEG compounds, such as Tween 80 / PEG-40 stearate; methyl glucaso sequistearate; polymeric emulsifiers, such as Permulen (TRI or TR2); liquid crystal systems, such as Arlatone (2121 ), Stepan (Mild RM1 ), Nikomulese (41 ) and Montanov (68) and the like. [0212] In certain embodiments the surfactant is preferably one or more of the following: a combination of steareth-2 and steareth-21 on their own or in combination with glyceryl monostearate (GMS); in certain other embodiments the surfactant is a combination of polysorbate 80 and PEG-40 stearate. In certain other embodiments the surfactant is a combination of glyceryl monostearate/PEG 100 stearate. In certain other embodiments the surfactant is a combination of two or more of stearate 21 , PEG 40 stearate, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of laureth 4, span80, and polysorbate 80. In certain other embodiments the surfactant is a combination of two or more of GMS and ceteareth. In certain other embodiments the surfactant is a combination of two or more of steareth 21 , ceteareth 20, ceteth 2 and laureth 4 In certain other embodiments the surfactant is a combination of ceteareth 20 and polysorbate 40 stearate. In certain other embodiments the surfactant is a combination of span 60 and GMS. In certain other embodiments the surfactant is a combination of two or all of PEG 40 stearate, sorbitan stearate and polysorbate 60
[0213] In certain other embodiments the surfactant is one or more of sucrose stearic acid esters, sorbitan laureth, and sorbitan stearate.
[0214] Without being bound by any particular theory or mode of operation, it is believed that the use of non-ionic surfactants with significant hydrophobic and hydrophilic components, increase the emulsifier or foam stabilization characteristics of the composition. Similarly, without being bound by any particular theory or mode of operation, using combinations of surfactants with high and low HLB's to provide a relatively close packed surfactant layer may strengthen the formulation.
[0215] In one or more embodiments the stability of the composition can be improved when a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed. The ratio between the at least one non-ionic surfactant having HLB of less than 9 and the at least one non-ionic surfactant having HLB of equal or more than 9, is between 1 :8 and 8:1 , or at a ratio of 4:1 to 1 :4. The resultant HLB of such a blend of at least two emulsifiers is preferably between about 9 and about 14.
[0216] Thus, in an exemplary embodiment, a combination of at least one non-ionic surfactant having HLB of less than 9 and at least one non-ionic surfactant having HLB of equal or more than 9 is employed, at a ratio of between 1 :8 and 8: 1 , or at a ratio of 4:1 to 1 :4, wherein the HLB of the combination of emulsifiers is preferably between about 5 and about 18.
[0217] In certain cases, the surface active agent is selected from the group of cationic, zwitterionic, amphoteric and ampholytic surfactants, such as sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
[0218] Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two Many amphiphilic molecules can show lyotropic liquid-crystalline phase sequences depending on the volume balances between the hydrophilic part and hydrophobic part. These structures are formed through the micro-phase segregation of two incompatible components on a nanometer scale. Soap is an everyday example of a lyotropic liquid crystal. Certain types of surfactants tend to form lyotropic liquid crystals in emulsions interface (oil-in-water) and exert a stabilizing effect
[0219] In one or more embodiments the surfactant is a surfactant or surfactant combination is capable of or which tends to form liquid crystals. Surfactants which tend to form liquid crystals may improve the quality of foams. Non limiting examples of surfactants with postulated tendency to form interfacial liquid crystals are: phospholipids, alkyl glucosides, sucrose esters, sorbitan esters.
[0220] In one or more embodiments the at least one surface active agent is liquid. Moreover for the purposes of formulating with liquid ethers a liquid surfactant is preferred. [0221] In one or more embodiments the liquid surfactant is a polysorbate, preferably polysorbate 80 or 60.
[0222] In one or more embodiments the at least one surface active agent is solid, semi solid or waxy. In a further embodiment they are soluble in oil and in another embodiment have a HLB of less than about 12.
[0223] It should be noted that HLB values may not be so applicable to non ionic surfactants, for example, with liquid crystals or with silicones. Also HLB values may be of lesser significance in a waterless or substantially non-aqueous environment. [0224] In one or more embodiments the surfactant can be, a surfactant system comprising of a surfactant and a co surfactant, a waxy emulsifier, a liquid crystal emulsifier, an emulsifier which is solid or semi solid at room temperature and pressure, or combinations of two or more agents in an appropriate proportion as will be appreciated a person skilled in the art. Where a solid or semi solid emulsifier combination is used it can also comprise a solid or semi solid emulsifier and a liquid emulsifier. In a preferred embodiment at least one surfactant is a liquid.
[0225] In one or more embodiments, the surface-active agent includes at least one non-ionic surfactant. Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. Non-ionic surfactants alone can provide formulations and foams of good or excellent quality in the carriers and compositions of the present invention.
[0226] Thus, in a preferred embodiment, the surface active agent, the composition contains a non-ionic surfactant. In another preferred embodiment the composition includes a mixture of non-ionic surfactants as the sole surface active agent. Yet, in additional embodiments, the foamable composition includes a mixture of at least one non- ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1 , or greater than about 8:1 ; or greater than about 14:1 , or greater than about 16:1 , or greater than about 20:1. In further embodiments, surface active agent comprises a combination of a non-ionic surfactant and an ionic surfactant, at a ratio of between 1 :1 and 20:1.
[0227] In one or more embodiments , a combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate and cocamidopropylbetaine) is employed, at a ratio of between 1 :1 and 20:1 , or at a ratio of 4:1 to 10:1 ; for example, about 1 :1 , about 4:1 , about 8:1 , about 12:1 , about 16:1 and about 20: 1 or at a ratio of 4: 1 to 10: 1 , for example, about 4:1 , about 6:1 , about 8:1 and about 10:1. [0228] For foams in selecting a suitable surfactant or combination thereof it should be borne in mind that the upper amount of surfactant that may be used may be limited by the shakability of the composition. If the surfactant is non liquid, it can make the formulation to viscous or solid. Subject to its miscibility, solid surfactants may be added first, and may require gentle warming and then cooling before being combined with the other ingredients. In general terms, as the amount of non-liquid surfactant is increased the shakability of the formulation reduces until a limitation point is reached where the formulation can become non shakable and unsuitable. Thus in one embodiment, any effective amount of surfactant may be used provided the formulation remains shakable. In other certain limited embodiments the upper limit for foamable formulations may be determined by flowability such that any effective amount can be used provided the formulation is sufficiently flowable to be able to flow through an actuator valve and be released and still expand to form a good quality foam. This may be due without being bound by any theory to one or more of a number of factors such as the viscosity, the softness, the lack of crystals, the pseudoplastic or semi pseudo plastic nature of the composition and the dissolution of the propellant into the composition. [0229] In certain embodiments the amount of surfactant or combination of surfactants is between about 0.05% to about 20%; between about 0.05% to about 15%. or between about 0.05% to about 10%. In a preferred embodiment the concentration of surface active agent is between about 0.2% and about 8%. In a more preferred embodiments the concentration of surface active agent is between about 1 % and about 6% or between about 1 % and about 4%. [0230] In some embodiments, it is desirable that the surface active agent does not contain a polyoxyethylene (POE) moiety, such as polysorbate surfactants, POE fatty acid esters, and POE alkyl ethers, because the active agent is incompatible with such surface active agents. For example, the active agent pimecrolimus is not stable the presence of POE moieties, yet benefits greatly from the use of dicarboxylic esters as penetration enhancers. In such cases, alternative surface active agents are employed. In an exemplary manner, POE - free surfactants include non-ethoxylated sorbitan esters, such as sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate, sorbitan monolaurate and sorbitan sesquioleate; glycerol fatty acid esters, such as glycerol monostearate and glycerol monooleate; mono-, di- and tri-esters of sucrose with fatty acids (sucrose esters), sucrose stearate, sucrose distearate sucrose palmitate and sucrose laurate; and alkyl polyglycosides, such as lauryl diglucoside.
Humectant
[0231] A humectant is a substance that helps retain moisture and also prevents rapid evaporation. Non limiting examples are propylene glycol, propylene glycol derivatives, glycerin, hydrogenated starch hydrosylate, hydrogenated lanolin, lanolin wax, D manitol, sorbitol, sodium 2-pyrrolidone-5-carboxylate, sodium lactate, sodium PCA, soluble collagen, dibutyl phthalate, and gelatin. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower.
Moisturizers
[0232] A moisturizer, is a substance that helps retain moisture or add back moisture to the skin. Examples are allantoin, petrolatum, urea, lactic acid, sodium PCV, glycerin, shea butter, caprylic/capric/stearic triglyceride, candelilla wax, propylene glycol, lanolin, hydrogenated oils, squalene, sodium hyaluronate and lysine PCA. Other examples may be found in the Handbook of Pharmaceutical Additives published by Gower. [0233] Pharmaceutical compositions of the present invention may in one or more embodiments usefully comprise in addition a heumectant or a moisturizer or combinations thereof.
Modulating Agent
[0234] The term modulating agent is used to describe an agent which can improve the stability of or stabilize a carrier or a foamable composition and or an active agent by modulating the effect of a substance or residue present in the carrier or composition. The substance or residue may for example be acidic or basic and potentially alter an artificial pH in a waterless or substantially non aqueous environment or it may be one or more metal ions which may act as a potential catalyst in a waterless or substantially non aqueous environment or it may be an ionisation agent or it may be an oxidizing agent. [0235] In one or more other embodiments the modulating agent is used in a waterless composition. In one or more embodiments the modulating agent is used to describe an agent which can affect pH in an aqueous solution.
[0236] The agent can be any of the known buffering systems used in pharmaceutical or cosmetic formulations as would be appreciated by a man of the art. It can also be an organic acid, a carboxylic acid, a fatty acid an amino acid, an aromatic acid, an alpha or beta hydroxyl acid an organic base or a nitrogen containing compound. [0237] In one or more further embodiments the modulating agent is used to describe an agent, which is a chelating or sequestering or complexing agent that is sufficiently soluble or functional in the waterless solvent to enable it to "mop up" or "lock" metal ions. [0238] In the embodiment modulating agent is used to describe an agent which can effect pH in an aqueous solution the term modulating agent more particularly means an acid or base or buffer system or combinations thereof, which is introduced into or is present in and acts to modulate the ionic or polar characteristics and any acidity or basisity balance of a waterless or substantially non aqueous carrier, composition, foamable carrier or foamable composition or resultant foam described herein. [0239] The terms pH, pKa, and pKb, buffers such measurements and terms are artificial in a waterless environment. In an embodiment of the present invention sufficient modulating agent is added to achieve an artificial pH in which the active agent is preferably stable. Such artificial pH may be acidic, maybe basic or may be neutral. [0240] In an embodiment of the present invention, the modulating or additional component is a pH adjusting agent or a buffering agent.
[0241] In one or more preferred embodiments of the present invention the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid ("EDTA") and salts thereof such as disodium EDTA, tetrasodium EDTA and calsium disodium EDTA; diethylenetriaminepentaacetic acid ("DTPA") and salts thereof; hydroxyethlethylenediaminetriacetic acid ("HEDTA") and salts thereof and nitrilotriacetic acid ("NTA"); more preferably EDTA, HEDTA and their salts; most preferably EDTA and its salts; citric acid buffers including, but not limited to citric acid and salts of citric acid, such as sodium citrate; an alpha hydroxyl acid; an aliphatic beta hydroxy acid; an aromatic acid; an aliphatic carboxylic acid; a dicarboxylic acid; organic acids (including, but not limited to, ascorbic acid, isoascorbic acid, ethanesulfonic acid, glycerophosphoric acid, acetohydroxamic acid, aconitic acid, alpha-ketocaproic acid, aminomalonic acid, hippuric acid, hydrochloric acid, methanesulfonic acid, oxalic acid, phosphoric acid, sorbic acid, iminodiacetic acid, carnitine, nicotinic acid and retinoids, such as retinoic acid and isotretinoin); and amino acids. Exemplary modulating agents include those described in U.S. Patent Publication No. 2008/0206159, filed November 29, 2007, entitled "Compositions With Modulating Agents," which is herein incorporated by reference in its entirety
[0242] In one or more embodiments of the present invention a preferred non limiting example of the chelating agent is EDTA. Typically, the chelating and sequestering agent is present in the composition at a level of up to about 5.0%, preferably 1.0 percent, by weight, of the composition.
[0243] Combinations of Modulating Agents may be a useful for example chelating agents may be usefully used in combination with another modulating agent such as an acid, a base or a buffer system or with various combinations of modulating agents. [0244] The modulating agent to the foamable composition of the present invention is further useful for adjusting the pH of the target area of application. [0245] In one or more embodiments, the modulating agent may also be a preservative or an antioxidant or an ionization agent. Any preservative, antioxidant or ionization agents suitable for pharmaceutical or cosmetic application may be used. Non limiting examples of antioxidants are tocopherol succinate, propyl galate, butylated hydroxy toluene and butyl hydroxy anisol. In one or more embodiments the modulating agent is a flavonoid. Ionization agents may be positive or may be negative depending on the environment and the active agent or composition that is to be protected. Ionization agents may for example act to protect or reduce sensitivity of active agents. Non limiting examples of positive ionization agents are benzyl conium chloride, and cetyl pyridium chloride. Non limiting examples of negative ionization agents are sodium lauryl sulphate, sodium lauryl lactylate and phospholipids.
[0246] In one or more embodiments the formulations described herein may further contain a modulating agent.
Microsponges
[0247] The Microsponges are rigid, porous and spongelike round microscopic particles of cross-linked polymer beads (e.g., polystyrene or copolymers thereof), each defining a substantially noncollapsible pore network. The Microsponges can be loaded with an active ingredient and can provide a controlled time release of the active ingredient to skin or to a mucosal membrane upon application of the formulation. The slow release is intended to reduce irritation by the active. Microsponge® delivery technology was developed by Advanced Polymer Systems. In one or more embodiments the composition comprises one or more active agents loaded into Microponges with an aqueous carrier or with a waterless carrier described herein which may comprise a modulating agent.
Propellants
[0248] Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane and fluorocarbon gases, or mixtures thereof. [0249] In an embodiment the propellant is1681 , which is a mixture of propane, isobutene and butane. In another embodiment it is AP 70, which is a mixture of propane, isobutene and butane with a higher pressure.
[0250] The propellant makes up about 5-25 wt% of the foamable composition. In some circumstances the propellant may be up to 35%. The propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable composition.
[0251] Alcohol and organic solvents render foams inflammable. It has been surprisingly discovered that fluorohydrocarbon propellants, other than chloro-fluoro carbons (CMCs), which are non-ozone-depleting propellants, are particularly useful in the production of a non-flammable foamable composition. A test according to European Standard prEN 14851 , titled "Aerosol containers - Aerosol foam flammability test" revealed that compositions containing an organic carrier that contains a hydrophobic organic carrier and/or a solvent, which are detected as inflammable when a hydrocarbon propellant is used, become non-flammable, while the propellant is an HFC propellant. [0252] Such propellants include, but are not limited to, hydrofluorocarbon (HFC) propellants, which contain no chlorine atoms, and as such, fall completely outside concerns about stratospheric ozone destruction by chlorofluorocarbons or other chlorinated hydrocarbons. Exemplary non-flammable propellants according to this aspect of the invention include propellants made by DuPont under the registered trademark Dymel, such as 1 , 1 , 1 ,2 tetrafluorethane (Dymel 134), and 1 , 1 , 1 ,2,3,3,3 heptafluoropropane (Dymel 227) 1 ,1 , difluoro ethane (Dymel 152) and 1 ,1 ,1 ,3,3,3 hexafluoropropane HFCs possess Ozone Depletion Potential of 0.00 and thus, they are allowed for use as propellant in aerosol products.
[0253] In one or more embodiments, the non inflammbale propellants are used in combination with the more traditional hydrocarbon propellants.
[0254] In one or more embodiments, where Dymel is used, it is used in such levels that the sensation effect is not primarily due to the propellant. [0255] Notably, the stability of foamable emulsions including HFC as the propellant can be improved in comparison with the same composition made with a hydrocarbon propellant.
[0256] In one or more embodiments foamable compositions comprise a combination of a HFC and a hydrocarbon propellant such as n-butane or mixtures of hydrocarbon propellants such as propane, isobutane and butane.
[0257] Some propellants may have a cooling effect. The evaporation of the propellant from newly released foam that has been applied to a body surface can, depending on the nature of the foam and the type and amount of propellant provide a cooling effect. In some cases the sensation is mild and in other cases the propellant can actually produce physical cooling on the skin surface. As will be appreciated such cooling effect may increase relative to the ability of the formulation to deliver increasing levels of propellant in contact with the skin.
[0258] Dimethyl ether is a product which evaporates very rapidly to produce a cooling effect and in one or more embodiments is used as part of the propellant system.
[0259] In one or more embodiments the propellant is a mixture of propane, butane and isobutene.
[0260] In one or more embodiments the propellant is a mixture of propane, butane and isobutene together with dimethyl ether.
[0261] In one or more embodiments the propellant makes up about 5-25 wt% of the foamable composition.
[0262] In certain other embodiments the amount of propellant can be increased to up to less than half of the composition, for example, where it is desired to produce a cooling effect in addition to a cooling sensation or where it is sought to produce an initial cooling effect followed by a cooling or other sensation .
Additional components
[0263] Additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamin or derivative thereof. [0264] In addition to the sensations and sensation agents and sensation modifying effects described herein it is possible to enhance the sensation of the user and to increase compliance, by for example making the product visually attractive. Thus, in certain further embodiments the additional component is one or more of a colored active agent, a colored excipient, a pigment, a dye, a colorant and a coloring agent. Similarly, in other certain embodiments the additional component is a fragrance or fragrance masking agent
Sensation or sensation modifying agent
[0265] The sensation modifying agent is selected from a cooling agent, a warming agent a relaxing or soothing agent; a stimulating agent; a refreshing agent; or mixtures thereof.
[0266] As will be appreciated by someone in the art two or more soothing, relaxing, cooling, stimulating, refreshing, and warming agents may be effectively combined in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
Cooling agents
[0267] In the context and without degradating from explanations given elsewhere, substances, which are known to provide a "cool" sensation or cooling effect on or following application to a body surface; and substances that, on or following topical application can ameliorate a hot sensation or a heating effect are called "cooling agents". Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a cooling sensation or effect or to ameliorate a hot sensation or heating effect, is suitable for use a cooling agent in accordance with the present invention. The cooling agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or a propellant or combinations of two or more agents. [0268] Hence, non limiting examples of cooling agents, which are all incorporated herein by reference are provided in US Patents No. 3,419,543, 4,020,153, 4,032,661 , 4,033,994, 4,034,109, 4,059,1 18, 4,060,091 , 4,070,449, 4,070,496, 4,136,163, 4,150,052, 4, 4,153,679, 157,384, 4,178,459, 4,193,936, 4,226,988, 4,230,688, 4,296,255, 4,459,425, 5,266,592, 5,608,1 19, 5,725,865, 5,773,410, 5,843,466, 5,959,161 , 6,214,788, 6,267,974, 6,303,817, 6,328,982, 6,359,168, 6,482,983, 6,592,884, 6,884,906 and7, 030,273 US Patent Application 20040067970, DE 2,202,535, DE 2,205,255, DE 2,503,555, DE 2,608,226, DE 4,226,043, GB 1 ,351 ,761 , GB 1 ,351 ,762, GB 1 ,421 ,744, JP 2004059474 and WO 2005049553; and in Watson et al, J. Soc. Cosmet. Chem. 29, 185-200 (1978); and Ottinger et al in J. Agric. Food Chem., 49, 5383-5390 (2001 ).
[0269] In an embodiment, the cooling agent has a further sensation or sensation modifying feeling or effect. [0270] In an embodiment, the cooling agent is menthol. In additional embodiment, the cooling agent is an isomer or a derivative of menthol, as exemplifies in the following schemes:
/-menthol d-menthol (+)-neo
Figure imgf000053_0002
Carvomenthol /-Menthone (mild cooling)
Figure imgf000053_0003
d-camphor (
Figure imgf000053_0001
+)-neoiso (-)-neoιso (+)-iso ) Acarvone (cooNng)
[0271] Additional examples of menthol derivatives are monomenthyl esters of di- and polycarboxylic acids:
Figure imgf000053_0004
p-Menthane-3,8-diol
Figure imgf000053_0005
Menthol ethylene glycol carbonate
[0272] Some derivatives have been developed to be substantially without smell. [0273] Useful exemplary menthol derivatives are menthol ethylene glycol carbonate, which is now known as Frescolat® type MGC, enthol Propylene Glycol Carbonate (Frescolat® type MPC), menthyl lactate (Frescolat ML®) and Menthone Glycerin Acetal (Frescolat MGA®).
Figure imgf000054_0001
Frescolat type MGC
Figure imgf000054_0002
[0274] Additional widely used menthol derivatives are 3-(/-Menthoxy)-1 ,2-propanediol, known as Cooling Agent 10; and the same structure with an additional methyl group in the glycerin part of the molecule:
Figure imgf000054_0003
Cooling Agent 10 /-Menthoxy-2-methyl 1 ,2-propanediol
[0275] Menthoxy-coolants are additional cooling menthol derivatives:
Figure imgf000054_0004
[0276] Cubebol is an example of a coolant with a C-C bond in the 3d position of p- menthane.
Figure imgf000055_0001
[0277] Cooling agents, which are not menthol derivatives, are also suitable for use in accordance with the present invention. Examples of such cooling agents are provided below:
Figure imgf000055_0002
4-Methyl-3-(1-pyrrolιdιnyl)-2[5H]- furanone n = 1 , 2 &. R = OMe 1 OEt, O Pr1 0-ιPR, OBu
Figure imgf000055_0003
5-mθthyl-4-(1-pyrrolιdιnyl)-3-[2H]- furanone 4,5-dιmethyl-3-(1-pyrrolιdιnyl)- 4-methyl-3-(1-pyrrohdinyl)-2[5H]-furanone
2[5H]-furanone
[0278] Exemplary cooling agents which can be used in the invention include, but are not limited to, menthol, isopulegol, 3-(l-menthoxy)propane-1 ,2-diol, 3-(l-menthoxy)-2- methylpropane-1 ,2-diol, p-menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl- 1 ,4-dioxas- piro[4,5]decane-2-methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl^-isopropyl-δ-methylcyclohexanecarb- oxamide, Japanese mint (Mentha arvensis) oil, peppermint oil, menthone, menthone glycerol ketal, menthyl lactate, 3-(l-menthoxy)ethan-1-ol, 3-(l-menthoxy)propan-1-ol, 3-(l- menthoxy)butan-1-ol, l-menthylacetic acid N-ethylamide, l-menthyl-4-hydroxypentanoate, l-menthyl-3-hydroxybutyrate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide, and spearmint oil. [0279] The cooling agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a cooling sensation or cooling effect upon application of the cooling foamable composition onto a body surface. [0280] In an embodiment, the cooling agent also possesses therapeutic properties. For example, menthol is being used in the therapy of psoriasis; relief of nasal complaints and sore throats; and WS-3 (N-Ethyl-p-menthane-3-carboxamide) and related N- substituted p-menthane carboxamides, as well as p-Menthane-3,8-diols are known insect repellents
Warming agents
[0281] In the context and without degradating from explanations given elsewhere, substances, which are known to provide a warming sensation or warming effect on or following application to a body surface; and substances that, upon or following topical application can ameliorate a cold sensation or a cooling effect are called "warming agents". Any agent which, when incorporated in the foamable composition in a concentration sufficient to exert a warming sensation or warming effect or to ameliorate a cold sensation or cooling effect, is suitable for use a warming agent in accordance with the present invention. The warming agent may be an excipient, an active ingredient or pharmaceutical, therapeutic or cosmetic agent or combinations of two or more agents. [0282] Exemplary substances, which are known to provide a sensation of warmth on application and called "warming agents", include polyhydric alcohols, capsicum (red pepper) powder, a capsicum tincture, capsicum extract, capsaicin, homocapsaicin, homodihydrocapsaicin, nonanoyl vanillyl amide, nonanoic acid vanillyl ether, vanillyl alcohol alkyl ether derivatives (JP-A-57-9729), such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether, isovanillyl alcohol alkyl ethers, ethylvanillyl alcohol alkyl ethers, veratryl alcohol derivatives, substituted benzyl alcohol derivatives, substituted benzyl alcohol alkyl ethers, vanillin propylene glycol acetal, ethylvanillin propylene glycol acetal, ginger extract, ginger oil, gingeol, and gingeron. [0283] The warming agent is incorporated in the composition in a concentration which, on one side is safe and on the other side provides a warming sensation or warming effect upon application of the warming foamable composition onto a body surface.
[0284] In an embodiment , the warming agent also possesses therapeutic properties. For example, capsicum powder, capsicum tincture and extract, as well as capsaicin and homocapsaicin are used for topically treating muscle and joint pain. Combination of a cooling agent and a warming agent
[0285] It is also possible to modulate, potentate, increase, reduce, or ameliorate the sensation effect by introducing into the composition a sensation modifying agent. Thus, the sensation effect or sensation induced by a first sensation or sensation modifying agent maybe reduced by addition of a second sensation or sensation modifying agent in the composition. For example, the cooling sensation of a cooling formulation may be reduced by the presence of a warming or warming modifying agent. Likewise, the warming sensation of a warming formulation may be reduced by the presence of a cooling or cooling modifying agent. Thus in one exemplary embodiment the composition comprises an effective amount of cooling peppermint oil and a lesser effective amount of capsaicin warming agent such that the cooling sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of peppermint oil cooling agent such that the warming sensation is the predominant sensation. In another embodiment the cooling and warming agents are selected so that the cooling and warming effects or sensations are staggered. For example, in one exemplary embodiment the composition comprises an effective amount capsaicin of and an effective amount of dimethyl ether cooling agent such that the cooling sensation is the initial predominant sensation and the warming sensation follows on as the subsequent predominant sensation. Other cooling and warming agents may be effectively combined as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
Soothing or Relaxing Agents
[0286] There are many different categories of agents which have a soothing effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other soothing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate. [0287] Non limiting examples of soothing agents are herb extracts, such as, aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, yarrow; calendula, comfrey, witch hazel and other astringents, sea weed, and oat extracts; oils, such as, almond oil, avocado oil, and comfrey; and essential oils, such as, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary; waxy or unctuous substances such as lanolin or vaselline jelly, minerals, such as, zinc oxide, calamine and selenium; vitamins, such as, tocopheryl acetate (vitamin E), and drugs, such as, analgesics, anesthetics, anti-inflammatory agents, and anti-histamines, muscle relaxants and the like. [0288] Other non limiting examples are menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-l-menthoxypropane-1 ,2-diol, ethyl l-menthyl carbonate, (1 S,3S,4R)-p- menth-8-en-3-ol, menthyl pyrrolidone carboxylate, N-substituted-p-menthane-3- carboxamides (as described in U.S. Pat. No. 4,136,163, which is incorporated herein by reference) and ketal coolants (as described in WO 93/23005, which is also incorporated herein by reference) including, for example, l-menthon-ld-isomenthon glycerin ketal. [0289] In one exemplary embodiment the composition comprises an effective amount of soothing hamamelis and a lesser effective amount of frescolate cooling agent such that the soothing sensation is the predominant sensation. In another exemplary embodiment the composition comprises an effective amount capsaicin of and a lesser effective amount of hamamelis soothing agent such that the warming sensation is the predominant sensation. In another embodiment, the soothing and warming agents are selected so that the soothing and warming effects or sensations are staggered or partially overlapping. In another embodiment, the soothing and cooling agents are selected so that the soothing and cooling effects or sensations are staggered or partially overlapping.
Stimulating or Refreshing Agents
[0290] There are many different categories of agents which have a stimulating or refreshing sensation or effect and which may be used in the present invention in an effective amount either on their own or in combination with an effective amount of other stimulating or refreshing agents or in combination with an effective amount of other sensation or sensation modifying agents as will be appreciated by someone in the art in order to produce a combined, staggered, consecutive, overlapping, reduced or increased effect or sensation, as is appropriate.
[0291] Non limiting examples are alcohols, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate .acetyl choline, serotonin, histamine , prostaglandins, other neurotransmitters; CNS stimulants; caffeine, quinine, and the like might be suitable stimulants in dosages or delivery systems where they essentially or primarily have a local or topical as opposed to systemic effect.
Specific Agents Ginger
[0292] Ginger is said to have several pharmacological activities, including anti-emetic, antithrombotic, antimicrobial, anticancer, antioxidant and anti-inflammatory properties. Also, ginger has been reported to have hypoglycaemic, hypo- and hypertensive, cardiac, prostaglandin and platelet aggregation inhibition, antihypercholesterolaemic, cholagogic and stomachic properties. Ginger has carminative properties and has also been tried for the prophylaxis of motion sickness and nausea and vomiting in pregnancy. In vitro studies have demonstrated that constituents of ginger, such as 6-, 8- and 10-gingerols and galanolactone, have antiserotonergic activity. Ginger oil is used in aromatherapy.
Capsicum
[0293] The capsaicinoids are principally responsible for the biological activity of capsicum. These pungent principles are thought to stimulate and aid digestion and to act as a counter-irritant when applied externally. Capsaicin has also been used as a neurochemical tool for studying sensory neurotransmission. Topical creams containing capsaicin 0.025% and 0.075% are used for symptomatic relief of osteoarthritis, and postherpetic neuralgia, respectively. Capsicum oleoresin and capsaicin are ingredients of a number of over-the-counter topical preparations for relief of pain in muscle, tendon and joints. Capsaicin has effects on nervous, cardiovascular, respiratory, thermoregulatory and gastrointestinal systems. Capsaicin has been used as a neurochemical tool for studying sensory neurotransmission.
Hamamelis
[0294] Witch hazel is characterized by its tannin constituents and astringent properties. It is also said to have haemostatic properties. The documented herbal uses are related to these astringent properties. It has been used topically in the treatment of haemorrhoids, eczema and dermatitis. Vasoconstriction was reduced in the hindquarters of rabbits. A fraction of an aqueous ethanolic bark extract was significantly active against herpes simplex virus type 1 (HSV-1 ). Topical applications of a hydroglycolic extract of witch hazel leaf reduced skin temperature perhaps due to a vasoconstrictor effect. After- sun lotion containing 10% hamamelis was reported to have suppressed erythema.
Peppermint oil
[0295] Peppermint oil is an aromatic carminative that relaxes gastrointestinal smooth muscle and relieves flatulence and colic. Peppermint oil is also used with other volatile agents in preparations for respiratory-tract disorders. It is also used in aromatherapy.
Menthol
[0296] Menthol is chiefly used to relieve symptoms of bronchitis, sinusitis, and similar conditions. For this purpose it may be used as an inhalation, usually with benzoin or eucalyptus oil, as pastilles, or as an ointment with camphor and eucalyptus oil for application to the chest or. When applied to the skin menthol dilates the blood vessels, causing a sensation of coldness followed by an analgesic effect. It relieves itching and is used in creams, lotions, or ointments in pruritus and urticaria. It has also been applied to the forehead, presumably as a counter-irritant, for the relief of headache. Menthol has a carminative action. (Sources: Matindale and Herbal Extracts Electronic Edition 2008)
Additional active agent
[0297] The foamable carrier is an ideal vehicle for active pharmaceutical ingredients and active cosmetic ingredients. In the context herein, active pharmaceutical ingredients and active cosmetic ingredients are collectively termed "additional active agent" or "additional active agents".
[0298] Suitable additional active agents include but are not limited to active herbal extracts, acaricides, age spot and keratose removing agents, allergen, analgesics, local anesthetics, antiacne agents, antiallergic agents, antiaging agents, antibacterials, antibiotics, antibum agents, anticancer agents, antidandruff agents, antidepressants, antidermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, antiyeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, asoconstrictors, vasodilators, vitamins, vitamin derivatives, vitamin A, vitamin A derivatives, vitamin D, vitamin D derivatives, flavanoids, wound healing agents and wart removers. As is known to one skilled in the art, in some instances a specific active agent may have more than one activity, function or effect.
Fields of Applications
[0299] The foamable composition is suitable for treating any inflicted surface. In one or more embodiments, foamable carrier is suitable for administration to the skin, a body surface, a body cavity or mucosal surface, e.g., the cavity and/or the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum (severally and interchangeably termed herein "target site"). [0300] A sensation modifying foamable composition can be used in any condition that can benefit from the modification of a cold or warm sensation, and in any condition that can benefit from stabilizing a cold or warm sensation, by applying a cooling or a warming foam on the target site. [0301] Examples of uses of a cooling foam composition include:
Treatment of over-heated body surface;
Treatment of the skin after sun-burn;
Treatment of the skin after blistering;
Treatment of the skin after radiation treatment, burn or injury;
Treatment of the skin after friction burn;
Treatment of the skin after inflammation;
Treatment of the skin after insect bite or sting;
Treatment of the skin after shaving;
Treatment of the skin after hair removal;
Treatment of the skin after laser treatment, burn or injury;
Treatment or preparation of the skin prior to radiation, laser, or heat treatment or hair removal;
Treatment of the skin after, during or before acupuncture;
Treatment of the skin after or during stress;
Treatment of the skin upon pain. [0302] Examples of uses of a warming foam composition include:
Treatment of over-cooled body surface;
Treatment of the skin after exposure to cold environment;
Treatment of the skin with inadequate circulation;
Treatment of the skin after wind exposure;
Treatment of the skin after liquid gas treatment, burn, or injury;
Treatment or preparation of the skin prior to liquid gas treatment;
Treatment of the skin after, during or before massage;
Treatment of the skin after or during stress.
[0303] By selecting a suitable sensation modifying agent, or a combination of at least two sensation modifying agents, or a combination of at lease one sensation modifying agent and at least one additional therapeutic agent, the foamable composition is useful in treating an animal or a human patient having any one of a variety of dermatological disorders, including dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, grannuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo.
[0304] Likewise, the foamable composition is suitable for treating a disorder of a body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. Non limiting examples of such conditions include chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum.
[0305] In an embodiment , the composition is useful for the treatment of an infection. In one or more embodiments, the composition is suitable for the treatment of an infection, selected from the group of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection.
[0306] In an embodiment, the composition is useful for the treatment of wound, ulcer and burn. [0307] The composition is also suitable for administering a hormone to the skin or to a mucosal membrane or to a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
Higher (Fatty) Alcohols
[0308] In some embodiments of the present invention, the compositions and carriers comprise one or more higher alcohols. These generally exclude "lower alcohols". The fatty alcohols are typically liquid at ambient temperature.
[0309] Fatty alcohols may defined as follows:
The fatty alcohols hereof have a melting point of 30° C. or less, preferably about 25° C. or less, more preferably about 22° C. or less.
[0310] The unsaturated fatty alcohols hereof are also nonvolatile. By nonvolatile what is meant is they have a boiling point at 1.0 atmospheres of at least about 260° C, preferably at least about 275° C, more preferably at least about 300° C.
[0311] Suitable fatty alcohols include unsaturated monohydric straight chain fatty alcohols, saturated branched chain fatty alcohols, saturated C8 -C12 straight chain fatty alcohols, and mixtures thereof. The unsaturated straight chain fatty alcohols will typically have one degree of unsaturation. Di- and tri- unsaturated alkenyl chains may be present at low levels, preferably less than about 5% by total weight of the unsaturated straight chain fatty alcohol, more preferably less than about 2%, most preferably less than about
1 %.
[0312] Preferably, the unsaturated straight chain fatty alcohols will have an aliphatic chain size of from C12 -C22, more preferably from C12 -C18, most preferably from C16 -
C18. Especially preferred alcohols of this type include oleyl alcohol and palmitoleic alcohol.
[0313] The branched chain alcohols will typically have aliphatic chain sizes of from
C12 -C22, preferably C14 -C20, more preferably C16 -C18. Exemplary branched chain alcohols for use herein include isostearyl alcohol, octyl dodecanol, and octyl decanol.
Examples of saturated C8 -C12 straight chain alcohols include octyl alcohol, caprylic alcohol, decyl alcohol, and lauryl alcohol. Furthermore, the higher alcohols may be selected from straight chain fatty alcohols, having 6 or more carbon atoms, which are liquid at ambient temperature, such as, but not limited to Hexanol, Octanol, Nonanol,
Decanol; branched alcohols, such as: 2 Octanol (Capryl Alcohol), Undecanol (Undecyl
Alcohol ), 2 Butyl Octanol (Isolauryl Alcohol ), Tridecyl Alcohol (Isotridecyl Alcohol), 2
Butyl Decanol, 2 Hexyl Octanol, lsomyristyl Alcohol , 2 Hexyl Decanol, lsocetyl Alcohol , 2
Octyl Decanol, 2 Hexyl Dodecanol, Isostearyl Alcohol , Isooctadecanol, lsooleyl Alcohol
(unsaturated and branched), lsoarachidyl Alcohol , 2 Decyl Tetradecanol, lsolignoceryl Alcohol, 2 Decyl Tetradecanol , 2 Tetradecyl Octadecanol, 2 Tetradecyl Eicosanol, 2 Hexadecyl Octadecanol , 2 Hexadecyl Eicosanol; additionally unsaturated alcohols, such as Erucyl Alcohol, Linoleyl Alcohol, oleyl alcohol may be employed.
Substantially Alcohol-Free
[0314] According to one or more embodiments, the foamable composition is substantially alcohol-free, i.e., free of short chain alcohols. Short chain alcohols, having up to 5 carbon atoms in their carbon chain skeleton and one hydroxyl group, such as ethanol, propanol, isopropanol, butaneol, iso-butaneol, t-butaneol and pentanol, are considered less desirable solvents or solvents due to their skin-irritating effect. Thus, the composition is substantially alcohol-free and includes less than about 5% final concentration of lower alcohols, preferably less than about 2%, more preferably less than about 1 %.
[0315] Other foamable compositions are described in: U.S. Publication No. 05- 0232869, published on October 20, 2005, entitled NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0205086, published on September 22, 2005, entitled RETINOID IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0018937, published on January 26, 2006, entitled STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF; U.S. Publication No. 05-0271596, published on December 8, 2005, entitled VASOACTIVE KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0269485, published on November 30, 2006, entitled ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF; U.S. Publication No. 07-0020304, published on January 25, 2007, entitled NON-FLAMMABLE INSECTICIDE COMPOSITION AND USES THEREOF; U.S. Publication No. 06-0193789, published on August 31 , 2006, entitled FILM FORMING FOAMABLE COMPOSITION; U.S. Patent Application No. 1 1/732547, filed on April 4, 2007, entitled ANTI-INFECTION AUGMENTATION OF FOAMABLE COMPOSITIONS AND KIT AND USES THEREOF; U.S. Patent Application No. 1 1/732547, filed on April 4, 2007, KERATOLYTIC ANTIFUNGAL FOAM; U.S. Patent Application No. 1 1/767,442, filed on June 22, 2007, entitled FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES; U.S. Patent Application No. 1 1/825,406, filed on July 5, 2007, entitled DICARBOXYLIC ACID FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF; U.S. Patent Application No. 1 1/900072, filed on September 10, 2006, entitled FOAMABLE VEHICLE AND VITAMIN AND FLAVONOID PHARMACEUTICAL COMPOSITIONS THEREOF; and U.S. Patent Application No. 1 1/947751 , filed November 29, 2007, entitled COMPOSITIONS WITH MODULATING AGENTS, all of which are incorporated herein by reference in their entirety. More particularly any of the active ingredients; the solvents; the surfactants; foam adjuvants; polymeric agents, penetration enhancers; preservatives, humectants; moisturizers; and other excipients as well as the propellants and methods listed therein can be applied herein and are incorporated by reference.
[0316] The invention is described with reference to the following examples. This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims.
Methodology
[0317] The formulas of the present invention may be made in the following general way with appropriate adjustments for each formulation as will be appreciated by someone skilled in the art. Polymers, if any, are mixed, swelled and solubilized in the waterless medium, when necessary, with appropriate heat until it forms a clear solution. Stabilizing surfactants added usually with heat, until a homogeneous mixture is obtained, the mixture is then allowed to cool. The remainder of the ingredients, are then added with mixing until they have dissolved in the medium. The active agent is usually added at the end once the modulating agent, if present, has been incorporated. For foam the canisters are then filled with the above waterless formula, sealed and crimped with a valve and pressurized with the propellant.
[0318] A general procedure for preparing foamable compositions is set out in WO 2004/037225, which is incorporated herein by reference.
Composition and Foam Physical Characteristics and Advantages
[0319] A pharmaceutical or cosmetic composition manufactured using the foamable carrier of the present invention is very easy to use. When applied onto the body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
[0320] The foamable composition of the present invention is stable, having an acceptable shelf-life of at least one year, or preferably, at least two years at ambient temperature, as revealed in accelerated stability tests or aging tests. In certain embodiments a product may satisfy stability tests if upon light shaking a homogenous formulation is restored and remains stable until well after dispensing. Organic carriers and propellants tend to impair the stability of emulsions and to interfere with the formation of stable foam upon release from a pressurized container. It has been observed, however, that the foamable compositions according to the present invention are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
[0321] The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam.
Quantitative and Qualitative Tests
Foam Quality
[0322] Foam quality can be graded as follows:
Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
Grade G (good): rich and creamy in appearance, very small bubble size, "dulls" more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
Grade F (fair): very little creaminess noticeable, larger bubble structure than a "fairly good" foam, upon spreading on the skin it becomes thin in appearance and watery.
Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
[0323] Topically administrable foams are typically of quality grade E or G, or occasionally FG, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
Foam Physical Characteristics
[0324] In terms of foam consistency and texture an acceptable foam is one, that exhibits the following characteristics: [0325] A "stable foam" is defined herein as a composition, which upon release from an aerosol can, creates a foam mass, which is sustained on a surface for at least one minute, more preferably at least two minutes, and yet more preferably for at least 5 minutes. A period of minutes is regarded as a short term, but nevertheless it allows a good and more than sufficient period of time for a subject to receive foam dispensed on a body surface and to spread it or to transfer it to another region and to spread it.
[0326] Foam texture should vary from a very fine creamy foam to a fine bubble structure.
[0327] Foam has to have specific gravity in the range of about 0.02 gr/mL to about
0.5 gr/mL, more preferably between about 0.04 gr/mL and about 0.2 gr/mL.
[0328] In terms of spreadability and absorption an acceptable foam is one, that does not readily collapse upon dispensing on the skin; spreads easily on a skin surface; at least partially absorbed following rubbing onto the skin, and more preferably, substantially absorbed following rubbing on the skin.
[0329] In terms of tactile properties an acceptable foam is one, that: creates a pleasant feeling after application; leaves minimal oily residue; and leaves minimal shiny residual look.
Shakability
[0330] 'Shakability' means that the composition contains some or sufficient flow to allow the composition to be mixed or remixed on shaking. That is, it has fluid or semi fluid properties. In some very limited cases it may still be possible to have a foamable composition which is flowable but not apparently shakable.
Breakability
[0331] A breakable foam is thermally stable or substantially so, yet breaks under sheer force. The breakable foam of the present invention is not "quick breaking", i.e., it does not readily collapse upon exposure to body temperature environment. Sheer-force breakability of the foam is clearly advantageous over thermally induced breakability, (due to, for example, the presence of alcohol) since it allows comfortable application and well directed administration to the target area.
Foam Collapse
[0332] A further aspect of the foam is breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
[0333] The foam of the present invention has several notable advantages, when compared with hydroalcoholic foam compositions, such as Breakability. The foam of the present invention is thermally stable and breakable under sheer force but is not "quick breaking which allows comfortable application and well directed administration to the target area.
Skin drying and skin barrier function. Short chain alcohols are known to dry the skin and impair the integrity of the skin barrier. By contrast, including a film forming agent in the composition of the present invention foes not cause unwanted skin barrier damage. Irritability. Due to the lack of lower alcohols (C1-C5) and improvement in skin barrier function, skin irritability is eliminated.
[0334] Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of less than 0.12 g/mL; or less than 0.10 g/mL; or less than 0.08 g/mL, depending on their composition and on the propellant concentration.
Examples
[0335] The invention is described with reference to the following examples. This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims
[0336] All % values are provided on a weight (w/w) basis.
[0337] In some cases the formulations are expressed in amounts up to 100% including the propellant. In other cases the formulations are expressed in amounts up to
100% not including the propellant, which is then added to the composition.
GENERAL METHODOLOGY
[0338] In one or more various embodiments the sensation or sensation modifying topical compositions can be prepared according to the general methodology set out below with appropriate changes as would be well appreciated by a man of the art. Emulsion Foam
1. Mix oily phase ingredients and heat to 750C to melt all ingredients and obtain homogeneous mixture.
2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
3. Add all other water soluble ingredients to water-polymer solution and heat to 750C.
4. Add slowly internal phase to external phase at 750C under vigorous mixing and homogenize to obtain fine emulsion.
5. Cool to below 4O0C and add sensitive ingredients with mild mixing.
6. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the hamamelis, and also for the capsaicin emollient emulsion compositions exemplified below. Waterless Foam
1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 750C to melt and dissolve the various ingredients.
2. Cool to below 4O0C and add sensitive ingredients with mild mixing.
3. Cool to room temperature.
This methodology is suitable, for example, for the preparation of the capsaicin waterless compositions exemplified below. Emulsion: Mint oil
1. Mix oily phase ingredients and heat to 750C to melt all ingredients and obtain homogeneous mixture.
2. Mix polymers in water with heating or cooling as appropriate for specific polymer.
3. Add all other water soluble ingredients to water-polymer solution and heat to 750C.
4. Add internal phase to external phase at 750C under vigorous mixing and homogenize to obtain fine emulsion.
5. Cool to below 4O0C.
6. Add sensitizing agents and any other active ingredient with mild mixing.
7. Cool to room temperature.
8. In case of Pemulene® stabilizer, dissolve the Pemulene® in the Mint oil and add to the emulsion.
Waterless: Mint oil
1. Dissolve the polymers in the main solvent with heating or cooling as appropriate for specific polymer. Add the all other ingredients and heat to 750C to melt and dissolve the various ingredients.
2. Cool to below 4O0C
3. Add sensitizing agents and any other active ingredient with mild mixing.
4. Cool to room temperature. Production under vacuum
[0339] Optionally, the foamable formulation may be produced under nitrogen and under vacuum. Whilst the whole process can be carried out under an oxygen free environment, it can be sufficient to apply a vacuum after heating and mixing all the ingredients to obtain an emulsion or homogenous liquid. Preferably the production chamber is equipped to apply a vacuum but if not the formulation can be for example placed in a dessicator to remove oxygen prior to filing and crimping. Canisters Filling and Crimping
[0340] Each aerosol canister is filled with PFF and crimped with valve using vacuum crimping machine. The process of applying a vacuum will cause most of the oxygen present to be eliminated. Addition of hydrocarbon propellant may without being bound by any theory further help to reduce the likelihood of any remaining oxygen reacting with the active ingredient. It may do so, without being bound by any theory, by one or more of dissolving in the oil or hydrophobic phase of the formulation, by dissolving to a very limited extent in the aqueous phase, by competing with some oxygen from the formulation, by diluting out any oxygen, by a tendency of oxygen to occupy the dead space, and by oxygen occupying part of the space created by the vacuum being the unfilled volume of the canister or that remaining oxygen is rendered substantially ineffective in the formulation.
Pressurizing Propellant Filling
[0341] Pressurizing is carried out using a hydrocarbon gas or gas mixture. Canisters are filled and then warmed for 30 sec in a warm bath at 50oC and well shaken immediately thereafter. Closure Integrity Test.
[0342] Each pressurized canister is subjected to bubble and crimping integrity testing by immersing the canister in a 600C water bath for 2 minutes. Canisters are observed for leakage as determined by the generation of bubbles. Canisters releasing bubbles are rejected.
FOAM TESTS
[0343] By way of non limiting example the objectives of hardness, collapse time and FTC stability tests are briefly set out below as would be appreciated by a person of the art.
Hardness
[0344] LFRA100 instrument is used to characterize hardness. A probe is inserted into the test material. The resistance of the material to compression is measured by a calibrated load cell and reported in units of grams on the texture analyzer instrument display. Preferably at least three repeat tests are made. The textural characteristics of a dispensed foam can affect the degree of dermal penetration, efficacy, spreadability and acceptability to the user. The results can also be looked at as an indicator of softness. Note: the foam sample is dispensed into an aluminum sample holder and filled to the top of the holder.
Collapse Time
[0345] Collapse time (CT) is examined by dispensing a given quantity of foam and photographing sequentially its appearance with time during incubation at 36°C. It is useful for evaluating foam products, which maintain structural stability at skin temperature for at least 1 min.
Viscosity
[0346] Viscosity is measured with Brookfield LVDV-II + PRO with spindle SC4-25 at ambient temperature and 10, 5 and 1 RPM. Viscosity is usually measured at 10RPM. However, at about the apparent upper limit for the spindle of ~>50,000CP, the viscosity at 1 RPM may be measured, although the figures are of a higher magnitude.
FTC (Freeze Thaw Cycles)
[0347] To check the foam appearance under extreme conditions of repeated cycles of cooling, heating, (first cycle) cooling, heating (second cycle) etc., commencing with - 1000C (24hours) followed by +4000C (24hours) measuring the appearance and again repeating the cycle for up to three times.
Chemical Stability
[0348] The amount of active agent present is analyzed in foam expelled from various pressurized canisters containing foam formulations using HPLC. Analysis is carried out at zero time and at appropriate time intervals thereafter. The canisters are stored in controlled temperature incubators at 5°C, at 25°C, at, 400C and at 50°C. At appropriate time intervals canisters are removed and the amount of active agent in the foam sample is measured.
Creaming by centrifugation
Principle of test
[0349] The centrifugation used in this procedure serves as a stress condition simulating the aging of the liquid dispersion under investigation. Under these conditions, the centrifugal force applied facilitates the coalescence of dispersed globules or sedimentation of dispersed solids, resulting in loss of the desired properties of the formulated dispersion. Procedure
[0350] Following preparation of the experimental formulation/s, allow to stand at room temperature for > 24 h. Handle pentane in the chemical hood. Add to each experimental formulation in a 20-mL glass vial a quantity of pentane equivalent to the specified quantity of propellant for that formulation, mix and allow formulation to stand for at least 1 h and not more than 24 h.
[0351] Transfer each mixture to 1.5 ml_ microtubes. Tap each microtube on the table surface to remove entrapped air bubbles.
[0352] Place visually balanced microtubes in the centrifuge rotor and operate the centrifuge at one or more of 10,000 rpm for 10 min, 3,000 rpm for 10 min or at 1 ,000 rpm for 10 min.
Bubble Size
[0353] Foams are made of gas bubbles entrapped in liquid. The bubble size and distribution reflects in the visual texture and smoothness of the foam. Foam bubbles size is determined by dispensing a foam sample on a glass slide, taking a picture of the foam surface with a digital camera equipped with a macro lens. The diameter of about 30 bubbles is measured manually relatively to calibration standard template. Statistical parameters such as mean bubble diameter, standard deviation and quartiles are then determined. Measuring diameter may also be undertaken with image analysis software. The camera used was a Nikon D40X Camera (resolution 10MP) equipped with Sigma Macro Lens (ref: APO MACRO 150mm F2.8 EX DG HSM). Pictures obtained are cropped to keep a squared region of 400 pixels x 400 pixels.
Foam Satisfaction Tests
[0354] Compositions of the present invention were separately applied to clean skin of a group of human subjects. After 5 minutes tested subjects were asked to provide a gauge of their satisfaction relating to the following parameters: Ease of application, skin absorption, stickiness, odor, oily residue, skin surface shiny appearance, composition stability; overall satisfaction; sensation change, such as cooling, relaxing, heating etc. The subjects gauged their response according to the following scoring system:
1 - very bad feeling
2 - Bad feeling
3 - feels "OK"
4 - Feels good
5 - Feels excellent, want more
The scores assigned by the subjects were added and an average result was recorded. Sensation quantification tests
[0355] In cases where a sensation agent was added to the composition, the above test was repeated after 15, 30, 60, 120 minutes and after washing off the composition from the skin surface (after 120 minutes). The subjects were asked to gauge their feeling of a sensation, such as sensation change, such as cooling, relaxing, heating etc. The scores assigned by the subjects were added and an average result was recorded. In some cases, as exemplified below, the sensation was observed over a prolonged or sustained period of time.
[0356] By "prolonged period of time" or "sustained period of time" or "substantial period of time" (used interchangeably herein), is meant a period of time of about five or more minutes, more typically, at least 15 minutes in which the subject senses a sensation pertaining to a sensation agent applied to a target or delivery site on/in the subject.
Foam Temperature Effects
[0357] In the Examples hereinbelow, the following test was performed to see if there were any temperature changes to a surface onto which a foam was placed:
1. Place a thermometer in a clean glass vial and allow it to come to equilibrium.
2. Measure and record the temperature.
3. Release foam about 5gm onto the thermometer.
4. Observe temperature for 300 sec.
The procedure was performed on regular; different cooling and heating foam formulations (per examples below).
Results: For all foams tested by the above method as seen in the examples hereinbelow, no detectable significant temperature difference was noted between the surface temperature, foam temperature and ambient initial temperature. This is indicative that the foams produced in the examples below did not exhibit a measurable exothermic or endothermic reaction. Thus, the foams tested should not induce a significant temperature effect at the target site primarily due to the cooling effect of the propellant. In certain embodiments, it may be possible for there to be an interaction between chemicals in the skin or other target site and the foam composition, particularly for the non-aqueous compositions. For example, by moisture in the skin being absorbed by hygroscopic pharmaceutical recipients, like glycols. Nevertheless, a main aim is to deliver a sensation via a foam vehicle, where the prime sensation is due to pharmaceutical stimulation rather than an actual physical effect. In one or more embodiments, the sensation may be a combination of pharmaceutical stimulation and physical effect. For example, where an excess of propellant may provide an initial physical cooling and the sensation agent provides a prolonged sensation, without further cooling. The vehicles disclosed herein are adapted to provide the main sensation with or without an initial physical cooling sensation.
SECTION A
COOLING
Example 1- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil a) Formulation
Figure imgf000074_0001
b) Emollient + avocado oil +10% menthol crystals: Mean cooling effect on three subjects over time is 12.7
Figure imgf000074_0002
Sum total of points for this formulation for all subjects is: 38
Figure imgf000075_0002
Sum total of points for this formulation for all subjects is: 107
[0358] Comments: Emollient emulsion foam provided a reasonable and prolonged cooling sensation; excellent foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art.
Note: The propellant can be added at a concentration of about 3% to about 25% or more.
Example 2- Emollient Emulsion Foamable Composition with 10% Menthol Crystals and Avocado Oil and 15% Ethanol a) Emollient +10% menthol crystals +15% ethanol: Formulation
Ingredient Name Function % w/w
Avocado oil emollient and solvent 10
PEG 40 Stearate Stabilizing emulsifier 2.31
Stearyl Alcohol Co-emulsifier and foam stabilizer 0.77 lsopropyl myristate emollient 4.62
Mineral Oil Emollient 4.62 hypromellose Stabilizing polymers 0.23 xanthan gum Stabilizing polymers 0.23
Polysorbate 80 Stabilizing emulsifier 0.77
GMS Co-emulsifier foam stabilizer 0.39
Menthol Cooling agent 10
ETHANOL Solvent - penetration enhancer 15
Water Solvent to 100
TOTAL 100
Propane/butane/isobutane 8
Figure imgf000075_0001
b) Emollient + avocado oil +10% menthol crystals + 15% ethanol: Mean cooling effect on four subjects over time is 13.34
Figure imgf000076_0001
Sum total of points for this formulation for all subjects is: 53.5 c) Emollient + avocado oil +10% menthol crystals + 15% ethanol: Foam satisfaction Parameters
Figure imgf000076_0002
Sum total of points for this formulation for all subjects is: 124
[0359] Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, water phase, surfactant combination supported by co emulsifiers and a combination of polymeric agents plus a polar solvent as a penetration enhancer. Menthol in the above formulation achieves good penetration on its own so the presence of 15% ethanol is of only marginal effect. Ethanol is not essential and may be omitted or replaced by other penetrating agents such as transcutol; DMI; and the like. See section on penetration agents. Note: The propellant can be added at a concentration of about 3% to about 25% or more.
Example 3- Emollient Emulsion Foamable Composition with 15% Menthol Crystals a) Formulation
Figure imgf000076_0003
Figure imgf000077_0001
Figure imgf000077_0002
b) Emollient +15% menthol crystals: Mean cooling effect on four subjects over time is 13.88
Figure imgf000077_0003
Sum total of points for this formulation for all subjects is 60.5 c) Emollient +15% menthol crystals: Foam satisfaction Parameters
Figure imgf000077_0004
Sum total of points for this formulation for all subjects is: 1 19
[0360] Comments: Emollient foam provided excellent and prolonged cooling sensation; good foam quality; moisturizing. Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non essential. Note: The propellant can be added at a concentration of about 3% to about 25% or more. Example 4- Emollient Emulsion Foamable Composition with 15% Peppermint Oil a) Formulation
Figure imgf000078_0001
b) Emollient +15% peppermint oil: Mean cooling effect on four subjects over time is 11.75
Figure imgf000078_0002
Sum total of points for this formulation for all subjects is: 47
Figure imgf000078_0003
Sum total of points for this formulation for all subjects is: 121 [0361] Comments: Emollient foam provided reasonable and prolonged cooling sensation; good foam quality; moisturizing; Comprises an oil phase, a water phase, a surfactant combination supported by a co-emulsifier and a combination of polymeric agents. The propylene glycol is non-essential. The peppermint oil reduces the viscosity of the emulsion and is matrix destabilizing. Note: The propellant can be added at a concentration of about 3% to about 25% or more.
Example 5- Emollient Emulsion Foamable Composition with 15% Menthol Crystals and 25% propellant a) Formulation
Figure imgf000079_0001
b) Emollient +25% propellant + Menthol crystals: Mean cooling effect on four subjects over time
Figure imgf000079_0002
Sum total of points for this formulation for all subjects is: 37 c) Emollient +25% propellant + Menthol crystals: Foam satisfaction Parameters
Figure imgf000079_0003
Sum total of points for this formulation for all subjects is: 76 [0362] Comments: Emollient foam provided good cooling sensation; good foam quality; doesn't require preservative.
Note: The propellant can be added at a concentration of about 3% to about 25% or more.
Example 6- Waterless Foamable Composition with 15% Menthol Crystals (Formula number - 28) a) Formulation
Figure imgf000080_0001
Figure imgf000080_0002
b) Mean cooling effect on four subjects over time
Figure imgf000080_0003
Sum total of points for this formulation for all subjects is: 42 c) Foam satisfaction Parameters
Figure imgf000080_0004
Sum total of points for this formulation for all subjects is: 82
[0363] Comments: Waterless foam provided reasonable and prolonged cooling sensation with a delayed onset; fairly good foam quality; moisturizing; doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG (for example 200, 400, 600) may be used. Note: The propellant can be added at a concentration of about 3% to about 25% or more.
Example 7- Waterless Foamable Composition with 10% Peppermint Oil (Formula number - 32) a) Formulation
Figure imgf000081_0001
Figure imgf000081_0002
a) Mean cooling effect on Four subjects over time is 9
Figure imgf000081_0003
Sum total of points for this formulation for all subjects is: 36 c) Foam satisfaction Parameters
Sum total of points for this formulation for all subjects is: 100
[0364] Comments: Waterless foam provided reasonable and medium term cooling sensation with delayed onset; fairly good foam quality; moisturizing; doesn't require preservative. Any high molecular weight PEG (for example 1500, 2000, 4000, 6000 or 8000) or combinations of high molecular weight PEG with lower molecular weight PEG (for example 200, 400, 600) may be used. The peppermint oil has a thinning effect on the composition, which is to some extent counterbalanced or ameliorated by the high molecular weight PEG. Note: The propellant can be added at a concentration of about 3% to about 25% or more.
RELAXING OR SOOTHING
Example 8- Emollient Emulsion Foamable Relaxing or Soothing Composition with Hamamelis
Figure imgf000082_0001
[0365] Comments: Emollient foam capable of providing a soothing sensation; excellent foam quality; moisturizing. It comprises an oil phase, water phase, a surfactant combination supported by co emulsifiers and a combination of polymeric agents, plus a preservative and a chelating agent. The chelating agent is non essential. The co emulsifiers are non essential and can be omitted although some adjustment may be needed to the surfactant combination as will be appreciated by someone skilled in the art. Note: The propellant can be added at a concentration of about 3% to about 25% or more. WARMING
Example 9- Prophetic Emollient Emulsion Foamable Warming Composition with Capsaicin and Mineral Oil
Figure imgf000083_0002
Example 10- Prophetic Waterless Foamable Warming Composition with Capsaicin
Figure imgf000083_0001
Example 11- Prophetic Emollient Emulsion Foamable Warming Composition with Capsaicin and MCT
Figure imgf000083_0003
[0366] Comments:
- It is possible to use any of the above exemplary warming formulations with other warming agents, for example, methyl salicylate. Apart from its warming effect methyl salicylate is an analgesic and counter irritant. Lists of applicable warming agents are described in the specification. An effective amount of the warming agent is introduced into the formulation in place of capsaicin and the amount of the main carrier is adjusted to bring the formulation to 100%, which in the case of the waterless composition is propylene glycol and in the case of the emollient emulsion composition is water. The amount of methyl salicylate is of the order of 5 to 10%.
- It is also possible to use combinations of warming agents. The combination of capsaicin with methyl salicylate, for example, may be useful. Methyl salicylate has a quick onset whilst capsaicin does not so a combination may be helpful in cases where pain relief is sought.
- It is also possible to modulate, potentate, increase, reduce, or ameliorate the warming effect by introducing into the composition a sensation modifying agent. I an embodiment the warming effect or sensation maybe reduced by addition of a cooling agent in the composition.
- The formulations may contain polar solvents, which contribute to skin penetration of an active agent
FOAM WITH ADDITIONAL THERAPEUTIC AGENTS
Example 12 -Foamable Oil In Water Emulsion Foamable Compositions, Containing Menthol As Cooling Agent And Coal Tar Extract And Salicylic Acid As Additional Therapeutic Agents
Figure imgf000084_0001
Figure imgf000085_0001
[0367] Comments: The above formulations provided excellent moisturizing emollient foams with improved sensation by ameliorating the negative sensation effect of coal tar.
Section B
Cooling Example 13
A) Waterless propylene glycol formulation containing peppermint oil as cooling agent
Figure imgf000085_0002
*G-E =Good to Excellent
[0368] Comments: This waterless single phase formulation provides a stable vehicle for peppermint oil that can generate good quality foam and which can withstand 3000rpm. The surfactants and a polymeric agent provide viscosity support and aid foaming. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the peppermint oil provides a sensation of cooling, which may be potentiated by the evaporation of propellant and the lower temperature of the foam compared to the skin.
B) A waterless PG formulation and two oil in water emulsion formulations containing menthol crystals as cooling agent
Figure imgf000086_0001
Figure imgf000087_0001
[0369] Comments: Formulation 5 is a single phase composition that provides a stable vehicle for menthol crystals that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming. The other two formulations 6 and 7 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. All the formulations can accommodate substantial amounts of cooling sensation agent. In an embodiment the cooling agent is a combination of at least two cooling agents. In a further embodiment the cooling agent may be used in combination with a soothing agent. The coal tar formulation is yellow prior to addition of the propellant but upon discharge from the canister and release as a foam the color is dissipated such that the foam is only slightly yellow, which may be an advantage for its use. Warming
Example 14 - A waterless PG formulation and two oil in water emulsion formulations containing capsaicin as warming agent
Figure imgf000088_0001
[0370] Comments: Formulation 3 is a waterless single phase composition that provides a stable vehicle for capsaicin that can generate good quality foam capable of withstanding 3000rpm and having a collapse time in excess of 5 minutes. The surfactants, adjuvant and a polymeric agent provide viscosity support and aid foaming. The other two formulations 1 and 2 are stable oil in water emulsions that can generate good quality foam, are resistant to centrifugation at 3000rpm and have a collapse time in excess of 5 minutes. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the capsaicin should provide a sensation of warming.
In an embodiment the warming agent is a combination of at least two warming agents. In a further embodiment the warming agent may be used in combination with a soothing agent.
Soothing
Example 15
A) Two oil in water stable emulsion formulations containing ginger oil as soothing agent
Figure imgf000089_0001
Figure imgf000090_0001
[0371] Comments: By altering the surfactant mix a good quality foam was generated that is resistant to centrifugation and has a collapse time in excess of 5 minutes. The vehicle is capable of supporting substantial amounts of ginger oil. On forming foam there is no significant temperature change when measured on a glass surface. When the formulation is applied to the skin, however, the ginger oil should provide a sensation of soothing.
B) Gel formulation containing aloe vera as soothing agent
Figure imgf000090_0002
[0372] Comments: These water gel formulations are single phase compositions that provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 1.5 minutes. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent. C) Emollient emulsion formulation containing aloe vera as soothing agent
Figure imgf000091_0001
[0373] Comments: These emollient emulsion formulations provide a vehicle for aloe vera that can generate good quality foam having a collapse time in excess of 5 minutes and is stable to centrifugation. When the formulation is applied to the skin, the aloe vera should provide a sensation of soothing. In an embodiment the soothing agent is a combination of at least two soothing agents. In a further embodiment the soothing agent may be used in combination with a cooling agent or with a warming agent. [0374] The references cited herein teach many principles that are applicable to the present invention. Therefore the full contents of these publications are incorporated by reference herein where appropriate for teachings of additional or alternative details, features and/or technical background.
[0375] It is appreciated that certain features, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art.

Claims

CLAIMSWhat is claimed is:
1. A composition that provides to a subject at least one sensation for a sustained period of time following application to the skin, the composition comprising: a. at least one sensation or sensation modifying agent, comprising one or more of a cooling agent, a warming agent, a relaxing or soothing agent, and a stimulating or refreshing agent; b. a foamable carrier; and c. a propellant having a concentration about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a non-crackling short term stable foam.
2. A composition according to claim 1 , wherein the sensation is provided at a delivery site of the subject.
3. A composition according to claim 1 or claim 2, wherein upon contact at a delivery site the sustained sensation is not primarily due to the propellant or an exothermic reaction.
4. A composition according to any of claims 1 to 3, wherein the foamable carrier is resistant to aging and/or suitable for delivery of at least one sensation or sensation modifying agent.
5. A composition according to any of claims 1 to 4, wherein a relaxing or soothing agent comprises a herb extract, an astringent, a sea weed extract, an oat extract; an oil, a waxy or unctuous substance, a mineral, a vitamin, a pharmaceutical agent, menthol, camphor, eugenol, eucalyptol, safrol, methyl salicylate, menthyl lactate, menthyl ethoxyacetate, menthone glycerinacetal, 3-l-menthoxypropane-1 ,2-diol, ethyl I- menthyl carbonate, (1 S,3S,4R)-p-menth-8-en-3-ol, menthyl pyrrolidone carboxylate, an N-substituted-p-menthane-3-carboxamide, hamamelis extract, ginger oil, or any mixture of two or more thereof.
6. A composition according to claim 5, wherein a herb extract comprises one or more of aloe vera, alpha bisabolol, D-panthenol, allantoin, hamamelis, chamomile, and yarrow.
7. A composition according to claim 5, wherein an astringent comprises one or more of calendula, comfrey, and witch hazel.
8. A composition according to claim 5, wherein an oil comprises one or more of almond oil, avocado oil, cardamone, eucalyptus, mentha piperita (peppermint), hyssop, and rosemary.
9. A composition according to claim 5, wherein a waxy or unctuous substance comprises one or more of lanolin and petrolatum (e.g., vaseline jelly).
10. A composition according to claim 5, wherein a mineral comprises one or more of zinc oxide, calamine and selenium.
1 1. A composition according to claim 5, wherein a vitamin comprises tocopheryl acetate.
12. A composition according to claim 5, wherein a pharmaceutical agent comprises one or more of an analgesic, an anesthetic, an anti-inflammatory agent, an antihistamine, and a muscle relaxant.
13. A composition according to any of claims 1 to 4, wherein a stimulating or refreshing agent comprises an alcohol, L-menthol, camphor, menthe oil, capsicum extract, capsaicin, benzyl nicotinate, salicylate, glycol salicylate, acetyl choline, serotonin, histamine, a prostaglandin, a neurotransmitter; a CNS stimulant, caffeine, quinine, or any mixture of two or more thereof.
14. A composition according to any of claims 1 to 13, wherein said foamable carrier comprises about 40% to about 99% by weight of the total composition, excluding the propellant, and is an aqueous emulsion, an aqueous gel, or a non-aqueous carrier.
15. A composition according to any of claims 1 to 14, wherein said foamable carrier comprises: a. at least one surface active agent at a concentration of about 0.1 % to about 10% by weight of the carrier; b. at least one polymeric agent at a concentration of about 0.1 % to about 5% by weight of the total composition; and c. at least one non-aqueous solvent.
16. A composition according to claim 15, wherein said foamable carrier further comprises one or more of: a. a co-emulsifier or foam stabilizer at a concentration of about 0.1 % to about 5% by weight of the total composition; b. a wax, viscosity, bulking or firming agent at a concentration of about 0.1 % to about 15% by weight of the total composition; c. a co-solvent at a concentration of about 0.1 % to about 20% by weight of the total composition; d. a penetration enhancer or potent solvent at a concentration of about 0.1 % to about 25% by weight of the total composition; e. a foam adjuvant agent, comprising a fatty alcohol having 15 or more carbons in the carbon chain, or a fatty acid having 16 or more carbons in the carbon chain, at a concentration of about 0.1 % to about 25% by weight of the total composition; f. a stabilizer at a concentration of about 5% to about 30% by weight of the total composition; and g. an agent providing an occlusive effect, at a concentration of about 5% to about 30% by weight of the total composition.
17. A composition according to any of claims 1 to 16, further comprising at least one additional active agent, which is a cosmetic active agent or a pharmaceutical active agent having a cosmetic or pharmaceutical effect other than a sensation or sensation modifying effect.
18. A composition according to claim 17, wherein the at least one additional active agent comprises at least one of an active herbal extract, an acaricide, an age spot and keratosis removing agent, an allergen, an analgesic, a local anesthetic, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial, an antibiotic, an antibum agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic, an antihistamine, an antihelminth, an antihyperkeratolytic agent, an antiinflammatory agent, an antiirritant, an antilipemic, an antimicrobial, an antimycotic, an antiproliferative agent, an antioxidant, an anti-wrinkle agent, an antipruritic, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic, an antiswelling agent, an antiviral agent, an anti-yeast agent, an astringent, a topical cardiovascular agent, a chemotherapeutic agent, coal tar or an extract thereof, a corticosteroid, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an insecticide, an insect repellent, a keratolytic agent, a lactam, a metal, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a photodynamic therapy agent, a retinoid, a sanative, a scabicide, a self tanning agent, a skin whitening agent, a vasoconstrictor, a vasodilator, a vitamin, a vitamin derivative, vitamin A or a derivative thereof, vitamin D or a derivative thereof, a wound healing agent, and a wart remover.
19. The composition of any of claims 1 to 18, further comprising an additional component, which is an anti-perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, a moisturizer, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, a vitamin, or a mixture of any two or more thereof.
20. A composition according to any of claims 15 to 19, wherein a polymeric agent comprises at least one of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, a cationic guar, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, a polyvinylpyrrolidone, a polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, a polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, a methylcellulose, a hydroxypropyl cellulose, a hydroxypropyl methylcellulose, a hydroxyethyl cellulose, a hydroxypropyl methyl cellulose, a methylhydroxyethylcellulose, a methylhydroxypropylcellulose, a hydroxyethylcarboxymethylcellulose, a carboxymethyl cellulose, a carboxymethylcellulose, a carboxymethylhydroxyethylcellulose, a cationic cellulose, a ployethylene glycol, xanthan gum, a sodium carboxymethylcellulose, microcrystalline- cellulose, aluminum starch octyl succinate, and a polyacrylate.
21. The composition of any of claims 1 to 20, wherein upon dispensing as a foam, has a density of about 0.01 to about 0.2 g/ml.
22. A topical composition according to any of claims 1 to 21 , containing a sensation or sensation modifying comprising at least one of: a. a combination of a cooling and a warming agent; b. a combination of a cooling and a soothing or relaxing agent; c. a combination of a cooling and a stimulating or refreshing agent; d. a combination of a warming and a stimulating or refreshing agent; e. a combination of a warming and a soothing or relaxing agent; f. a combination of a cooling, a warming and a soothing or relaxing agent; and g. a combination of a cooling, a warming and stimulating or refreshing agent.
23. A topical composition according to any of claims 1 to 17, and 19 to 22, containing: a. a sensation or sensation modifying agent comprising menthol at a concentration of 0.5 to about 3% by weight of the composition; b. at least one additional active agent comprising: i. coal tar or coal tar extract at a concentration of about 2% to about
20% by weight of the composition; and ii. at least one other active agent comprising salicylic acid, hydrocortisone, or both, in a concentration of about 0.5% to about 10% by weight of the composition.
24. A composition for providing a subject with at least one sensation for a sustained period of time, the composition comprising: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a silicone oil; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
25. A composition for providing a subject with at least one sensation for a sustained period of time, the composition comprising: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a triglyceride; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
26. A composition for providing a subject with at least one sensation for a sustained period of time, the composition comprising: a. coal tar or coal tar extract; b. a mixture of mint and peppermint oil; c. a silicone oil and a triglyceride; d. a surfactant; e. a buffering system; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
27. A composition according to any of claims 24 to 26, wherein the buffering system comprises an EDTA, a citrate buffer, or a mixture thereof.
28 A composition according to any of claims 24 to 27, wherein the composition further comprises a polymeric agent, a foam adjuvant, or a combination thereof.
29. A composition according to any of claims 24 to 28, wherein the composition further comprises a penetrating agent, a humectant, or a combination thereof.
30. A composition according to any of claims 24 to 29, wherein the coal tar or coal tar extract is present in the composition at a concentration of about 2% to about 20% by weight.
31. A composition according to any of claims 24 to 30, wherein the surfactant is present in the composition at a concentration of about 2% to about 8.5% by weight.
32. A waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising: a. about 10% by weight of a cooling agent; b. about 81 % to about 83% by weight of a glycol; c. about 6% by weight of one or more surfactants; d. about 1 % by weight of a polymeric agent; and e. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
33. The composition of claim 32, wherein the cooling agent is peppermint oil or menthol crystals.
34. The composition of claim 32 or claim 33, wherein the glycol is propylene glycol.
35. The composition of any of claims 32 to 34, wherein the surfactant comprises steareth 2, polysorbate 80, glyceryl monostearate, or mixtures thereof.
36. The composition of any of claims 32 to 35, wherein the polymeric agent is hydroxypropyl cellulose.
37. The composition of any of claims 32 to 36, further comprising a foam adjuvant.
38. The composition of claim 37, wherein the foam adjuvant is cetostearyl alcohol.
39. A waterless composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising: a. about 0.03% by weight of a warming agent; b. about 97.97% by weight of a glycol; c. about 2% by weight of one or more surfactants; and d. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
40. The composition of claim 39, wherein the warming agent is capsaicin.
41. The composition of claim 39 or claim 40, wherein the glycol is propylene glycol.
42. The composition of any of claims 39 to 41 , wherein the surfactant is steareth 2.
43. A composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising: a. about 10% by weight of a warming agent comprising ginger; b. about 81 % to about 85% by weight of water; c. about 4.5% to about 6% by weight of one or more surfactants; d. about 0.6% by weight of a polymeric agent; e. optionally, about 2% by weight of a foam adjuvant; and f. a propellant at a concentration of about 3% to about 45% by weight of the total composition, wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
44. The composition of claim 43, wherein the warming agent comprises ginger oil.
45. The composition of claim 43 or claim 44, wherein the surfactant comprises steareth 2, steareth 21 , polysorbate 80, glyceryl monostearate, PEG-40 stearate, or a mixture thereof.
46. The composition of any of claims 43 to 45, wherein the polymeric agent comprises xanthan gum, Methocell K100M, or a mixture thereof.
47. The composition of any of claims 43 to 46, wherein the foam adjuvant comprises cetostearyl alcohol.
48. A composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising: a. about 2% by weight of aloe vera; b. about 90% to about 94% by weight of a polar solvent; c. about 2% to about 4% by weight of one or more surfactants; and d. about 2% to about 4% by weight of a polymeric agent.
49. The composition of claim 48 wherein the composition further comprises a propellant at a concentration of about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
50. The composition of claim 48 or claim 49, wherein the polar solvent comprises water, diethylene glycol monoethyl ether, or a mixture thereof.
51. The composition of any of claims 48 to 50, wherein the surfactant comprises polysorbate
52. The composition of any of claims 48 to 51 , wherein the polymeric agent comprises Avicel RC581.
53. A composition for providing a subject with at least one sensation at a delivery site for a sustained period of time, the composition comprising: a. about 2% by weight of aloe vera; b. about 77% by weight of a polar solvent; c. about 1 1 % by weight of a hydrophobic carrier; d. about 7% by weight of one or more surfactants; e. about 2% by weight of a foam adjuvant; f. about 0.6% of a polymeric agent; and g. a propellant at a concentration of about 3% to about 45% by weight of the total composition; wherein the composition is stored in an aerosol container and upon release expands to form a short term stable foam.
54. The composition of claim 53, wherein the surfactant comprises steareth 2, steareth 21 , or a mixture thereof.
55. The composition of any of claims 53 or claim 54, wherein the polar solvent comprises water.
56. The composition of any of claims 53 to 55, wherein the polymeric agent comprises xanthan gum, Methocell K100M, or a mixture thereof.
57. The composition of any of claims 53 to 56, wherein the foam adjuvant comprises cetostearyl alcohol.
58. The composition according to any of claims 24 to 31 , further comprising a hydrophobic solvent, wherein the combination of the additional hydrophobic solvent and silicone oil, the combination of the additional hydrophobic solvent and triglyceride, or the combination of the additional hydrophobic solvent, silicone oil, and triglyceride, is present in the composition at about 6% to about 22% by weight of the composition.
PCT/IB2009/005005 2008-01-08 2009-01-08 Sensation modifying topical composition foam WO2009087578A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2711703A CA2711703A1 (en) 2008-01-08 2009-01-08 Sensation modifying topical composition foam
ZA2010/05630A ZA201005630B (en) 2008-01-08 2010-08-04 Sensation modifying topical composition foam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/971,197 2008-01-08
US11/971,197 US20080253973A1 (en) 2002-10-25 2008-01-08 Sensation modifying topical composition foam

Publications (2)

Publication Number Publication Date
WO2009087578A2 true WO2009087578A2 (en) 2009-07-16
WO2009087578A3 WO2009087578A3 (en) 2010-06-10

Family

ID=40853523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/005005 WO2009087578A2 (en) 2008-01-08 2009-01-08 Sensation modifying topical composition foam

Country Status (3)

Country Link
CA (1) CA2711703A1 (en)
WO (1) WO2009087578A2 (en)
ZA (1) ZA201005630B (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US20130123720A1 (en) * 2010-06-11 2013-05-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
EP2772245A1 (en) 2013-02-27 2014-09-03 Symrise AG Ginger extract for the protection of stem cells
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
EP3097905A1 (en) 2015-05-28 2016-11-30 Symrise AG Cosmetic compositions
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
ITUB20160058A1 (en) * 2016-01-19 2017-07-19 Farm S R L C U S Composition of a preparation for the treatment of insect bites with vasoconstrictive, soothing, anti-inflammatory and anti-reddening activity
US9757397B2 (en) 2011-07-05 2017-09-12 Novan, Inc. Methods of manufacturing topical compositions and apparatus for the same
WO2017207021A1 (en) 2016-05-30 2017-12-07 Symrise Ag Medicament comprising ginger root co2 extract
WO2017215729A1 (en) 2016-05-30 2017-12-21 Symrise Ag Cosmetic compositions comprising sclareolide
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
WO2018001485A1 (en) 2016-06-30 2018-01-04 Symrise Ag Medicament and cosmetic composition comprising resorcinol derivatives
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2018053213A1 (en) * 2016-09-19 2018-03-22 The Procter & Gamble Company Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin
RU2666997C2 (en) * 2013-02-01 2018-09-13 Ддропс Компани Liquid menthol-containing compositions
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US10226483B2 (en) 2013-08-08 2019-03-12 Novan, Inc. Topical compositions and methods of using the same
US10265334B2 (en) 2011-07-05 2019-04-23 Novan, Inc. Anhydrous compositions
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10322081B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CN110149795A (en) * 2016-12-02 2019-08-20 西姆莱斯股份公司 Cosmetic mixture
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US10925689B2 (en) 2014-07-14 2021-02-23 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
WO2021053093A1 (en) * 2019-09-20 2021-03-25 Unilever Ip Holdings B.V. Antiperspirant compositions
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
WO2021204568A1 (en) 2020-04-07 2021-10-14 Universität Basel A topical composition for treatment of pruritus
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414920A1 (en) * 1989-03-17 1991-03-06 Taisho Pharmaceutical Co. Ltd Aerosol preparation for external use
EP0484530A1 (en) * 1989-07-28 1992-05-13 Hisamitsu Pharmaceutical Co., Inc. Foamed aerosol preparation
WO1992011839A1 (en) * 1991-01-08 1992-07-23 Leonard Mackles Anhydrous aerosol
EP0993827A1 (en) * 1997-06-13 2000-04-19 Taisho Pharmaceutical Co., Ltd Aerosols
JP2001072963A (en) * 1999-09-03 2001-03-21 Daizo:Kk Water-in-oil type bubblelike aerosol composition and preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414920A1 (en) * 1989-03-17 1991-03-06 Taisho Pharmaceutical Co. Ltd Aerosol preparation for external use
EP0484530A1 (en) * 1989-07-28 1992-05-13 Hisamitsu Pharmaceutical Co., Inc. Foamed aerosol preparation
WO1992011839A1 (en) * 1991-01-08 1992-07-23 Leonard Mackles Anhydrous aerosol
EP0993827A1 (en) * 1997-06-13 2000-04-19 Taisho Pharmaceutical Co., Ltd Aerosols
JP2001072963A (en) * 1999-09-03 2001-03-21 Daizo:Kk Water-in-oil type bubblelike aerosol composition and preparation thereof

Cited By (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9427605B2 (en) 2005-03-24 2016-08-30 Novan, Inc. Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US11583608B2 (en) 2009-08-21 2023-02-21 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9119781B2 (en) * 2010-06-11 2015-09-01 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US20200009160A1 (en) * 2010-06-11 2020-01-09 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind d analogue and a corticosteroid
US10688108B2 (en) 2010-06-11 2020-06-23 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10660908B2 (en) 2010-06-11 2020-05-26 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10682364B2 (en) 2010-06-11 2020-06-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US20190388439A1 (en) * 2010-06-11 2019-12-26 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind d analogue and a corticosteroid
EP2859886A1 (en) * 2010-06-11 2015-04-15 Leo Pharma A/S A pharmaceutical spray composition
US20190381074A1 (en) * 2010-06-11 2019-12-19 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind d analogue and a corticosteroid
US20130123720A1 (en) * 2010-06-11 2013-05-16 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US10716799B2 (en) 2010-06-11 2020-07-21 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US20190015430A1 (en) * 2010-06-11 2019-01-17 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US9566286B2 (en) 2010-06-11 2017-02-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10130640B2 (en) 2010-06-11 2018-11-20 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
US10617698B2 (en) 2010-06-11 2020-04-14 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
US20150313919A1 (en) * 2010-06-11 2015-11-05 Leo Pharma A/S Pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
US10265334B2 (en) 2011-07-05 2019-04-23 Novan, Inc. Anhydrous compositions
US9757397B2 (en) 2011-07-05 2017-09-12 Novan, Inc. Methods of manufacturing topical compositions and apparatus for the same
US10500220B2 (en) 2011-07-05 2019-12-10 Novan, Inc. Topical compositions
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
RU2666997C2 (en) * 2013-02-01 2018-09-13 Ддропс Компани Liquid menthol-containing compositions
EP2772245A1 (en) 2013-02-27 2014-09-03 Symrise AG Ginger extract for the protection of stem cells
US10258564B2 (en) 2013-02-28 2019-04-16 Novan, Inc. Topical compositions and methods of using the same
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11285098B2 (en) 2013-02-28 2022-03-29 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US10226483B2 (en) 2013-08-08 2019-03-12 Novan, Inc. Topical compositions and methods of using the same
US10828323B2 (en) 2013-08-08 2020-11-10 Novan, Inc. Topical compositions and methods of using the same
US11723858B2 (en) 2014-07-11 2023-08-15 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10736839B2 (en) 2014-07-11 2020-08-11 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
US10322081B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US11040006B2 (en) 2014-07-11 2021-06-22 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
US10925689B2 (en) 2014-07-14 2021-02-23 Novan, Inc. Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same
WO2016189046A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising purple coneflower pressed juice
WO2016189024A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising sclareolide
WO2016188988A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising e/z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one
WO2016189038A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising ginger root extracts
EP3097905A1 (en) 2015-05-28 2016-11-30 Symrise AG Cosmetic compositions
US10849864B2 (en) 2015-07-28 2020-12-01 Novan, Inc. Combinations and methods for the treatment and/or prevention of fungal infections
ITUB20160058A1 (en) * 2016-01-19 2017-07-19 Farm S R L C U S Composition of a preparation for the treatment of insect bites with vasoconstrictive, soothing, anti-inflammatory and anti-reddening activity
US10912743B2 (en) 2016-03-02 2021-02-09 Novan, Inc. Compositions for treating inflammation and methods of treating the same
US11166980B2 (en) 2016-04-13 2021-11-09 Novan, Inc. Compositions, systems, kits, and methods for treating an infection
WO2017207021A1 (en) 2016-05-30 2017-12-07 Symrise Ag Medicament comprising ginger root co2 extract
WO2017215729A1 (en) 2016-05-30 2017-12-21 Symrise Ag Cosmetic compositions comprising sclareolide
WO2018001485A1 (en) 2016-06-30 2018-01-04 Symrise Ag Medicament and cosmetic composition comprising resorcinol derivatives
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
WO2018053213A1 (en) * 2016-09-19 2018-03-22 The Procter & Gamble Company Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin
CN109715251A (en) * 2016-09-19 2019-05-03 宝洁公司 To improve foam compositions, aerosol product and its application method to the feeling beneficial effect of skin
US11123272B2 (en) * 2016-12-02 2021-09-21 Symrise Ag Cosmetic blends
CN110149795A (en) * 2016-12-02 2019-08-20 西姆莱斯股份公司 Cosmetic mixture
CN110149795B (en) * 2016-12-02 2023-10-03 西姆莱斯股份公司 cosmetic mixture
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
WO2021053093A1 (en) * 2019-09-20 2021-03-25 Unilever Ip Holdings B.V. Antiperspirant compositions
WO2021204568A1 (en) 2020-04-07 2021-10-14 Universität Basel A topical composition for treatment of pruritus

Also Published As

Publication number Publication date
WO2009087578A3 (en) 2010-06-10
CA2711703A1 (en) 2009-07-16
ZA201005630B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
US9320705B2 (en) Sensation modifying topical composition foam
WO2009087578A2 (en) Sensation modifying topical composition foam
US11103454B2 (en) Wax foamable vehicle and pharmaceutical compositions thereof
US10322085B2 (en) Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10363216B2 (en) Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US8119109B2 (en) Foamable compositions, kits and methods for hyperhidrosis
US9439857B2 (en) Foam containing benzoyl peroxide
US20120156144A1 (en) Foamable Compositions, Kits and Methods for Hyperhidrosis
EP2494959B1 (en) Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20150025060A1 (en) Foamable Compositions and Kits Comprising One or More of a Channel Agent, a Cholinergic Agent, A nitric Oxide Donor and Related Agents and Their Uses
US20080152596A1 (en) Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20070292359A1 (en) Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
EP2029106A2 (en) Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
WO2008110872A2 (en) Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2711703

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2864/KOLNP/2010

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700695

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09700695

Country of ref document: EP

Kind code of ref document: A2